Assessing and improving rational antimicrobial use in urban and rural health care facilities in Vietnam by Do, Thi Thuy Nga
Open Research Online
The Open University’s repository of research publications
and other research outputs
Assessing and improving rational antimicrobial use in
urban and rural health care facilities in Vietnam
Thesis
How to cite:
Do, Thi Thuy Nga (2017). Assessing and improving rational antimicrobial use in urban and rural health care
facilities in Vietnam. PhD thesis The Open University.
For guidance on citations see FAQs.
c© 2015 The Author
Version: Version of Record
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
ASSESSING AND IMPROVING RATIONAL ANTIMICROBIAL USE IN URBAN 
AND RURAL HEALTH CARE FACILITIES IN VIETNAM 
 
 
 
 
by 
 
 DO THI THUY NGA  
 
 
 
 
 
 
A thesis submitted to the Open University U.K 
For the degree of Doctor of Philosophy in the field of Life Sciences 
 
 
 
 
 
Oxford University Clinical Research Unit 
Hanoi, Viet Nam 
May, 2016 
 
 
  
ii 
Abstract 
The global problem of antimicrobial resistance (AMR) is particularly pressing in 
developing countries including Vietnam, where the infectious disease burden is high and cost 
constrains the replacement of older antimicrobials with newer, more expensive ones. Along 
with surveillance and infection control, responsible use of antimicrobials is one of the main 
objectives of the Vietnam National Action Plan on combating AMR. This thesis aims to get a 
better understanding of how antimicrobials are used in the Vietnamese community and how 
its use can be improved, to tailor evidence-based interventions and inform policies in 
controlling AMR.  
To assess the current situation of community access and use of antimicrobials and 
identify determinants associated with current practice, an observational study was conducted 
in 30 private pharmacies in northern Vietnam. This study was followed by a randomised 
controlled trial (RCT) to evaluate a point of care (POC) C-reactive protein (CRP, a biomarker 
of inflammation) test in reducing unnecessary antimicrobial prescribing for patients with non-
severe acute respiratory infections (ARI) and analysis of the economic impact and acceptance 
of this intervention among users.     
In private pharmacies, profit incentives coupled to poor knowledge about AMR are key 
drivers of over the counter dispensing of antimicrobials regardless the existence of 
regulations. Using a simple rapid blood test to identify customers who do not benefit from 
antimicrobial therapy would be a potential solution. Primary healthcare stations where over-
prescription of antimicrobials for self-limiting infections are common, were chosen for the 
intervention. CRP POC testing reduced unnecessary AB use for ARI patients without 
compromising patient’s recovery. This supports and extends findings from European trials by 
showing that such a stewardship approach is applicable even in resource constrained settings. 
However, there were several obstacles identified among users regarding test adherence 
associated with large between-site heterogeneity that need to be addressed to maximize the 
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intervention’s effect in the future. More importantly, our cost analysis indicated that to 
encourage adoption at scale, proper funding mechanisms to balance the invested costs and 
achieve global impact on AMR is recommended.  
 In summary, antimicrobial use in Vietnam is largely uncontrolled both in the 
community and the healthcare system leading to overuse and over-prescription for non-severe 
ARI. Use of commercially available CRP tests can be an effective, scalable and economically 
viable approach, even in highly resource-constrained settings. For the future, we are looking 
at ways to optimise use of POC biomarker testing in primary healthcare and private pharmacy 
setting. The potential for biomarker based tests to be combined with rapid pathogen detection, 
enhancing test algorithm adherence, use of CRP tests with equal financial incentives as as 
selling of antimicrobials and introducing pay for performance mechanisms may be crucial 
parts for optimisation.  
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Chapter 1 
Introduction 
The term “antibiotics” was first used in 1942 by Selman Waksman to refer to 
substances naturally produced by microorganisms that selectively inhibit the growth of other 
microorganisms (1). By strict definition, antibiotics do not include substances that are 
synthetic (sulfonamides and quinolones), or semisynthetic (methicillin and amoxicillin), or 
those, which come from plants (quercetin and alkaloids) or animals (lysozyme). A broader 
term “antimicrobials”, which was derived from the Greek meaning “against (anti) little 
(mikros) life (bios)”, largely refers to all agents that act against microbial organisms including 
bacteria (antibacterials), viruses (antivirals), fungi (antifungals), and protozoa (antiprotozoals) 
as well as synthetic and semisynthetic agents.  
Antimicrobial resistance (AMR) is the potential of a microbial organism to resist the 
effect of medicine previously used to treat them. This broader term also covers antibiotic 
resistance, which applies to bacteria and anti-bacterial drugs. Among antimicrobial classes, 
antibacterials are the largest and most widely studied group. Thus, the terms “antimicrobial” 
and AMR are often used interchangeable with the term “antibiotic” and “antibiotic 
resistance”. In my thesis, “antimicrobial” and AMR will be used to refer to medications with 
antibacterial spectrum only and the resistance against these substances among bacteria.  
Since the introduction in clinical practice of penicillin and streptomycin in the 1940s, 
antimicrobials have revolutionised prevention, treatment and outcome of infectious diseases 
(2). However, these advances are being threatened increasingly by the development and 
spread of antimicrobial resistance. Infections which were previously treatable are becoming 
more difficult to cure, resulting in increasing costs, to both individual patients and the 
healthcare system, and higher mortality rates (3). Without proper and enforced policies to stop 
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the spread of AMR, the currently estimated annual 700,000 deaths would increase to 10 
million per year in 2050 (4). The global problem of antimicrobial resistance is particularly 
pressing in developing countries, where the infectious disease burden is high, antimicrobials 
are available without prescription and costs constrain the replacement of older antimicrobials 
with newer, more expensive ones that also cover resistant organisms (5).  
Antimicrobial pressure is a key factor promoting development of resistance in bacteria 
(6), but the drivers for antimicrobial use are multi-factorial. Although antimicrobial resistance 
is primarily a medical problem, the causes of resistance are ecological, epidemiological, 
socio-cultural and economic. Patients, physicians, veterinarians, clinics and hospitals, and 
retailers - from large pharmacies to local drug sellers - have little motivation to weigh the 
negative impact of their use of antimicrobials on others, especially those in the future (7).  In 
order to improve the current situation, solutions must alter incentives for these stakeholders to 
act in society’s best interests (8).  
In this introductory chapter, I discuss the following topics: (1) Overview of 
antimicrobials, (2) Situation of global antimicrobial use (AMU) and resistance, (3) Potential 
control measures to tackle AMR, (4) local (Vietnamese) context, (5) Biomarker guided AMU 
– a potential control measure and (6) Objectives of my thesis. This introduction gives insight 
where interventions can be targeted to improve the current situation of antimicrobial use in 
Vietnam - which in turn may help to control AMR. 
1.1 Overview of antimicrobials  
1.1.1 Definitions 
Antimicrobials for human or animal use comprise a variety of natural, semisynthetic or 
synthetic substances used to treat infections by inhibiting the growth of or kill 
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microorganisms without significant toxicity to the human or animal host. Antimicrobials with 
an antibacterial spectrum are used both in the treatment and prevention of bacterial infections. 
Bacteria are generally classified by their membrane’s structural differences that can be 
visualised using the Gram stain, named after the Danish microbiologist, Hans Christian Gram, 
who developed this staining method in 1884 (9, 10). A thick layer of peptidoglycan in the 
membrane of Gram-positive bacteria retains the crystal violet dye during the decolourisation 
in the staining procedure. The thin peptidoglycan layer of Gram-negative bacteria is 
decolourised in this step and subsequently stained by a counter stain (safranin or fuchsine).  
Among other structural differences, Gram-negative bacteria have two membranes with a 
selectively permeable outer membrane that inhibits certain drugs and antimicrobials to 
penetrate the cell. Thus, Gram-negative bacteria in general are more resistant to 
antimicrobials than Gram-positive bacteria.  
1.1.2 Development of antimicrobial resistance 
 Antimicrobials, together with vaccines, are the two most crucial discoveries in the 
history of medicine and have shaped the recent evolution of mankind. The modern 
“antimicrobial era” was initiated by Paul Ehrlich and Alexander Fleming. In 1910, a “magic 
bullet” (an organoarsenic compound called arsphenamine sulphonamide marketed as 
Salvarsan) was discovered by Ehrlich and Sahachiro Hata, showing significant effect in the 
treatment of syphilis, a then endemic and incurable disease (11). Despite its high toxicity, this 
agent was the most commonly prescribed drug for this venereal disease until it was replaced 
by penicillin in the 1940s (12). Penicillin was discovered in 1928 by a Scottish biologist: 
Alexander Fleming. After being introduced for clinical treatment in the 1940s, penicillin 
helped to save thousands of lives from wound infections and sepsis during World War II (13).  
Soon after penicillin’s introduction, more antimicrobial compounds were discovered between 
the 1940s and 60s; a period known as the golden period of antimicrobial development, with 
  
 
4 
introduction of many new classes of antimicrobials, including: streptomycin (Selman 
Waksman, 1944), chloramphenicol, tetracyclines, macrolides and glycopeptides (1950s). The 
first quinolone antimicrobial, nalidixic acid, was introduced in 1962. A range of 
cephalosporins was developed during the 1970s to 80s. In the 1980s, finally, the carbapenems 
and fluoroquinolone antimicrobials were introduced (14, 15). 
 The major concern with antimicrobial development is that after introduction of any 
new antimicrobial, resistance to it will ultimately emerge (figure 1-1) (16). Among Gram-
positive pathogens, penicillin resistant Streptococcus pneumoniae, methicillin-resistant 
Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium (VRE) and 
fluoroquiolone resistant Neisseria gonorrhoeae	are of particular concern (17). Among Gram-
negative bacteria, resistance to 3rd generation cephalosporins followed by fluoroquinolones, 
carbapenems and now colistin among Enterobacteriaceae pose a serious, worldwide threat 
that have changed therapeutic and infection control guidelines and resulted in a steep increase 
in mortality and treatment costs (18-21). 
 From 1970s to 1990s, a dramatic increase in penicillin resistance among S. 
pneumoniae and S. aureus has been attributed to excessive global usage of penicillins (3, 22, 
23). In S. pneumoniae resistance is mediated by accumulation of chromosomal mutations in 
the genes coding for the penicillin- binding proteins (PBPs), essential components of the 
bacterial cell wall (24, 25). Resistance mechanism among S. aureus relate to production of 
penicillinases which inactivate antimicrobial agents in the penicillin class, and all other beta-
lactams (see below) (26, 27). The discovery and introduction of methicillin in 1959 was 
considered a certain and definite defense against the penicillinases, but the rapid subsequent 
emergence of MRSA in 1962, mediated by mecA, which encodes for a novel penicillin-
binding protein, PBP-2a, proved this to be an illusion (28, 29). Posing resistance to most then 
available antimicrobials, MRSA was one of the first multi-drug resistant (MDR) pathogens in 
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the hospital. Recent spread outside the hospital, MRSA has now also become a major 
community-acquired (CA) pathogen (30). 
 After widespread usage of broad-spectrum cephalosporins in the 1980s, a decade later, 
resistant Enterobacteriaceae started to be isolated in hospitals, caused by plasmid mediated 
production of extended-spectrum beta-lactamases (ESBLs), which have now become endemic 
in hospitals and communities worldwide (31, 32). Resistance evolution was largely attributed 
to the global spread of CTX-M type extended-spectrum β-lactamases (ESBLs) which are 
predominant among Escherichia coli and SHV type, which is dominant among Klebsiella 
pneumoniae (33). These genes and their derivatives including TEM-1, TEM-2, or SHV-1 are 
carried on plasmids, which facilitates the transfer of these genes among bacteria species (34, 
35). ESBLs mediate resistance to all penicillins and third and fourth generation 
cephalosporins, limiting making treatment options for ESBL-producing gram-negative 
pathogens caused infections. 
 Carbapenems, retained as one of the limited treatment options for serious infections 
caused by ESBL-producing organisms, thus started to be used more widely, eventually 
resulting in the global emergence of carbapenem-resistant Enterobacteriaceae (CRE) (28). 
The emergence of CRE is attributed to bacterial acquisition of carbapenemases, enzymes that 
inactivate these agents. K pneumoniae carbapenemase (KPC-1) was first found in 1996 in the 
carbapenem-resistant K pneumoniae (36). The genes encoding carbapenemases are usually 
located on plasmids or other transferable elements, allowing bacteria to acquire genes 
conferring resistance to other classes of antimicrobials, such as aminoglycoside-modifying 
enzymes, fluoroquinolone-resistance factors, and beta-lactamases to become pan-drug-
resistant (PDR) pathogens  (37-39). 
 Polymyxins, including colistin, an old family of antimicrobials that had become 
redundant due to dosing difficulties and toxicity, were now recovered as the last resort 
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antimicrobials to treat serious infections caused by these CREs including those caused by 
New Delhi Metallo-beta-lactamase (NDM) producing strains (40). Recently detected, NDM-1 
resistance gene confers resistance to most antimicrobials except polymyxins. Unfortunately, 
plasmid mediated resistance to this last resort drug has recently emerged in China, south Asia, 
Europe, Africa and South America, attributed to the mcr-1 plasmid (41-46). 
 Though the impact of antimicrobial resistance in the community is less severe than in 
hospitals, these findings have raised major concerns that the emergence and persistence of 
multidrug-resistant pathogens may bring back the pre-antimicrobial era, where patients 
hospitalised for something trivial (like appendicitis) may die from a progressive infection as 
antimicrobials have become ineffective. Currently, antimicrobial research and development 
mainly concerns derivatives of older classes of antimicrobials and only few are potentially 
novel compounds. As per 2014, 37 antimicrobial derivatives are under development in the 
US, of which 22 are potentially effective against Gram-negative pathogens (47). Among 
these, 33 are derivatives and 4 are new compounds of a novel beta-lactamases inhibitor and 
an existing beta-lactam). In 2015, a new antimicrobial compound against Gram-positive 
pathogens was discovered in an uncultivable soil bacterium, named teixobactin.  Mutants of 
S. aureus or Mycobacterium tuberculosis resistant to teixobactin were not found in vitro 
indicating that this finding may open a new path in modern antimicrobial research and 
development with the potential to avoid or delay the development of resistance (48).  
 
 
  
 
7 
 
Figure 1-1 Development of antimicrobial resistance: A timeline of key events (16) 
PDR = pan-drug-resistant; R = resistant; XDR = extensively drug-resistant  
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1.1.3 Antimicrobial classifications, mechanism of action and resistance 
1.1.3.1 Classification 
There are several ways to classify antimicrobials, including: spectrum, route of 
administration, type of activity, chemical structure or mechanism of action. Broad spectrum 
antimicrobials are effective against a broad range of microorganisms in contrast to narrow 
spectrum antimicrobials. Bactericidal antimicrobials can kill the bacteria while bacteriostatic 
antimicrobials inhibit the growth of bacteria (figure 1-2).  
 
 
Figure 1-2 Basic antimicrobial classification 
 (Source: https://explorable.com/history-of-antimicrobials) 
 Practically, the most useful classification system is the WHO Anatomical Therapeutic 
Chemical (ATC) classification, which is used for the classification of active ingredients of 
drugs according to the organ or system on which they act and their therapeutic, 
pharmacological and chemical properties (table 1-1). The ATC system is a valuable tool for 
measuring drug consumption and adverse drug reaction monitoring as products with various 
dosage forms and strengths of a substance will mostly have the same ATC code. 
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Table 1-1 Anatomical Therapeutic Chemical Classification System of Antimicrobials 
ATC-code Antimicrobial group 
J01 Antibacterials for Systemic Use  
J01A TETRACYCLINES 
J01AA Tetracyclines 
J01B AMPHENICOLS 
J01BA Amphenicols 
J01C BETA-LACTAM ANTIBACTERIALS, PENICILLINS 
J01CA Penicillins with extended spectrum 
J01CE Beta-lactamase sensitive penicillins 
J01CF Beta-lactamase resistant penicillins 
J01CG Beta-lactam inhibitors 
J01CR Combination of penicillins, incl. beta-lactamase inhibitors  
J01D OTHER BETA-LACTAM ANTIBACTERIALS 
J01DB 1st generation cephalosporins 
J01DC 2nd generation cephalosporins 
J01DD 3rd generation cephalosporins 
J01DE 4th generation cephalosporins 
J01DF Monobactams 
J01DH Carbapenems 
J01DI Other cephalosporins and penems 
J01E SULFONAMIDES AND TRIMETHOPRIM 
J01EA Trimethoprim and derivatives 
J01EB Short-acting sulfonamides 
J01EC Intermediate-acting sulfonamides 
J01ED Long-acting sulfonamides 
J01EE Combinations of sulfonamides and trimethoprim, incl. derivatives 
J01F MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS 
J01FA Macrolides 
J01FF Lincosamides 
J01FG Streptogramins 
J01G AMINOGLYCOSIDE ANTIBACTERIALS 
J01GA Streptomycins 
J01GB Other aminoglycosides 
J01M QUINOLONE ANTIBACTERIALS 
J01MA Fluoroquinolones 
J01MB Other quinolones 
J01R COMBINATIONS OF ANTIBACTERIALS 
J01RA Combinations of antibacterials 
J01X OTHER ANTIBACTERIALS 
J01XA Glycopeptide antibacterials 
J01XB Polymyxins 
J01XC Steroid antibacterials 
J01XD Imidazole derivatives 
J01XE Nitrofuran derivatives 
J01XX Other antibacterials 
(Source: https://www.whocc.no/atc_ddd_index/)  
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1.1.3.2 Mechanism of action 
There are five fundamental mechanisms of action for antimicrobials (figure 1-3): (1) 
inhibition of bacterial cell wall synthesis by inhibiting the synthesis of peptidoglycans – a 
crucial cell wall constituent of both Gram-positive and Gram-negative bacteria (beta-lactams, 
glycopeptides) (49, 50); (2) inhibition of transcription (rifamycins) or translation (30S 
ribosome site: tetracyclines, aminoglycosides; 50S ribosome site: macrolides, lincosamides, 
amphenicols, tetracyclines and streptogramins) (51-55); (3) inhibition of nucleic acid 
synthesis (imidazole derivatives) or supercoiling (quinolones); (4) alter cell membrane 
(polymyxins); (5) antimetabolite activity (sulfonamides, trimethoprim) (56).  
 
 
Figure 1-3 Antimicrobial classes and mechanism of action  
(Source: http://www.upinhealth.com/antimicrobial-classes-and-mechanisms-of-action/) 
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1.1.3.3 Mechanism of antimicrobial resistance 
Antimicrobial resistance is a natural phenomenon as bacteria produce and use 
antimicrobials (antibioitcs) against other bacteria leading to low-level of natural selection for 
resistance (57). Resistance (figure 1-4) (58) may be caused by (1) enzymatic inactivation of 
the antimicrobial compound, (2) modification of antimicrobial targets including over-
amplification of target and (3) alteration of the permeability of the cell membrane by either 
decreased influx (porin loss) or increased efflux (efflux pumps). Antimicrobial resistance 
genes encoding these resistance mechanisms can be located either in the chromosomal DNA 
or on transferable elements that may be integrated in the chromosome (integrons, 
transposons) or separate as plasmids (59). Plasmids, other transferable elements and genes 
encoding resistance mechanisms in general can be transmitted to other bacteria, known as 
horizontal gene transfer. This may occur through three main mechanisms: conjugation, 
transduction and transformation.  
 
Figure 1-4 Mechanism of bacterial resistance to antimicrobial (58) 
The classes of antimicrobials affected by each of the mechanisms are listed in the boxes 
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1.2 Situation of global antimicrobial use and resistance  
1.2.1 Global human antimicrobial consumption  
Antimicrobial pressure is the single most important factor promoting development of 
drug resistance in bacteria. Inappropriate antimicrobial use (e.g. too broad, without clinical 
indication, too low dose, too short duration) represents an avoidable additional pressure (60). 
To slow down the development of antimicrobial resistance, a control strategy to reduce the 
inappropriate use of antimicrobials in both community and health care facilities is required 
(61). Assessing variations in volumes and patterns of antimicrobial consumptions across 
countries is therefore crucial to develop rational-use policies to combat antimicrobial 
resistance.  
 IMS Health MIDAS (IMS Health, Danbury, CT, USA) is an American commercial 
organisation that tracks sales of the global pharmaceutical market through two main channels: 
retail pharmacies and hospital pharmacies (62). In each sector, the volume of antimicrobials 
sold are collected to quantify antimicrobial consumption either directly from manufacturers or 
indirectly from wholesalers. Annual reports are available in 71 countries for 16 classes of 
antimicrobials with volume of consumption estimated in standard units sold, which is defined 
as a single dosage unit such as a pill, capsule or ampule. The methodology applied varies by 
nations depending on their health systems (63). In high-income countries, IMS data is 
collected from both public and private channels while in low and middle income countries 
where IMS has no access to public channel, data is largely based on private sector. 
Consumption in some countries may be underestimated because the survey does not cover the 
entire market. Thus, interpreting and comparing consumption data should be performed with 
review the covered sectors and distribution channels. Nevertheless, IMS data are useful in 
looking at trends in consumption over time, benchmarking, and relative use of the different 
antibiotic classes. 
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Between 2000 and 2010, total global antimicrobial consumption in humans increased 
by 36% (compared to 19% 1990-2000) and reached 73 billion standard units of the smallest 
identifiable dose in 2010, in which penicillins and cephalosporins accounted for the majority 
of 60% (62). From 2000-2010, antimicrobial consumption was stable or declined in most 
high-income countries. The growth in BRICS countries (Brazil, Russia, India, China and 
South Africa), however, accounted for three-quarters of the total increase in global 
consumption against one-third of overall global population increase in this 10-year period 
(figure 1-5). In the hospital sector, up to 57% of the overall increase was attributable to China 
while 23% of the retail sales increase was attributable to India.  
In 2010, the overall national antimicrobial consumption was highest in India with 12.9 
billion units (10.7 units per person), followed by China with 10 billion units (7.5 units per 
person) and the US with 6.8 billion units (22.0 units per person). Australia and New Zealand 
were two exceptional high-income countries reporting a substantial increase in antimicrobial 
consumption per capita between 2000 and 2010 with corresponding rise from 25 to 87 units 
and 26 to 70 units per person. The reason for this significantly higher consumptions compared 
with European countries is not known. Additionally, there was a significant difference in 
consumption per person across high-income countries with similar economic status. For 
instance, 7.9 units per person in Netherland compared to 23.1 units per person in France. In 
Asia, the high-income countries including Hong Kong, Malaysia, Singapore, and South Korea 
ranked within the top eight nations of antimicrobial consumption per capita.  
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Figure 1-5 Total antimicrobial consumption in selected countries, 2000-2010 
The trend of antimicrobial consumption among nine selected countries between 2000 (grey) 
and 2010 (blue). Total consumption is expressed in standard units.    
(Source: IMS Health MIDAS database)  
Worldwide, there is a significant increase in the global consumption of carbapenems 
(40%) and polymyxins (13%), which are considered “last-resort drugs” for treatment of 
multidrug resistant infections such as carbapenem-resistant Enterobacteriaceae (CRE). In the 
five years from 2005-2010, the highest increase in retail carbapenems sales was observed in 
India, Pakistan and Egypt. Despite the relatively low consumption of carbapenems per 1,000 
inhabitants, Vietnam was also among countries with an increasing trend in the sales of this 
group (figure 1-6) (64). Global consumption of glycopeptides doubled in 2010 compared to 
2000 and has also increased rapidly in European countries for treating MRSA infection (47).  
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Figure 1-6 Carbapenem retail sales in selected countries in standard units per 1000 
population, 2005-2010 (62) 
In Vietnam, available IMS data for the period of the 4th quarter of 2008 to the 3rd 
quarter of 2009 was collected from 439 retail pharmacies and 62 hospitals in 5 major cities 
across the country including Ha Noi, Ho Chi Minh City, Hai Phong, Da Nang and Can Tho 
(65). Considering the number of units sold, the most commonly sold antimicrobials are 
similar in retail pharmacies and hospital pharmacies. Oral cephalosporins (J01D01) are the 
most commonly sold antimicrobials at both pharmacy types, followed by oral broad spectrum 
penicillins (J01C01), macrolides and fluoroquinolones. Important differences between 
pharmacies and hospitals are that the bulk of injectable antimicrobials are sold in hospitals 
and rarely in retail pharmacies. Therefore, the intravenous antimicrobials aminoglycosides 
and carbapenems are dispensed mainly in hospitals and rarely in retail pharmacies. Older 
antimicrobials like chloramphenicol are mostly sold in the retail pharmacy and little in the 
hospital. The sales of polymyxins (e.g. colistin) are negligible, as these drugs are not yet 
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registered in Vietnam for systemic use in drug-resistant infections, even though it is listed on 
the common used drugs list. In term of the value in USD of the sales data, injectable drugs are 
more costly and have a big impact on the treatment budget. Injectable cephalosporins have the 
highest sales value in the hospitals, followed by carbapenems. Also in the retail pharmacy 
injectable cephalosporins become more important when considering the value (figure 1-7). 
These IMS data show a significant increase of global consumption of antimicrobials including 
consumption of carbapenems and polymyxins, especially in low and middle-income 
countries.  
 
 
Figure 1-7 Sales data of antimicrobials in Vietnam (65) 
Lelf two panels: Average sales of antimicrobial per year in USD in retail pharmacy (top) and 
hospital (bottom). Right two panels: Average sold units of antimicrobials in retail pharmacy 
(top) and hospital (bottom). 
1.2.2 Global antimicrobial resistance 
  In 2014, the World Health Organisation issued the global report on surveillance of 
antimicrobial resistance (3). With data obtained from 129 member countries for nine bacteria-
  
 
17 
antimicrobial combinations of public health importance, this report provides a broad picture 
of global situation of antimicrobial resistance. Among 129 reported countries, 114 provided 
data for at least one of the nine selected combinations. Data for all these combinations were 
available in 22 countries. Most data were based on healthcare associated infections. In most 
developing countries where a national surveillance system does not exist, resistance data 
come from individual studies rather than national reports and is therefore incomplete. Due to 
the non-representativeness of surveillance data, results interpretation and comparison should 
be performed with caution. In the report, it is shown that E. coli, K. pneumoniae, and S. 
aureus, which commonly cause community and hospital acquired infections, are the 
pathogens with the largest resistance threat proportions of resistance organisms (3). In five of 
six WHO regions, countries reported E. coli resistance of more than 50% to fluoroquinolones 
and third-generation cephalosporins. In 2013, carbapenem-resistant E.coli was reported in 26 
countries, among them the highest rate was documented in India with 11%, followed by 
Vietnam with 9%. Third generation cephalosporins resistance in K. pneumoniae was more 
than 30% in most WHO member countries and exceeded 60% in some regions (87% in 
Bolivia). The rate of MRSA exceeded 20% in all WHO regions and was even above 80% in 
some regions (47). Other pathogens associated with community acquired infections of high 
global concern included S. pneumoniae, nontyphoidal Salmonella, Shigella spp., and N. 
gonorrhoeae. Resistance rates of 25% or more to penicillin among S. pneumoniae was 
reported in all six WHO regions, and exceeded 40%-50% in some countries. 
  To enable comprehensive monitoring and analysis of the occurrence and trends of 
AMR globally using standardised methodology, in 2015 the WHO has issued the Global 
Antimicrobial Resistance Surveillance System (GLASS) manual to support the Global Action 
Plan on Antimicrobial Resistance (66). This manual describes the GLASS standards for 
collection and analysis of resistance data of a list of important (sentinel) bacterial pathogens 
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in humans to enable data aggregation and sharing at national and international level. 
Pathogens presented above are prioritised for monitoring in this GLASS manual.   
1.2.2.1  Antimicrobial resistance in South East Asia 
National surveillance systems to collect data on antimicrobial resistance have not yet 
been established in most South-East Asian countries (3). Among 11 countries, 6 (Bhutan, 
Korea, India, Myanmar, Nepal and Thailand) have national surveillance systems in place 
(67). However, for selected bacterial pathogens, the available resistance data from these 
systems is insufficient. For instance, data on Shigella species resistant to fluoroquinolones are 
available in only three countries (Vietnam, Nepal and India); MRSA data are available from 
four countries (India, Nepal, Myanmar and Thailand). Other pathogen/antimicrobial 
(“bug/drug”) combinations such as E. coli/3rd generation cephalosporin, E. 
coli/fluoroquinolones; K. pneumoniae/3rd generation cephalosporin; K. 
pneumoniae/carbapenems are available in five out of six reporting countries. These limited 
available resistance data reveal that AMR is a growing challenge in this region. Among 5 
(India, Nepal, Myanmar, Thailand and Indonesia) reporting countries, resistance to third 
generation cephalopsporins among E. coli isolates ranged from 16-68%. Corresponding 
figures for fluoroquinolones were 32-64%. Among K. pneumoniae isolates in 4 (Thailand, 
Myanmar, Malaysia and Philippines) reporting countries, resistance to third-generation 
cephalosporins ranged from 34%-81% while resistance to carbapenems ranged from 0-8%. 
 Based on country’s priorities and resources, participating nations are recommended to 
decide the organisms included on a list of pathogens of global concern to be covered with 
good quality and representative of the population monitored. In the countries where national 
surveillance systems do not exist, GLASS provides guidance in compiling harmonised, 
standardised AMR data for the infections and pathogens of global priority from surveillance 
sites, and in sharing these data to form a global picture.  
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1.2.2.2  Situation of antimicrobial resistance in Vietnam 
Vietnam, having a relatively high burden of infectious diseases, including a large 
portion of bacterial diseases considered treatable with antimicrobials, already experiences 
high levels of antimicrobial resistance (65). Among top ten causes of death, lower respiratory 
infections was the 4th leading cause, killing 25 thousand (4.8%) people in 2012 (68).  Despite 
the absence of a nationwide surveillance program, the following presented figures indicate the 
seriousness of the antimicrobial resistance situation in Vietnam.  
• Vietnam was among three countries having the highest prevalence of erythromycin-
resistant (80.7%) S. pneumoniae, the most common cause of bacterial respiratory 
infections, among the 11 countries in the Asian Network for Surveillance of Resistant 
Pathogens (ANSORP) in 2008-2009 (69).  
• Among 289 S. pneumoniae and 195 Haemophilus influenzae isolates obtained from 
adults and children with community acquired respiratory infections in 11 hospitals 
from a survey of antimicrobial resistance (SOAR 2009-2011), the susceptibility rate 
of S. pneumoniae to amoxicillin/clavulanic acid, cefuroxime, cefaclor and 
azithromycin was 96.9%, 18.7%, 8% and 4.2%, respectively. 40.5% of H. influenzae 
isolates produced beta-lactamase and 13.8% were beta-lactamase negative ampicillin 
resistant (BLNAR) (70). 
• In 2013, carbapenem resistance was also reported in 9% and 22% in all isolates E. 
coli and K. pneumoniae collected from 16 hospitals, posing Vietnam among countries 
with alarming carbapenem resistance rates (47). 
• In 2012-2013, the hospital acquired infections prevalence reported from 16 hospitals 
nationwide accounted for 29.5% (965/3266 patients), among them pneumonia was 
predominant with 79.4% (804/1012). The most commonly detected HAI pathogens  
were Acinetobacter baumannii  (24.4%), Pseudomonas aeruginosa (13.8%), and K. 
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pneumoniae (11.6%), with carbapenem resistance rates of 89.2%, 55.7%, and 14.9% 
respectively (71). 
1.3 Potential control measure to tackle antimicrobial resistance 
1.3.1 Why tackling antimicrobial resistance is essential  
Currently, it’s estimated that antimicrobial resistance attributable deaths are about 
700,000 per year, which is lower than other major causes of deaths such as cancer (8.2 
million), diabetes (1.5 million) and road traffic accidents (1.2 million). However, with an 
ongoing escalation in resistance, by 2050, it is estimated to lead to up to 10 million deaths per 
year, 2% to 3.5% loss in gross domestic product (GDP) and global social costs of up to 100 
trillion USD [102]. Antimicrobial resistance poses an increasing threat to global health and 
has serious medical and economic impacts in all parts of the world however Asia and Africa 
will be continents with the highest estimated burden of AMR with 4,730,000 and 4,150,000 
deaths per year by 2050, respectively (72).  
Because of resistance, treatment of serious nosocomial and community-acquired 
infections is becoming more challenging. If the current situation is not controlled, we might 
return to the pre-antimicrobial era. Also, as a consequence, several high-risk treatments that 
include serious compromise of the immune system like cancer treatments or organ 
transplantation require antimicrobial prophylaxis and may become more challenging. For 
instance, among 416 Spanish patients undergoing kidney transplantations, 58 were infected 
with multi drug resistant (MDR) bacteria, predominantly Gram-negative. Death or graft 
failure was significantly higher among patients infected by MDR bacteria (19% vs. 8 %) (73). 
In India, over 50,000 neonatal sepsis deaths (30% of sepsis mortality) are caused by 
antimicrobial resistance (74). In Tanzania, the mortality rate from resistant Gram-negative 
BSI (43.5%) was more than double that of malaria (20.2%) (75).  Antimicrobial-resistance 
also poses a financial burden to the healthcare systems. In the US, it is estimated that 
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healthcare expenditures and productivity losses including both direct and indirect costs due to 
AMR amounts to about USD$ 20 – USD$ 35 billion annually (76). In the United Kingdom 
(UK), 0.4% to 1.6% of real GDP lost attributed to AMR (77). Despite the lack of global data 
on antimicrobial resistance burden, especially for developing countries without a sufficient 
surveillance system, these data indicate that all continents have to deal with this global issue 
(47, 78).  
1.3.2 Global action plan on antimicrobial resistance 
In 2015, a global action plan on antimicrobial resistance was issued by WHO that 
emphasises the need for more evidence to develop effective policy interventions in the 
struggle against the global problem of antimicrobial resistance, especially in LMICs (79). The 
plan outlines five strategic objectives including: (1) to improve awareness and understanding 
of antimicrobial resistance through effective communication, education and training; (2) to 
strengthen the knowledge and evidence base through surveillance and research; (3) to reduce 
the incidence of infection through effective sanitation, hygiene and infection prevention 
measures; (4) to optimise the use of antimicrobial medicines in human and animal health; 
(5) to develop the economic case for sustainable investment that takes account of the needs 
of all countries and to increase investment in new medicines, diagnostic tools, vaccines and 
other interventions. Along with surveillance and infection control, responsible use of 
antimicrobials is considered the most effective policy area within and between nations with 
different income levels. To optimise antimicrobial use in both human and animal medicine, an 
improvement in the diagnostic technology with effective, rapid and low-cost diagnostic tools 
which are easily integrated into clinical, pharmacy and veterinary practice is required.  
1.3.3 Vietnamese National Action Plan (2013) 
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As bacterial infectious diseases remain common in Vietnam, access to effective 
antimicrobials is crucial. The increasing resistance rates in Vietnam are now jeopardising this 
access, as many antimicrobial regimens advised in current treatment guidelines are unlikely to 
be effective. However, the available information is not well collated and communicated, and a 
‘strong voice’ advocating for action against inappropriate antimicrobial use is needed.  
In 2013, Vietnam became the first country in WHO’s Western Pacific Region to 
approve a national action plan to combat antimicrobial resistance. The plan was developed in 
response to the call from the World Health Organisation to have a timely plan to deal with 
antimicrobial resistance before spring 2017 and largely based on data from GARP situation 
analysis (Appendix D), the National Action Plan outlines steps for implementing actions to 
reach six objectives: (1) Raise awareness of community and health workers on drug 
resistance; (2) Strengthen, improve national surveillance system on the use of antimicrobials 
and drug resistance;  (3) Ensure adequate supply of quality medicines to meet the needs of 
people; (4) Promote proper safe use of drugs; (5) Promote infection control; (6) Promote 
proper safe antimicrobial use in livestock, poultry, aquaculture and cultivation. To date, 
several key activities have been conducted, including (1) Setting up national surveillance 
network on AMU and AMR with adequate reporting system based on existing surveillance 
network of 16 hospitals nationwide; (2) Developing quality standards (QSs) on appropriate 
use of antimicrobials for certain conditions including community acquired pneumonia (CAP) 
and exacerbation of chronic obstructive pulmonary disease (COPD) in Vietnamese hospitals 
(80); (3) Organising a number of One-Health AMR meetings, workshops with multi-
stakeholders and advocacy campaign/events such as AMR awareness week to raise public 
awareness on AMR.  
 The expected outcomes by 2020 include an active national surveillance system; 
strengthened infection control and responsible use of antimicrobials in both humans and 
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animals. Progress towards achieving these outcomes will be led by the Ministry of Health. 
However, sustained, coordinated and complementary efforts of other ministries including 
Ministry of Rural and Agriculture Development, Ministry of Industry and Trade, Ministry of 
Natural Resource and Environment and international development partners are crucial to 
implement the activities and achieve objectives in the National Action Plan. Since a “One 
Health” approach is emphasised as a main mechanism to control AMR, a government-led 
multi-stakeholder and multisectoral engagement and action is required.  
Two years after, four Vietnamese government ministries and foreign development 
partners (including OUCRU) in Vietnam signed an aide-memoire for multisectoral action to 
combat antimicrobial resistance in Vietnam. This engagement takes Vietnam’s AMR 
response forward and commits to coordinate and jointly implement the national action plan 
across different sectors. An antimicrobial awareness week was launched nationwide for the 
first time in 2015 and again in 2016 in an effort to raise awareness among the general public, 
prevent antimicrobial resistance and promote reasonable use of the drug. These efforts 
indicate that the need for policies and interventions to control the use of antimicrobials is 
recognised by the political, medical and pharmaceutical leadership of Vietnam.  
Effective recommendations to alter antimicrobial use must consider the incentives for 
all related stakeholders including manufacturers, providers and purchasers. Mapping and 
addressing of the incentive structures is difficult and requires long-term cooperation between 
local stakeholders and policy makers. Regular review of any intervention is necessary to 
assess whether it has been successful in modifying these incentives and changing behaviour.  
1.4 Vietnam context 
1.4.1 Basic indicators 
The Socialist Republic of Vietnam is situated in Southeast Asia with China, Laos, and 
Cambodia as bordering countries (figure 1-8), Vietnam is approximately 331,000 km² in area, 
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of which three-quarters are mountainous and hilly. The majority of the population (72%) lives 
in rural areas and the remaining 28% lives in urban areas, with an annual urbanisation rate of 
3.03% per year. With a population over 93 million in 2014, Vietnam is the 13th most 
populous country in the world (table 1-2). 
 
 
 
Figure 1-8 Map of Vietnam  
(Source: http://www.naturalearthdata.com/, made by OUCRU Mapping team) 
In the past decade Vietnam has been one of the countries with highest growth. Since 
the initiation of the doi moi reforms in 1986, Vietnam has transformed from one of the 
poorest in the world, with a per capita income of around 100 USD to 2100 USD in the end of 
2015, making Vietnam a lower middle income country (81). Vietnamese children have good 
access to education, resulting in a literacy rate of 93.4% in 2014 compared to 90% in 5 years 
ago. Life expectancy is high compared to other developing nations, with current estimates at 
70.4 years for males and 75.6 years for females.  
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In 2000, 189 UN Member States have agreed to try to achieve 8 Millennium 
Development Goals, which combat poverty, hunger, disease, illiteracy, environmental 
degradation, and discrimination against women, to be achieved by 2015 (82). The Millennium 
Development Goals are now transitioning into 17 Sustainable Development Goals including 
new areas such as climate change, economic inequality, innovation, sustainable consumption, 
peace and justice, among other priorities, to be completed by 2030 (83). Vietnam has made 
good progress towards achieving the Millennium Development Goals (MDGs) with almost all 
the health-related MDGs have already been achieved (84). Overall morbidity and mortality 
have decreased among vulnerable groups like women and young children. Infant mortality 
rate per 1000 live births reduced from 21.6 in 2010 to 19 in 2014 (85). Maternal mortality is 
relatively low at 54/100,000 births in 2015, when compared to some neighbouring countries, 
such as Cambodia where maternal mortality remains high at 161/100,000 or at 197/100,000 in 
Laos (23) (table 1-2). Health spending in Vietnam has increased rapidly and the total 
expenditure as a share of GDP rose from 5.2% in 1995 to 6.9% in 2012 (86).  
The Vietnamese government funds 88% of the Expanded Program on Immunisation 
(EPI) recommended vaccines. As a result, over 90% of Vietnamese children receive the 
recommended vaccinations, including Bacillus Calmette–Guérin (BCG), Diphtheria, 
Pertussis and Tetanus (DPT), Hepatitis B (Hep B), polio, and measles. Vaccination against H. 
influenzae type b (Hib) and rubella have been introduced in EPI since in 2009. Vaccination 
coverage is lower in poorer and remote areas (87, 88). Others such as the pneumococcal and 
influenza vaccine are not scheduled to be introduced through EPI and are currently only 
available commercially in Vietnam. 
There is a deficiency in human resources in health care, with a low ratio of nurses to 
doctors, a lack of specialists and trained managers (89). These shortages in healthcare workers 
are particularly acute in remote areas. For instance, in remote areas, the rate of health care 
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staff with a university degree (doctors-pharmacist) is 4.3 doctors/10,000 inhabitants and 0.2 
pharmacist/10,000 inhabitants. In contrast, in the big cities, this number is significantly 
higher: 9 doctors/10,000 inhabitants and 4.5 pharmacists/10,000 inhabitants (65). While only 
30% of the population living in the urban areas, qualified health workers are mostly 
concentrated here including 82% of total university pharmacists, 59% of doctors and 55% of 
nurses (90).  
Table 1-2 Key health and development indicators in Vietnam 
Indicator Year Number 
Population (millions) 2014 93,4 
Population growth rate (%) 2014 1.03 
Life expectancy (male/female) 2014 70.4/75.6 
Income per capita (USD) 2015 2,100 
Infant mortality rate (per 1000) 2010-15 18.3 
Maternal mortality ratio (per 100,000 live births) 2014 59 
Adult literacy rate (%) 2014 93.4 
Health expenditure (% of GDP) 2012 6.9 
Hospital beds/10,000 people 2014 23 
Doctors/10,000 people 2014 7.8 
Pharmacists/10,000 people 2014 1.96 
Sources: World Health Organisation, World Bank, United Nations, CIA World Factbook (23, 
41, 43) 
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1.4.2 Structure of the healthcare system 
Twenty-five years ago, Vietnam’s health care system was solely supported by the 
central government and the public sector was the only provider of healthcare services. At that 
time, drugs were scarce. To make health care more accessible, the government implemented 
several measures, including: the introduction of user fees at public hospitals, health insurance 
schemes, the legalisation of the pharmaceutical industry, and the deregulation of the retail 
trade in drugs (91). This has transformed the structure of Vietnam’s health care into a mixed 
public-private system, where most drugs are now available at relatively low cost. 
1.4.2.1 The public sector 
The public healthcare system is divided into four levels from central to commune 
(figure 1-9). Each level comprises several units that are responsible for different aspects of 
healthcare services including: (1) medical examination & treatment, (2) primary health care, 
preventive medicine (including vaccination) & National Health targeted Programs (NHPs) 
and (3) population and family planning. At the central level, the Ministry of Health (MoH) is 
responsible for national management of the whole health care system including research 
institutions, medical colleges and 44 national hospitals. At provincial level, there are 63 
health bureaus corresponding to 63 provinces nationwide. Generally, in each province, there 
is a general hospital and a number of specialised institutions. At the lower level, there are 615 
district hospitals, 686 regional polyclinics and 10,926 community health centres in communes 
(90). Commune health centres and regional polyclinics are responsible for primary health care 
delivery and, except for emergencies, are the first point of contact with the public health care 
system. These primary care facilities provide preventive and curative services and refer 
patients to larger centres for more advanced diagnostic and therapeutic services. The 
commune health stations are managed by the District Health Centres (90). In spite of attempts 
to provide care for common conditions at lower levels of the health system, provincial and 
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national hospitals still are preferred sources for accessing inpatient services resulting in the 
overcrowding in these facilities.   
According to social insurance statistics, in 2017, 81.7% of the total population was 
covered by health insurance (92). With the policy that ensures everyone is automatically 
covered from birth, this rate would be expected to reach 100% in 2020. To get health 
insurance reimbursement, patients have to visit their local primary care facilities where they 
are registered (89). Otherwise, they need permission for transferring to higher levels except 
emergencies. Without this permission, health insurance will only cover 40% (at central level) 
to 60% (at provincial level) of total hospital cost. For out-patient health care cost, patients 
have to share 20% co-payment if the cost exceed 200,000 VND.     
 
Figure 1-9 The structure of health care system in Vietnam  
(Source: A health financing review of Vietnam, WHO, 2011(93)) 
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1.4.2.2 The private sector 
Since the market reforms in 1986, more than 100 private hospitals, 30,000 private 
clinics, and 21,600 private pharmacies and distributors have been established (94). These 
private practices play an increasing important role in providing medical services, especially 
for outpatient care. The positive contributions of the private sector to the health system 
include providing more convenient conditions for patients and alleviating the overcrowding in 
the public healthcare facilities. The private sector has been scrutinised due to their insufficient 
quality of service. As profit-oriented facilities, overuse of high technologies and expensive 
medicine has been observed in many instances (95). As the low-cost alternative for the poor 
citizens, there are a number of unlicensed private providers, especially in rural areas, which 
are often out of control of the local authorities (96). With service provided by inexperienced 
practitioners, inappropriate treatment has commonly been reported in several studies (95, 97). 
1.4.2.3 Commune healthcare based system 
The main function of commune healthcare based system is to deliver most primary 
care services and NHPs to the population, especially in rural and mountainous areas. NHPs 
include hygiene, vaccinations, antenatal care, safe delivery and health education. This  also 
provides screening examination, treatment and referrals for outpatients (90).  
Strengthening the commune healthcare based system is a priority in Vietnam’s health 
system development towards universal health coverage (98). With 460 out of 693 districts 
having separate district hospitals for curative care and health centers for preventive medicine 
service delivery and management of commune health stations (CHSs) and 233 district health 
centers perform both preventive and curative care functions, this network covers primary care 
for the whole population (90).  
Nationwide, 99% of communes have a CHS with 78% employing a doctor; 98% of 
CHSs have midwives or obstetric/pediatric assistant doctors; 78% of villages and urban 
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neighborhoods are served by village health workers, in rural and mountainous areas this 
reaches 95%. Along with the increase in the number, the quality of health workers has also 
improved. The proportion of staff with university or higher education in districts and 
communes has increased from 17% in 2000 to 21.3% in 2013. Nevertheless, there is still a 
shortage of health workforce and inadequate training to meet current needs with 
disproportionate distribution of health workers between urban and rural areas (99). 
Accounting for only 28% of the total population, 59% of doctors and 82% of pharmacists 
serve urban facilities.  
The quality of treatment services is poor and unmanaged at the commune level. Apart 
from the inadequate facilities, equipment and medicines, the limited expertise of health 
workers at CHSs is considered a critical factor for CHS service quality (100) This is one of 
the factors that leads to hospital overcrowding at higher levels. Among patients coming to 
central hospitals, 54 – 65% have diseases and health conditions that are diagnosable and 
treatable at the lower levels.  
1.4.3 Access to healthcare  
Access to healthcare through high granularity is one of the strengths of the Vietnamese 
healthcare system (90). With above limitations of the commune healthcare based system, the 
poor and those with health insurance use the commune health centres more regularly than the 
more wealthy citizens (91). Still, the richer households account for a larger share of the health 
services provided than poorer households. Since free health care was abandoned, health 
seeking behaviour has changed extensively: private healthcare facilities provide the rich with 
greater access to more and better health services while the poor often access to medicines via 
self-medication or private pharmacies. Self-medication is cheaper and less time consuming 
than visiting a health care provider. A study showed that the average household expenditure 
per episode of illness for self-treatment is 19,616 VND, for private providers 35,206 VND, 
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and for public providers 95,795 VND (91). There is still 18.3% of the total population that are 
not been covered by health insurance (92). This explains the preference for self-medication, 
but results in high numbers of inappropriate drug use. 
1.4.4 Legal framework of antimicrobial dispensing   
The most important law regarding antimicrobial use is the Drug Law of 2005 (101). 
The goal of this law was to improve appropriate antimicrobial use by permitting 
antimicrobials to be dispensed only with a prescription. This law also requires the patient to 
comply with the prescription strictly, to provide feedback to prescribers, and to report any 
side effects. Furthermore, this law prohibits advertisements for prescription-only drugs, like 
antimicrobials. For the outpatient setting a specific law has been developed in 2007 
(Regulation No 04/2008/QD-BYT), and adjusted in 2016 (Circular No 05/2016/TT-BYT) 
regulating prescription for outpatients. Only doctors working in legal health care centres and 
as an exception, assistant doctors in remote areas, can be delegated to prescribe. The 
prescribers are allowed to prescribe after a medical examination and are responsible for their 
prescription. Interestingly, this law also states that the prescriber should ‘not prescribe to 
satisfy the irrational requirement of the patient’. A prescription is valid for five days after it is 
signed by the prescriber. Despite these laws and regulations, most drug sellers continue to sell 
antimicrobials freely, without a prescription. Currently, there is no sanction for not complying 
with regulations regarding selling prescription-only drugs without a prescription. This may 
explain why to this moment no pharmacy has been penalised for antimicrobial dispensing 
without prescription.  
In 2007, a regulation to improve the quality of pharmacies was issued and re-stated in 
the Circular 46 in 2011 on implementing Good Pharmacy Practice (GPP). GPP requires the 
pharmacy to have proper facilities (area, drug storage), to supply of high quality healthcare 
products, record drug consumption, and not to sell prescription drugs without a prescription. 
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Furthermore, the responsible pharmacist should have a presence at their drugstore, in case 
patients need a consultation. Pharmacists will become part of providing health information to 
their clients, besides a quality drug provider. As a requirement of Ministry of Health, attaining 
GPP status is compulsory for all pharmacies that want to dispense prescription-only drugs. 
Pharmacies without GPP certificate are allowed to dispense over-the-counter drugs only.  
As of 2013, all of Vietnamese pharmacies are supposed to have implemented measures to 
attain GPP certificated. In the big cities like Hanoi, all pharmacies are GPP certificated (3644 
GPP pharmacies) and 98% pharmacies in Ho Chi Minh city (2286/4550) while the rate is 
much lower than 50% in remote areas (102). However, GPP only bring improvement in 
facilities (area, drug storage), but not in dispensing practice including compliance with the 
prescription regulation.  
1.4.5 The reasons for inappropriate antimicrobial usage 
Causes of inappropriate antimicrobial prescription are the same as in other countries 
including perceived expectations of patients, time constraints, lack of knowledge, lack of 
diagnostic capability, and financial benefits for the prescriber. Limited knowledge amongst 
consumers, drug sellers and pharmacists about the value and risks of antimicrobials is part of 
the problem but there are also financial incentives to sell antimicrobials and immediate 
personal benefits in taking antimicrobials that outweigh the future societal risks. Even within 
the health care sector, limited knowledge regarding appropriate indications for antimicrobial 
treatment, limited capacity for laboratory confirmation of a bacterial cause of infection, and 
incentives to prescribe have led to the widespread inappropriate prescribing of antimicrobials. 
A major challenge is to identify and modify the incentives for inappropriate prescribing. 
Furthermore, the high out-of-pocket expenditure in Vietnam forces patients to seek health 
care in the cheapest way. Therefore, both health care workers and the public in Vietnam need 
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to be targeted with appropriate interventions to enable changes in their behaviour and 
incentives (103).  
1.5 Biomarker guided antimicrobial use – a potential control measure  
1.5.1 Biomarkers in acute infections 
 There are a number of biomarkers, proteins or components of the immune system, that 
act as an acute reactant to infection/inflammation (104-107). These have been studied as 
potential substances to facilitate rapid diagnosis and guide therapeutic decisions (e.g. 
antimicrobial prescription) in acute infections (108). Currently, several tests have been 
developed that allow to diagnose infections by testing for the presence of several biomarkers 
(109). In the correct clinical context these tests could have an additional diagnostic value to 
assist prescribers in identifying patients with infections that are more likely to respond to 
antimicrobial treatment and therefore, reduce unnecessary use of antimicrobials. 
1.5.2 C-reactive protein (CRP) 
C-reactive protein (CRP), a 24kDa protein, is an acute phase reactant produced by 
hepatocytes. It was first detected in serum of patients with pneumonia (110). Its name is 
derived from the reaction with C-polysaccharide in pneumococcal cell walls. CRP can also 
bind to chromatin in nuclear DNA-histone complexes. Once bound, it is able to activate the 
classical complement pathway. Acting as an opsonin, CRP flags up pathogens and damaged 
host cells for phagocytosis by binding to ligands on their cell surfaces (111). Increased 
production of this protein is triggered by pro-inflammatory cytokines released by infection or 
tissue damage such as tumor necrosis factor (TNF)-α, interleukin (IL)-1and IL-6 which are 
involved in protecting against bacteria (112). These cytokines are produced in the initial 
phases of the bacterial infection, stimulating neutrophils and macrophages to destroy bacteria. 
In the initial phase of viral infections, however, controlling the infection is done by type I 
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interferons (IFN-alpha and beta), macrophages and natural killer (NK) cells (113). CRP levels 
thus increase in bacterial infections and generally elevates much less or not at all in response 
to viral infections due to the virus-stimulated synthesis of α-interferon by macrophages, 
which, in turn, inhibits TNF synthesis. Therefore, it may be used to distinguish bacterial 
infections from viral infections. 
1.5.3 Mechanism of changes in CRP levels and clinical applications 
Normally, CRP is present at very low serum concentrations of less than 3 mg/L. In the 
presence of infection, transcription of CRP is rapidly induced by pro-inflammatory cytokines 
and serum concentration can rise 1000-fold (up to 500 mg/L) within 24-48 hours in cases of 
severe infection (114, 115). Transcription is also rapidly switched off after the acute phase 
response has subsided. Posing moderate specificity (70%) and high sensitivity (86%), an 
elevated CRP value provides a valuable addition to careful clinical and laboratory assessment 
in differentiating viral or self-limiting from bacterial infections and making a decision 
whether a patient requires antibiotic treatment (116). Except deranged liver function, very few 
factors interfere with CRP production. CRP concentrations are unaffected by anaemia, 
immunoglobulin levels, age or sex. During pregnancy, CRP levels will be higher in the 
second and third trimester (117-119). These characteristics make it a suitable biomarker for 
the presence of an inflammatory / infectious process – a process that may benefit from 
antimicrobial intervention. Other clinical applications of CRP include screening for early 
onset of sepsis in neonates (120) and monitoring response to (long-term) antimicrobial 
treatment (121, 122).  
1.5.4 Alternative biomarker – Procalcitonin  
Among other alternative biomarkers, PCT has been the most studied and found to be a 
promising biomarker (107, 123). PCT has been shown to have higher diagnostic accuracy 
compared to CRP with higher sensitivity (88% vs 75%) and specificity (81% vs 67%) in 
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differentiating bacterial from noninfective causes of inflammation among patients 
hospitalised for suspected bacterial infections (116). This result has been supported in a recent 
prospective study investigating the diagnostic value of PCT, CRP, IL-6 and SAA for bacterial 
infection in 326 febrile adult patients. At the cut-off value of 0.26 ng/ml, PCT was shown to 
be superior to CRP, IL-6 and SAA in early diagnosis of bacterial infection with areas under 
the curve (AUC) of 0.804, 0.693, 0.658 and 0.687, respectively (124). However, other 
prospective studies conducted in Cambodia, Laos and Thailand in febrile patients yielded 
conflicting result by showing that CRP had higher AUC in discriminating between bacterial 
and viral infections than procalcitonin (AUC 0.83 (0.81–0.86) compared with AUC 0.74 
(0.71–0.77), p < 0.0001). At a threshold of 10 mg/L, CRP had a higher sensitivity (95% 
versus 90%) and specificity (49% vs 39%) in detecting bacterial infections compared to PCT 
at a low threshold of 0.1ng/ml. At a threshold of 20 mg/L sensitivity and specificity of CRP 
was 86 % and 67 %, respectively compared to 60% and 76% of PCT cut-off 0.5 ng/ml (125).  
1.5.5 Biomarkers for optimising antimicrobial therapy for in-patients 
Among a number of biomarkers which have been studied in acute infections, only CRP 
and PCT have been evaluated well enough to use in daily practice for optimising 
antimicrobial therapy (126-128). Other biomarkers are not suitable (yet) because of a poor 
performance, limitations in result interpretation, studied in too small population (<50 patients) 
or too few studies (108, 129).  
CRP has been tested in various conditions such as sepsis, CAP or COPD, but only few 
focused on optimising antimicrobial therapy (127, 130, 131). An individual, prospective, 
randomised, controlled trial was conducted in 176 newborns with sepsis (131). Findings 
showed that the mean treatment duration was significantly lower in the CRP-guided group 
with 3.7 (median, 4; range 3 to 6) days versus 5.5 (median, 5; range, 5 to 7) days in control 
group (p<0.05). It was concluded that CRP could be a key indicator to shorten the duration of 
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antimicrobial therapy in a subgroup of newborns with suspected bacterial infection. In another 
study, in 22/50 (44%) consecutive neonates with suspected septicemia antimicrobial therapy 
was stopped on 3rd day as CRP was normal (£ 10 mg/L) (130). In 4/50 (8%) patients, 
antimicrobials could be stopped within 5-7 days as CRP values returned to normal and in 
24/50 (48%) duration of antimicrobial treatment was extended beyond 7th day, as CRP values 
were high or rising persistently. The correlation between CRP, raised micro ESR and positive 
blood culture was significant (p < 0.005). Among 100 infants with suspected sepsis, 99 were 
correctly identified by the repeat CRP estimation as not requiring further antimicrobial 
treatment (negative predictive value, 99%; 95% confidence intervals, 95.6 to 99.97%) (127). 
A recent validation study showed the diagnostic value of a host-protein based assay 
combining CRP and two other biomarkers (tumour necrosis factor-related apoptosis-inducing 
ligand (TRAIL) and interferon gamma induced protein-10 (IP-10)) in differentiating bacterial 
and viral infections among hospitalised children under five years-old with LRTIs (132). The 
assay showed higher sensitivity of 86·7% (95% CI 75·8–93·1) and specificity of 91·1% (87·9–
93·6) than CRP in distinguishing bacterial from viral infections among 577 patients aged 2-60 
months with lower respiratory infections or fever. However, incorporation bias could not be 
excluded as the assessed assay is included in the reference standard resulting in 
overestimation of the outcome. Additionally, the test was not superior to CRP in bacterial 
infections diagnosis (p=0·321) indicating that two additional substances did not significantly 
improve diagnostic accuracy compared with CRP. Despite the few available studies 
confirming its usefulness, this approach has the potential to optimise antimicrobial therapy. 
Compared to CRP, PCT has been more widely tested for optimising antimicrobial 
therapy in both children and adults. To date, 12 randomised, controlled studies using a similar 
approach have been published and provide consistent results (133-144). All these studies have 
used a similar algorithm to help decide on the initiation and continuation of antimicrobial 
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therapy, with a lower PCT threshold of <0.25 ng/mL to encourage physicians to withhold 
antimicrobial prescription (145). The absolute risk reduction of antimicrobial administration 
varies between 11% and 72% across these studies compared with “usual care” based on local 
recommendations and physicians’ judgment and preferences. In view of currently available 
data, PCT is superior to CRP in optimising antimicrobial therapy. Nevertheless, as of now 
PCT is an expensive test (10$) as compared to CRP test (below 3$) and a rapid diagnostic test 
at the point of care is not available, restricting its wider use in developing countries (107, 
116). Efforts are being put in the development of point-of-care testing which allow rapid 
diagnosis at the bedside and the development of new methods, such as the analysis of gene 
expression (genomics) or of ribonucleic acid (RNA) which allow to identify new markers for 
better diagnosis, stratification of prognosis, and targeting antimicrobial therapy (146).  
1.5.6 CRP rapid diagnosis test in primary care in high-income settings for out-patients 
To date, there are three individual randomised controlled trials (RCT) and three cluster-
RCT (3284 patients including 139 children) evaluating use of point-of-care C-reactive protein 
test in guiding antimicrobial prescription versus standard care in primary care patients with 
acute respiratory infections (ARIs) in high-income countries (147). Four trials have used a 
similar algorithm with a CRP cut-off of <20 mg/L to encourage physicians to withhold 
antimicrobial prescription (148-151). A lower CRP threshold of <10 mg/L has been used in 
one study to delay antimicrobial prescription (152). The remaining study used a higher CRP 
cut-off of <50 mg/L to adjust the treatment decision (153). An overall reduction in 
antimicrobial prescription was found in the the C-reactive protein guided groups compared to 
standard of care with a pooled effect estimate risk ratio (RR) of 0.78 (95% confidence interval 
(CI) 0.66 to 0.92). However, a high level of heterogeneity (I2 statistic = 68%) was found due 
to difference in study design. Separately, cluster-RCTs have yielded higher effects with RRs 
of 0.68, 95% CI 0.61 to 0.75; I2 statistic = 0% compared to RRs of 0.90, 95% CI 0.80 to 1.02; 
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I 2 statistic = 5% for individual RCTs. A difference in clinical recovery was not found though 
an increased risk of hospitalisations in the C-reactive protein guided group could not be 
excluded. Findings from these trials showed that point-of-care CRP testing significantly 
reduced antimicrobial use without affecting patient-reported outcomes although the degree of 
reduction remains uncertain (147).  
Currently, point-of-care CRP tests are used as standard practice in primary care in some 
Scandinavian countries in patients with respiratory symptoms and have reduced the use of 
antimicrobials safely and cost-effectively (154, 155). Extending this strategy to other settings 
could reduce the unnecessary use of antimicrobials and curtail the spread of drug resistance. 
In low  and middle income countries this is particularly important as second line 
antimicrobials can be unaffordable. Before implementation in resource constrained settings, a 
more precise effect estimate is needed to assess the costs of the intervention and compare the 
use of a point-of-care biomarker to other antimicrobial-saving strategies. 
1.6 Objectives of this thesis 
To develop community-based interventions that may be used to improve antimicrobial 
consumption in Vietnam, which in turn will slow down the development of antimicrobial 
resistance, understanding the current situation of community level antimicrobial access and 
use and assessing potential control measure is of the essence. Therefore, I propose the 
following research questions: 
1. What are the financial and behavioural incentives driving antimicrobial dispensing in 
the community? 
Since the market reforms in Vietnam, many private pharmacies now exist, with easy 
public access to medicines as a result despite legislation preventing this being in place. The 
knowledge of the drug sellers is poor and drug dispensing is generally inappropriate. 
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Appropriate antimicrobial selling will reduce antimicrobial sales and therefore have an impact 
on pharmacy profits. To enable to develop effective strategies it is important to understand the 
magnitude of the profitability of antimicrobial sales in rural and urban pharmacies as well as 
other main drivers supporting current community antimicrobial practices from two aspects: 
supply and demand. 
2. Can a Point-of-Care diagnostic, C-reactive protein (CRP) test, reduce antimicrobial 
prescribing for acute respiratory infections (ARI) safely in the primary care setting, and 
to what extent? 
Effectiveness and safety of point of care (POC) C-reactive protein (CRP) in reducing 
unnecessary antimicrobial use have been proven in high-income countries (147, 155). 
However, no similar trials have been investigated in LMICs where inappropriate access and 
antimicrobial resistance is among the highest. Different social, clinical and environmental 
factors may affect its impact and impact may thus be different in LMICs. Therefore, in order 
to reduce inappropriate community antimicrobial prescribing safely in these settings, it is 
necessary to confirm its effectiveness and safety in resource constrained settings. Findings 
from this study will be the basis for further extension to the dispensing channel in settings 
where antimicrobials are commonly dispensed over the counter.   
3. What is the economic impact of POC CRP test to reduce antimicrobials use in a lower 
middle income country (LMIC) setting of Vietnam? 
In poor countries with low health system capacity, it is important to select interventions 
that require relatively little resources. Therefore, diagnostic interventions aimed at improving 
antimicrobial stewardship should meet acceptance in the healthcare system regarding their 
cost-effectiveness. Current evidence that POC CRP is cost-effective is limited (155-157)  
More accurate estimates of the economic impacts of POC CRP strategy compared with 
standard of care from a health care perspective is crucial to guide future investment, 
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especially in LMICs.  
4. What is the acceptance of using a CRP test among patients and health care workers in 
the community setting? 
Uptake of new technology in clinical practice is challenging and dependent on opinions 
of healthcare workers and patients about importance and feasibility of the proposed 
interventions (158). Previous qualitative studies assessing the acceptance of POC CRP test 
conducted in European countries only included healthcare providers. An understanding of 
both patients and healthcare providers’ views and experiences of using proposed intervention 
in practice is helpful to access the feasibility and acceptability of the intervention, which 
inform implementation in a wider scale. 
To address the research questions above, I conducted four studies to achieve four 
specific objectives as follow: 
1. An observational study to assess antimicrobial sales in private pharmacies to identify 
the economic and behavioural incentives for antimicrobial dispensing in urban and 
rural pharmacies in northern Vietnam (Chapter 2) 
2. An open-label randomised controlled trial to evaluate the efficacy and safety of the 
point-of-care C-reactive protein test in reducing unnecessary antimicrobial prescribing  
for acute respiratory infections in ten primary healthcare centres (Chapter 3) 
3. A health economics analysis to evaluate the economic implications of C-Reactive 
Protein point of care testing in the management of acute respiratory infections in the 
Vietnamese primary health care setting (Chapter 4) 
4. A qualitative study to assess the acceptance of C-reactive protein POC testing among 
patients and health care providers in the same community settings (Chapter 5).  
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Chapter 2 
Antimicrobial sales in rural and urban private pharmacies in northern Vietnam: an 
observational study 
2.1 Background  
Pharmaceutical products are indispensable for the treatment and prevention of diseases. 
In developing countries the demand for health care has increased. In Vietnam, health 
expenditure accounted for 7.1% of GDP in 2014, compared to 6.2% in 2011 (85). Household 
direct out-of-pocket health expenditure as a share of the total health expenditure ranged from 
50% to 70% (159). Pharmaceutical spending shared a large proportion of total health 
expenditure with 50.9% compared to 8.8% in Malaysia (160). The per capita annual 
expenditure on pharmaceutical products in Vietnam in 2010 was $104 compared to $148 in 
China and $51 in India (161). The majority of the drug costs are incurred at drug retailers. 
Since the market reforms in 1986 in Vietnam, 21,600 private pharmacies now exist, with easy 
access to medicines as a result. The private pharmacies also provide consulting for customers 
about drug use but the knowledge of the drug sellers is poor and drug dispensing is generally 
inappropriate (162). In 2011, the Ministry of Health has issued a circular on the ‘principles 
and criteria of implementing good pharmacy practice (GPP)’ to enhance the service quality of 
pharmacies (163). However, the impact of GPP in dispensing practice remains largely 
unknown.  
Since their introduction in 1940s, antimicrobials have revolutionised modern healthcare 
and together with vaccines have had the highest impact on human health of all drugs. 
However, their effectiveness has been threatened by the development of antimicrobial 
resistance. Both appropriate and inappropriate use of antimicrobials is a key driver of 
antimicrobial resistance development. However, overuse or misuse of antimicrobials (e.g. low 
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dose, too short duration, or treatment of self-limiting infections) provides an avoidable 
additional pressure leading to more antimicrobial resistance (164). In many countries 
inappropriate use of antimicrobials is common practice in the community setting, where 
antimicrobials are readily dispensed for self-limiting upper respiratory tract infections without 
a prescription (165-168). To slow down the development of antimicrobial resistance, an 
important control strategy is to reduce the inappropriate use of antimicrobials in both 
community and hospital settings. The incentives behind inappropriate antimicrobial 
dispensing need to be fully understood, so intervention strategies can be developed based on 
that knowledge.  
In Vietnam, health seeking behaviour has changed since market reforms that were 
initiated since 1980s. User fees at public hospitals, health insurance schemes, the 
commercialisation of the pharmaceutical industry, and the deregulation of the retail trade in 
drugs have led to significant but also uncontrolled improvements in the quality and 
accessibility of health care. However, they have also increased out-of-pocket health 
expenditures as a proportion of total health expenditure. The high out-of-pocket expenditures 
encourage people to bypass the health care system, and obtain medicines – including 
antimicrobials – directly via self-medication or private pharmacies without proper diagnosis 
(91, 169). According to one study in 2002, the average household expenditure per episode of 
illness is 1.1 USD for self-treatment, 1.9 USD for private providers, and 5.2 USD for public 
providers. The relative higher costs of the health care system explains the preference for self-
medication, which results in many cases of inappropriate drug use (91).  
Even though prescriptions are legally required, antimicrobials (and a wide range of 
other drugs) can be purchased directly by consumers at pharmacies or drug outlets (170). 
Self-diagnosis is not accurate, but self-treatment is common. Previous studies have shown 
that most antimicrobials are sold without prescription. According to a community-based study 
  
 
43 
undertaken in 1999, 78 percent of antimicrobials were purchased in private pharmacies 
without a prescription. 67 percent of the participants consulted the pharmacist while 11 
percent decided themselves about antimicrobial use (171). Only 27 percent of the pharmacy 
staff had correct knowledge about antimicrobial use and resistance (162). Reportedly, 
prevalence of self-medication with antimicrobials through private pharmacies in rural 
Vietnam is 80%, and is even higher in children with 88% of the children receiving self-
medication before hospital visit (172). These results raised concerns about drugs being sold 
without prescriptions and the common practice of self-medication. Judicious use of 
antimicrobials can decrease unnecessary adverse effects of antimicrobials as well as out-of-
pocket costs to the patient. But more importantly, decreased antimicrobial usage will help 
delay the rise of drug resistant bacteria, which is now a growing world-wide public health 
problem (173). 
As other countries in the region, the development and spread of antimicrobial 
resistance is increasing in Vietnam. In order to improve this situation, one of the most 
important policies is to raise awareness by providing information training about appropriate 
antimicrobial use, especially those who sell drugs, "who directly deliver drugs to patients". 
Appropriate antimicrobial selling will reduce antimicrobial sales and therefore have an impact 
on pharmacy profits. To enable to develop effective strategies it is important to understand the 
magnitude of the profitability of antimicrobial sales in rural and urban pharmacies. 
The present study aims to understand the economic and behavioural incentives that 
support inappropriate dispensing of antimicrobials at private pharmacies in urban and rural 
settings in Vietnam. This is crucial for designing effective interventions to reduce the 
inappropriate antimicrobial use in the community. 
2.2 Materials and Methods 
The WHO Operational package (174) provides a range of indicators, which can be 
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studied at the national level of countries to evaluate three dimensions of pharmaceutical 
services: access, quality and rational use. We adhered to the recommended indicators as much 
as possible and adjusted when needed for geographical areas and pharmacies selection, 
observation time and supervision of data collection. 
2.2.1 Study sites and selection of pharmacies  
  The study was conducted at two well-established demographic surveillance sites (DSS) 
in the Hanoi region in 2010 (figure 2-1).  As the study aims to understand the situation of 
antimicrobial dispensing at private pharmacies in both urban and rural settings in Vietnam , 
one urban (Dong Da) and one rural (Bavi) district were selected. Bavi is a rural community 
situated 60 km west of Hanoi. The district covers an area of 410 km2 and has 262,000 
inhabitants. Agriculture is the main source of income. Bavi district is heterogeneous in terms 
of geographical characteristics and representative for rural settings in and around Hanoi. The 
basic health care system includes a district hospital with 150 beds, 3 regional polyclinics, 32 
commune health stations, and 90 licensed private health facilities including private clinics, 
pharmacies, drug stores and drug outlets (175). Dong Da is the biggest urban district of Hanoi 
that covers an area of 10 km2 and has 352,000 inhabitants, with a public health care system 
including a district hospital with 300 beds, 3 regional polyclinics, 1 antenatal clinic, 21 
commune health stations and 278 private pharmacies located in this district (176). With these 
characteristics, Dong Da district is considered a typical urban district in Hanoi.  
  There are two demographic surveillance sites (DSS) in these districts (FilaBavi and 
Dodalab) with well-established relationships between the healthcare system and the study 
teams. These features made it possible for invited pharmacies to participate in the study and 
to respond to sensitive issues such as the financial mechanism, including profits and drug 
management.   
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Figure 2-1 Location of study sites 
Observed pharmacies located in Ba vi district (red) and Dong Da district (blue) 
Private pharmacies in each site were randomly selected from a government pharmacy 
registry, using the Excel random number function for the rural and urban settings. To assess 
the situation of self-medication in the community, outlets directly surrounding hospitals were 
excluded in this selection. The randomly selected pharmacies were approached sequentially 
based on ascending random number allocation to get permission to participate until 15 shops 
in each site were reached. Two urban pharmacies refused to participate, no refusals occurred 
in the rural setting. All pharmacies that agreed to participate in the study allowed observers in 
their pharmacy during three days to observe and record drug sales and prices. 
2.2.2 Sample size  
 One of the major areas of focus in this cross-sectional study was the selling of 
antimicrobials without a prescription and the revenue of antimicrobial sales as compared to all 
sales. Based on previous work we expected 80% of customers to buy antimicrobials without a 
Dong Da 
district 
Ba Vi 
district 
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prescription (177). With α=0.05, Z1-α = 1.96 and a precision of d=5%, we calculated that at 
least 246 drug transactions needed to be observed. In a pilot study, we observed that there 
were approximately six antimicrobial transactions per pharmacy per day in a rural pharmacy. 
Due to the limited number of observers, we selected 15 stores in each setting to be observed. 
To capture the estimated number of expected antimicrobial transactions, it’s needed to 
observe each drug store in 3 consecutive days (3 days x 15 stores x 6 transaction/day = 270 
transactions). We selected an equal number of urban and rural pharmacies to facilitate 
comparison although urban sales are expected to be considerably higher.  
2.2.3 In-pharmacy observation 
 During three consecutive days from 9AM to 5 PM during opening time of the 
pharmacy, investigators observed and recorded all information related to pharmacy and drug 
selling practices onto data capture forms. The forms captured the following basic pharmacy 
data: facilities, number of staff and education level, presence of Good Pharmacy Practice 
(GPP) certificates, and presence of pharmaceutical guidelines. Pharmacies that have a GPP 
certificate are required to ensure a supply of high quality healthcare products and deliver 
sufficient information and advice to the consumer. The GPP policy also requires pharmacies 
to have proper facilities (area, drug storage), and comply with prescription regulation.  
 For the observation of drug transactions, we captured the following information: 
gender, estimated age of customer, indication for buying drugs (coded according to the 
International Classification Primary Care – ICPC edition 2), presence of a prescription, 
compliance to prescription, and any advice provided by drug seller. In cases in which a 
prescription was provided we checked whether the drug on the prescription was substituted by 
another drug with a different generic name or a different content/concentration than on the 
prescription was dispensed or a different dosage/duration than on the prescription was 
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dispensed. In case any of the above was done, we then determined that there was non-
compliance with the prescription. 
 A “drug transaction” in this study included the purchase of any drug or other items 
present in the pharmacy (e.g. herbal medicine, cotton wools, band aid, etc.). Purchased drugs 
were recorded according to brand name, which was subsequently recoded into the 
corresponding generic name and Anatomical Therapeutic Chemical (ATC) Classification 
System (178). For each drug we also recorded the origin, unit, dosage, and selling price.  
 The observers included pharmacists who recently graduated from Hanoi Pharmacy 
University, master pharmacy students, and trained field workers. They were trained in 
observation skills, interview skills and how to complete the capture forms by senior and 
experienced investigators. The training included presentation and explanation of the study, 
discussion, interaction and case practice by acting as drug sellers/owners and interviewers. 
Furthermore we performed a pilot in two pharmacies (one in urban, one in rural) to test the 
questionnaire and revise if needed. The pilot pharmacies were not selected for the real 
observation. 
 The pharmacist/seller was informed that the observation would be for all drug sales, 
and thus not antimicrobials specifically, to reduce any potential biases by the observation. The 
observations were supervised and randomly checked by supervisors. At the end of each 
observing day, supervisors collected the forms and were checked for completeness. Bigger 
pharmacies had two observers present. Pharmacy customers were not interviewed by the 
study staff. All data capture forms and questionnaires were designed in the English language 
and send for peer review to experts in the field. The revised version was then translated into 
Vietnamese and piloted in a rural and urban pharmacy. 
2.2.4 Post-observation questionnaire  
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After the observation, one drug-seller and one pharmacy owner per pharmacy were 
asked to complete a semi-structured questionnaire that focused on antimicrobial sales and 
their opinions about important causes for irrational antimicrobials dispensing in their region. 
Answers were provided on a 5-point rating scale which is named “likert scale” after its 
inventor, psychologist Rensis Likert: “1=strongly disagree” to “5=strongly agree” (179). 
There are three general indicators to estimate reliability (180) including: (1) stability or test-
retest reliability which is the consistency of a measure evaluated over time,  (2) internal 
consistency reliability which the consistency of results across items or set of scale, often 
measured with Cronbach’s alpha, (3) interrater reliability (also called inter-observer 
agreement) is the degree to which different observers give consistent answers or estimates. In 
my analysis, to assess the reliability of survey responses, Cronbach’s alpha was analysed with 
respondents’ scores for all questionnaire items by SPSS. It is a measure of the internal 
consistency of a set of scale or test items, expressed as a number between 0 and 1 with values 
above 0.7 being acceptably consistent (181). All forms were anonymous to encourage 
interviewees to frankly share information. In total, 43 informants attended this survey 
including 26 respondents in urban pharmacies and 17 in rural site. Among them, 4 
respondents in urban and 13 in rural were both pharmacy owners and sellers. 
2.2.5 Qualitative assessment  
2.2.5.1 Rationale for choosing qualitative research  
 Qualitative research methods have become more common in health services related 
research (182). While quantitative research aims to analyse phenomena in terms of trends and 
frequencies, qualitative research seeks to determine the meaning of a phenomenon through 
description and thus enables to answer questions that may not be easily answered by 
quantitative data (183). The advantage of qualitative research is that it is able to provide a 
comprehensive description of an issue relating to personal behaviors, beliefs, opinions, 
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emotions, and relationships of individuals. Qualitative research seeks answers about: (1) why 
people behave the way they do; (2) how opinions and attitudes are formed; (3) how people are 
affected by the contextual factors; (4) what are the differences between studied populations. 
In combination with quantitative methods, qualitative research can aid to interpret and deepen 
insight into the studied phenomenon (184). Therefore, to investigate behavioural incentives, 
qualitative methods including focus group discussions (FGD) and semi-structured in-depth 
interviews were used to better explore experiences and opinions of the drug sellers and 
pharmacists, as well as their perceptions of the factors that impact on inappropriate 
antimicrobial dispensing.  
2.2.5.2 Methods of collecting qualitative data  
Data collection methods in qualitative research aim to systematically collect 
information about study objects including people or phenomena and about the settings in 
which they occur. There are three main approaches to collect qualitative data including: (1) 
observations, (2) textual and visual materials review and (3) interviews (individual and group) 
(185). Among these methods, individual interviews and focus group discussions are the most 
commonly used in qualitative healthcare research to assess a set of personal beliefs, habits, 
opinions of those participating in the discussion as well as perceptions in the studied 
population that they represent (186).  
a. Individual interviews 
This method consists of three fundamental types: structured, semi-structured and 
unstructured interviews (186, 187). In structured interviews, the interviewer follows a 
structured questionnaire, which includes a list of predetermined questions to be asked. 
Structured interviews are therefore relatively quick and easy to conduct. However, its 
limitation is that there is little or no chance for follow-up questions to be further investigated. 
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Consequently, it does not allow the evaluator to assess the “depth” of an issue. Conversely, 
unstructured interviews, in which a formal interview schedule or question order is not 
provided encourage the interviewers to seek for free and open responses (188). It allows the 
interviewer to be flexible in conducting the interview to particular respondents or situations. 
Respondents are also encouraged to express perceptions in their own words which allow to 
capture the meaningfulness of their experience and warrant in-depth exploration. 
Disadvantages of this method are that it is relatively resource and time consuming, difficult to 
manage and it requires well-trained interviewers. Inconsistencies can be induced due to 
allowed flexibility resulting in interpreting bias.  It is generally used when significant “depth” 
is required or nothing is known about the explored subject. Semi-structured interviews with a 
set of key questions help to define the aspects to be investigated (189). This format provides 
useful guidance to respondents on what they should talk about. Unlike structured interviews, 
this format also allows further discovery with follow-up questions to warrant “depth” of 
information. Therefore, it is most commonly used in healthcare related research. In my thesis, 
I chose the semi-structured interview format to facilitate individual interviews. 
b. Focus group discussion 
 With similar features to less structured interviews such as depth and insight, this 
technique is used to generate information on collective opinions (190). Compared to 
individual interviews, its advantage is that a broader scope would be quickly obtained about 
the topic in focus and providing a good chance for debate and discussion between participants 
(191, 192). In this techniques, a monitor or facilitator who guides the discussion plays a 
crucial role (193). The moderator should be able to ensure that all respondents have an equal 
chance to contribute and avoid bias the situation by personal opinions. Participants are 
encouraged to share their own experience and knowledge on a few predetermined themes 
allowing differences of opinions to be discussed. However, transcription of FGDs is more 
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complex and time consuming than individual interviews. FGDs should be avoided if 
participants are uncomfortable to openly exchange their views with each other as interaction 
is key to a successful discussion. Group composition is an important feature in FGDs because 
this affects the quality of discussion and outcomes (194). There is no “best” formula to group 
mix by ages, gender, socioeconomic and professional status. The impact of group mix should 
be considered by the researcher before conducting discussions. Having six to eight 
participants in a FGD is an optimal size (195). Large groups might be hard to manage and 
participants would have insufficient opportunities to share their own views. Conversely, small 
groups will risk limited discussion and achieving poor data.  
2.2.5.3 Sampling in qualitative assessment  
 Contrasting quantitative research, statistical representativeness is not considered a 
requirement in sampling in qualitative research (182). Qualitative data collection is normally 
more expensive and time consuming, thus using of a probability sample is unsuitable (196). 
To enhance the value of exploration in the “human” side of an issue, sampling in qualitative 
research tends to identify specific groups of people who hold relevant features to the studied 
phenomena. Therefore, sampling strategies in qualitative studies largely depend on the 
purpose of the study, given the time and resources available (197). 
 In our investigation, one FGD was held in the rural area and a total of six individual in-
depth interviews were performed in both sites due to difficulties in finding participants for the 
FGD, especially in urban area. The FGD included the following participants: two pharmacy 
owners, one drug seller and three commune health centre workers. All of them had a primary 
degree in pharmacy and those working in commune health centres (CHCs) were also assistant 
doctors. The in-depth interviews were done with three rural (two pharmacy owners and one 
CHC staff) and three urban participants (two participants were both pharmacy owner and drug 
seller and one drug seller. One owner is a pharmacist and the two other participants had a 
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secondary degree in pharmacy). English guidelines were developed to cover general and 
specific issues for asking participants to discuss their own experiences and opinions. Both 
discussion and in-depth interviews included the following themes: (1) financial incentives, (2) 
knowledge of government regulations and (3) potential solutions for controlling inappropriate 
antimicrobial dispensing practices (table 2-1).  
 All discussions in both sites were led by a female senior pharmacist who had relevant 
training and experience. If needed, findings of the observation and questionnaire were 
presented during FGD and interviews to support the discussion. All contents of conversations 
were recorded and transcripts were made and translated into English. All reported qualitative 
characteristics including moderator, study design, analysis and findings meet consolidated 
criteria for reporting qualitative research (COREQ), which includes a 32-item checklist for 
interviews and focus groups. 
Table 2-1 Discussion topics for FGD and in-depth interview  
1) Financial incentives  
1.1 What is the importance of antimicrobial sales compared to other drugs in your 
pharmacy? 
1.2 What factors affect the sales of antimicrobials? Can we change these factors or not? 
1.3 Why are antimicrobials still sold when there is no prescription? 
1.4 What is role of distributors /prescribers /patients? 
1.5 What type of patients demand antimicrobial without prescription and is this common? 
1.6 If a customer requests antimicrobials when not needed, would you sell or not? 
2) Knowledge of government regulation 
2.1 What do you know about antimicrobial resistance and the role of inappropriate 
antimicrobial use? How did you acquire this knowledge? 
2.2 Are current government regulations sufficient to control inappropriate antimicrobial use? 
2.3 Will Good Pharmacy Practices help to improve control of inappropriate antimicrobial 
use? 
3) Solutions 
3.1 What would happen if antimicrobial sales decline due to compliance with current 
regulations on dispensing antimicrobials?  
3.2 In your opinion, what do we need to do to improve the situation of antimicrobial use and 
resistance in Vietnam?  
3.3 What are the roles and responsibilities of other stakeholders like industry & government? 
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2.2.6 Ethical considerations 
  The Ethical Review Board of Hanoi Medical University approved the study (Decision 
No: 78/HDDD-YHN). Permission was obtained from the local health bureau for the study and 
verbal consent was obtained from the owner of each participating pharmacy. All pharmacy 
data was anonymised.  
2.2.7 Data analysis 
2.2.7.1 Quantitative data analysis 
  Collected data were cleaned and entered into a Microsoft Access database, designed 
and maintained by a statistician (Dr. Tran Thanh Do) in Hanoi Medical University. 
Antimicrobial sales data was summarised using median and interquartile range (IQR) for 
skewed distributed data. Potential differences between urban versus rural pharmacies were 
compared by Mann-Whitney test for non-normal continuous data, Wilcoxon sign rank test for 
paired non-normal data and Chi-square test for categorical variables. P-values less than 0.05 
were considered significant (2 tailed). 
In terms of revenue, the contribution of antimicrobial sales to the total drug sales for 
each pharmacy was calculated. In addition, we calculated the retail mark-ups of the twenty 
most sold antimicrobials. The mark up is the difference between the cost and selling price of a 
particular product. Here, we used the percentage mark up to assess the profit of antimicrobials 
that was calculated as (selling price – purchasing price) / purchasing price x 100%. The 
purchase prices were obtained from major wholesalers and distributers in northern Vietnam. 
Data was analysed by SPSS software, version 16 (SPSS Inc., Chicago (IL), USA). The 
currency exchange rate of Vietnam Dong (VND) to US dollar (USD) at the time of study was: 
1 USD = 18,500 VND. 
2.2.7.2 Qualitative data analysis 
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Qualitative data collected from in-depth interviews and focus group discussions were 
analysed by content analysis which is widely used and accepted in qualitative research to 
analyse text data from FGDs and IDIs (198). The goal of content analysis is to provide 
knowledge and understanding of the phenomenon by focusing on the characteristics of 
language as communication with attention to the content or contextual meaning of the text 
(199). There are three different approaches to interpret meaning from the content of text data 
including: conventional (text data is the direct origin of coding categories), directed (initial 
codes are indirectly derived from a theory or relevant research findings) and summative 
(involves counting and comparisons of keyword or content) (200). In this study, the 
summative approach that blends qualitative and quantitative analyses, while preserving the 
essential features of each, was chosen to improve the robustness of qualitative content 
analysis (201). Data from transcripts were analysed by listening to the tapes and reading and 
re-reading the transcripts to become familiar with the data and to categorise information. We 
used both the Vietnamese transcripts and the English translated version to identify common 
themes. Connections within and between themes were identified. The main themes and 
connections were used to identify important causes of inappropriate antimicrobial dispensing 
in urban and rural pharmacies (202). 
2.3 Results  
2.3.1 Pharmacy characteristics 
  Among thirty randomly selected pharmacies (15 urban and 15 rural), six urban 
pharmacies had a Good Pharmacy Practice (GPP) certificate, whilst none of the rural 
pharmacies had a GPP certificate.  
  None of the private pharmacy owners in the rural area were pharmacists, whereas 5 
owners of urban pharmacies were pharmacists. Most (10) urban pharmacies had more than 
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one drug seller working in each store while rural pharmacies usually (11) had one seller per 
outlet. Drug sellers in the urban pharmacies had a higher level of education: 3/28 had a 
university degree on pharmacy, 21/28 were assistant pharmacists, and 4/28 had an elementary 
degree on pharmacy. In the rural pharmacies none were pharmacist, 9/17 were assistant 
pharmacists, 4 were elementary pharmacists and 4 were doctor assistants. Three urban 
pharmacies had a pharmacist on site in charge of managing and dispensing drugs. Only one 
pharmacy had up-to-date reference books available in the pharmacy and frequently used for 
consultation, the remaining did not (table 2-2). 
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Table 2-2 Pharmacy baseline information 
 
Characteristics outcomes 
Urban  
n (%) 
Rural  
n (%) 
Pharmacy is GPP licensed 6 (40) 0 (0) 
Pharmacy owner’s degree   
   Pharmacist  5 (33) 0 (0) 
   Licensed renter            10 (67) 15 (100) 
         Assistant Pharmacist 9 (60) 10 (67) 
         Elementary Pharmacist 1 (7) 1 (6) 
          Assistant Doctor                                       0 (0) 4 (27) 
Number of drug sellers in pharmacy   
                1 seller 5 (33) 11 (73) 
                2 sellers 7 (47) 4 (27) 
                3 sellers 3 (20) 0 (0) 
Drug seller’s degree   
   Pharmacist 3 (11) 0 (0) 
   Assistant Pharmacist 21 (75) 9 (54) 
   Elementary Pharmacist  4 (14) 4 (23) 
   Assistant Doctor 0 4 (23) 
Drug seller uses  references / guidelines   
   Frequent 1 (7) 0 (0) 
   Sometimes 4 (27) 6 (40) 
   Rare 2 (13) 3 (20) 
   Never 8 (53) 6 (40) 
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2.3.2 Client information 
  In total, 2083 clients visited urban pharmacies and 870 rural pharmacies during the 
observation over three days. At both sites, most clients were female: 61.8% and 69.8% in 
urban and rural pharmacies, respectively. Age of clients was estimated by the observer 
according to four age categories: under 15 years-old, 16-25 ys, 26-40 ys, 41-60 ys and above 
60 ys. Therefore, prescriptions for children were not captured in sufficient detail. The most 
common age category visiting the pharmacy was 26 to 40 years-old with 53.5% in urban and 
31.7% in rural area. Customers under 15 year-old accounted for 1.2% and 4.9% in urban and 
rural area, respectively (figure 2-2).  
 
Figure 2-2 Client profile  
Estimated age group of clients in urban (blue) and rural (red). 
2.3.3 Observation of drug sales 
 In total 2953 drug sale transactions (2083 urban and 870 rural) were observed between 
the 30 pharmacies (table 2-3). The proportion of transactions that included antimicrobials was 
high: 24% (499/2083) in the urban sites and 30% (257/870) in the rural sites (p=0.002). Most 
0
5
10
15
20
25
30
35
40
45
50
≤15 16-25 26-40 41-60 >60
Pe
rc
en
ta
ge
Age	group
Urban
Rural
  
 
58 
antimicrobials were sold without a prescription: 88% (439/499) in urban and 91% (234/257) 
in rural area (p=0.2). Compliance to regulations was better in the pharmacies that had a 
pharmacist on site with 19% (21/112) of total antimicrobials transactions having prescription 
versus only 10% (62/644) in the shops without pharmacist (p=0.004). 
Table 2-3 Antimicrobials dispensing practices according to prescription regulation 
 
Outcomes 
Urban 
(n=2083) 
Rural 
(n=870) 
Transaction with antimicrobials 499 (24%)* 257 (30%)* 
With prescription 60 (12%) 23 (9%) 
         Comply with prescription  49 (82%) 18 (78%) 
         Not comply with prescription           11 (18%) 5 (22%) 
Without prescription 439 (88%) 234 (91%) 
           Client made decision 221 (50%)* 66 (28%)* 
           Drug seller made decision 218 (50%) 168 (72%) 
* Significant different between urban and rural group using chi-square test (p<0.05) 
There was no significant difference between GPP versus non-GPP pharmacies regarding 
antimicrobials dispensing practices. Pharmacies with a GPP certificate sold antimicrobials 
without prescription in 88% (196/224) of cases, similar to 90% (477/532) (p=0.38) rate in 
pharmacies without such a certificate. In term of self-medication, 50% (221/439) of the urban 
pharmacy customers decided by themselves which antimicrobials to buy, whereas the rural 
clients more often asked for advice from drug sellers, with only 28% self-prescribed (p < 
0.0001). 
  It was observed that antimicrobials were the most common drug sold at the pharmacies 
in both areas (17% in urban and 18% in rural, p=0.15), followed by herbal medicines (15% in 
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urban and 11% in rural, p<0.0001). However, in terms of monetary value, herbal medicines 
was the most important group which contributed to total sales of both urban and rural 
pharmacies with 24% in urban and 27% in rural, followed by antimicrobials (24% in urban 
versus 18% in rural), analgesics group and vitamins (figure 2-3).  
 
Figure 2-3 Average sales in USD per pharmacy per day by therapeutic groups in urban 
versus rural (in USD) 
TM: Herbal medicines, J01: Antimicrobials, N02: Analgesic, A11: Vitamins, S01: 
Ophthalmological, R05: Cough and cold preparation, B06: Haematological agent, R06: 
Antihistamine, R01: Nasal preparations, M01: Anti-inflammatory and anti-rheumatic 
products, G03: genial system, C09: rennin-angiotensin, G01: Gynaecological, C08: Calcium 
channel blocker, A02: Acid related disorders. 
 Average number of customers per pharmacy per day was 46 in the urban and 19 in the 
rural area. Among them, 11 clients in the urban area had transactions with antimicrobials and 
6 clients in the rural area (figure 2-4).  
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Figure 2-4 Average number of observed clients per pharmacy per day 
Average number of encounters per pharmacy per day in urban pharmacies (left column) and 
in rural pharmacies (right column). Antimicrobials encounters per pharmacy per day (blue) 
and encounters without antimicrobials (grey). 
  Other therapeutic groups, such as cardiovascular system, nervous system, or 
corticosteroid medications, were rarely dispensed in all observed pharmacies. Three most 
common sold antimicrobials in the urban area were: amoxicillin (13%), azithromycin (12%), 
cephalexin (9%) while in rural pharmacies these were amoxicillin (27%, p<0.0001), 
cephalexin (20%, p<0.0001) and ampicillin (12% versus 4% in urban setting, p<0.0001). The 
main difference between the urban and rural pharmacies was that older antimicrobials, such 
as chloramphenicol, and co-trimoxazole, were more commonly dispensed in the rural area. In 
the urban area more new and expensive drugs such as amoxicillin-clavulanic acid, 2nd and 3rd 
generation cephalosporins (cefuroxime, cefixime), and azithromycin were sold. 
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2.3.4 Reasons for antimicrobials purchasing 
  The most common reasons for buying antimicrobials in the urban sites were cough 
(32%) followed by throat symptoms/complaints (18%), fever (10%). Meanwhile, in the rural 
sites these were fever (22%), abdominal pain (13.5%), cough (12.2%), diarrhoea (11.5%) and 
throat symptoms (4.9%) (table 2-4). Antimicrobials were often sold in combination with other 
drugs: analgesics 17% (189/1122), cough and cold preparations 16% (182/1122), vitamins 9% 
(99/1122), corticosteroids 9% (98/1122), and herbal medicines 5% (54/1122). 
Table 2-4 Top ten common reasons for antimicrobial purchasing 
Urban Rural 
Code Symptom % Code Symptom % 
R05 Cough 31.6 A03 Fever 21.7 
R21 
Throat 
symptom/complaint 
17.8 D01 
Abdominal pain/cramps 
general 
13.5 
A03 Fever 9.7 R05 Cough 12.2 
D82 
Limited 
function/disability  
7.4 D11 Diarrhoea 11.5 
F01 Eye pain 5.2 R21 
Throat 
symptom/complaint 
4.9 
R74 Upper ARI 5.2 D82 Teeth/gum disease 4.6 
S02 Pruritus 3.3 S02 Pruritus 3.9 
D11 Diarrhoea 2.6 F01 Eye pain 3.6 
F73 
Eye 
infection/inflammation  
1.9 N01 Headache 3.6 
A80 Trauma/injury NOS 1.5 H01 Ear pain/earache 2.6 
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2.3.5 Economic indicators of antimicrobial sales 
  Antimicrobials represented a considerable proportion of total revenues per day: 24% 
(27.9USD/115.8USD) in urban and 18% (3 USD/16.5 USD) in rural area (p=0.59) (figure 2-
3). Urban pharmacies showed higher sales of imported antimicrobials with median sales of 
11.5 USD per pharmacy per day (IQR = 5.3 – 41.7) compared to domestic antimicrobials 
(median=5.1 USD, IQR= 4.2-6.6, P-value 0.003). The opposite was observed in the rural area 
where very little imported products were sold with median sales of 0 USD per pharmacy per 
day compared to domestic products in term of total antimicrobials monetary sales with 
median sale of 1.6 USD (IQR=1.4-3.1), p value < 0.001). In the rural sites, available imported 
brands such as amoxicillin or cephalexin were mostly from India, with relatively low prices as 
compared to other brands. Meanwhile, more expensive imported brands were sold in urban 
pharmacies. 
  Retail mark-ups of twenty most common sold antimicrobial generics across all 
pharmacies in each setting varied considerably. In the urban area, mark-ups ranged from 17-
243% (median=54%, IQR=30-79%) and in the rural area from 21-186% (median=58.5%, 
IQR=39-67%). There was no significant difference between the mark ups between the two 
regions (p=0.76). Several imported brands that were only dispensed in urban pharmacies 
showed relatively high mark-ups such as: augmentin (amoxicillin – clavulanic acid), zinnat 
(cefuroxime), zithromax (azithromycin) as compared to domestic products (table 2-5). 
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Table 2-5 Mark-ups of 20 most common sold generic antimicrobials 
Generic name Origin 
 
ATC 
code 
 
 Unit 
Price* 
(USD) 
 
 USD 
 
 
% Mark-up$  
Unit/Content   
 Urban Rural 
Amoxicillin  Vietnam J01CA
04 
Tablet/500mg 0.02 78 67  
Amoxicillin  India J01CA
04 
Tablet/500mg 0.04 54 54  
Amoxicillin  Austria J01CA
04 
Tablet/500mg 0.04 88 NA  
Cephalexin  Vietnam J01DA
01 
Tablet/500mg 0.04 67 67  
Cephalexin  India J01DA
01 
Tablet/500mg 0.05 58 58  
Cephalexin  France J01DA
01 
Tablet/500mg 0.07 25 NA  
Ampicillin Vietnam J01CA
01 
Tablet/500mg 0.02 122 43  
Ampicillin India J01CA
01 
Tablet/500mg 0.03 100 40  
Chloramphenicol Vietnam J01BA
01 
Tablet/250mg 0.03 17 59  
Cotrimoxazole Vietnam J01EC
01 
Tablet/480mg 0.01 33 67  
Metronidazole Vietnam J01XD
01 
Tablet/250mg 0.01 82 150  
Lincomycin Vietnam J01FF
02 
Tablet/500mg 0.03 41 25  
Penicillin Vietnam J01RA
01 
Tablet/1MIU 0.02 60 50  
Spiramycin Vietnam J01FA
02 
Tablet/0.75 MIU 0.04 43 29  
Spiramycin France 
Sanofi-
France 
J01FA
02 
Tablet/0.75 MIU 0.14 68 21  
Ciprofloxacin Vietnam J01M
A02 
Tablet/500mg 0.02 233 186  
Ciprofloxacin German J01M
A02 
Tablet/200mg 0.65 33 NA  
Erythromycin Vietnam J01FA
01 
Pack/250mg 0.08 103 69  
Erythromycin  France J01FA
01 
Pack/250mg 0.23 31 67  
Azithromycin German 
Pfizer 
J01FA
10 
Bottle/200mg/5ml 5.19 19 NA  
Cefuroxime UK J01DA
06 
Tablet/500mg 1.06 27 NA  
Cefixime Banglades
h 
J01DA
23 
Pack/200mg 0.20 49 NA  
Amoxicillin+        
Clavulanic acid GSK J01CR
02 
Pack/250mg 0.37 62 NA  
Roxythromycin India J01FA
06 
Tablet/150mg 0.06 81 NA  
Klarithromycin USA J01FA
09 
Tablet/250mg 0.43 31 NA  
Tobramycin Belgium J01GB
01 
Vial/0.3% 2.05 18 NA  
Cefpodoxim India J01DA
33 
Tablet/100mg 0.04 19 NA  
Clindamycin India J01FF
01 
Tablet/300mg 0.05 117 NA  
$ Difference between the cost and selling price of a particular product. *Unit price is for 
smallest unit such as: tablet, vial, bottle or pack   
  The semi structured questionnaire on antimicrobial dispensing practices with drug 
sellers and drug store owners by semi-structured questionnaire, 41% (7/17) of rural 
respondents and 27% (7/26) of urban informants conceded that 20% to 40% of their total 
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profit was due to antimicrobial sales (p=0.33). Meanwhile 53% (9/17) in rural and 23% (6/26) 
in urban site thought that profit from antimicrobials accounted for less than 20% (p=0.04). 
Only 6% (1/17) of rural respondents and 4% (1/26) in urban considered that profits from 
antimicrobials accounted for 40-60% of their total profit. 
2.3.6 Causes for inappropriate antimicrobial selling 
  All rural pharmacy respondents thought that the fear of losing a customer leads to 
dispensing of antimicrobials without prescription. This opinion was shared with 69% (18/26) 
of urban respondents. Pressure from patients that demand antimicrobials was considered a 
significant driver of irrational dispensing practices in rural pharmacies according to 77% 
(13/17) of respondents, and 39% or urban respondents (p=0.01). Only 27% (7/26) of the 
respondents in urban and 24% (4/17, p=0.8) in rural area considered that knowledge of drug 
sellers was insufficient to dispense antimicrobials appropriately. The majority of urban 
respondents (69%) thought that inappropriate prescription of doctors contributed to irrational 
antimicrobial selling, whereas trust in doctors appeared stronger among respondents in rural 
setting (29%, p=0.01). 31% in urban and 35% in rural sites conceded that inappropriate 
dispensing of antimicrobials to be due to high profitability of antimicrobial sales (p=0.75). 
71% (12/17) rural participants blamed inappropriate dispensing on other causes like quality of 
diagnostics and access to medical services versus 46% (12/26) in urban site (p=0.12) (table 2-
6). Only a minority 8% of urban and 18% of rural respondents thought that the current 
situation of antimicrobials dispensing was appropriate and does not need to be improved 
(p=0.32). 
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Table 2-6 Mentioned reasons for irrational antimicrobials dispensing 
 
Reasons 
 
Reasons 
Outcomes 
Percentage of respondents within area 
agreed with given reasons Urban 
(n=26) 
Rural 
(n=17) Fear of losing customers 18 (69%) 17 (100%) 
Pressure from patient’s demand 10 (38%)* 13 (76%)* 
Insufficient knowledge of  dispensers 7 (27%) 4 (23%) 
Inappropriate prescribing of doctors 18 (69%)* 5 (29%)* 
High profitability of antimicrobials 8 (31%) 6 (35%) 
Other (quality of diagnosis or health services) 12 (71%) 12 (46%) 
* Significant different between groups using Chi-square test (p value <0.05) 
2.3.7 Qualitative study 
2.3.7.1 Incentives structure 
  Most interviewees in both the urban and rural setting did not think that profits from 
antimicrobial sales predominated in comparison with other drugs. According to their opinion, 
vitamins, tonic drugs or functional foods are more profitable than the antimicrobial group, 
which, however, is not confirmed by our quantitative data. “Antimicrobials are commonly 
used items and customers know well their prices. That is why it not as profitable as less 
popular drugs like vitamins, tonics or functional foods” was the response of one rural seller. 
Nevertheless, they conceded that pharmacy’s income would be affected if they comply with 
prescription regulation. “Not only antimicrobials but also thirty other groups have to be 
dispensed with a prescription. If we wait for a prescription, we sell hardly anything and total 
sales would be definitely influenced” according to one urban seller.   
  All rural interviewees stated that patients’ demand is a common factor affecting the sale 
of antimicrobials. An example of this is described as: “I need to satisfy clients’ demand. 
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That’s in the interest of our business!” According to their opinion, this factor can be changed 
if patients’ awareness is improved and when the knowledge of sellers is strong enough to give 
professional advice. Meanwhile, fear of losing customers is common among urban sellers. “If 
I refuse to sell antimicrobials without prescription, I will lose that customer for another 
pharmacy as they can easily buy anywhere”. 
  Both urban and rural respondents reported that patients often avoided visiting doctors 
due to the inconvenience, and would rather go directly to a private pharmacy as the first 
choice for mild disease. “It’s very annoying and time-consuming to be examined in a hospital. 
And private clinic are very costly, as they do many kinds of test. Our customers only go to see 
doctors in case of severe disease”. 
2.3.7.2 Knowledge on antimicrobials/resistance and regulations 
  All urban and rural participants expressed that they will give antimicrobials in case of 
suspected infection such as upper respiratory infections with fever, cough and sputum or even 
an injury to prevent infection. In addition, some rural interviewees noted that customers 
consider antimicrobials to be a ‘miracle drug’ that can treat many kinds of diseases and 
sometimes they demand it simply for maintaining a private stock for self-medication. 
Meanwhile, all urban interviewees believed that misconceptions about antimicrobial use 
changed among the urban population where there are better economic conditions and higher 
educational levels. “Recently, public awareness of drugs’ side effects has been improved, so 
there is less abuse of antimicrobials than before” according to an urban seller. 
  All interviewees stated that they had heard about antimicrobial resistance. However, 
qualitative data also revealed insufficient knowledge of antimicrobial resistance among drug 
sellers and pharmacy owners, especially in the rural area. Most urban drug sellers 
demonstrated reasonable knowledge regarding the possible effects of resistance on all 
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populations, whereas some rural sellers did not. “Antimicrobial resistance occurs in those 
overusing it. I do not abuse, so for me there is no need to worry” (Rural seller).  
  Most respondents believed that patient-related factors such as self-medication and poor 
adherence to antimicrobial regimens contribute to the problems of antimicrobial resistance. It 
has been reported in the rural setting that patients often buy antimicrobials for an 
inappropriate duration. “I advised the customer to take antimicrobials for at least 5 days, but 
they do not have enough money so they usually buy for just 2.5 days (10 tablets). When they 
recover, they will stop taking drugs, otherwise they would have bought more” (Rural seller).  
  Regarding the knowledge of government regulations, most rural respondents did not 
know about GPP. “This is the first time I heard about GPP” said a rural seller. They also 
revealed misconception about prescription regulation by stating that: “Some kind of weak 
antimicrobials such as amoxicillin or ampicillin can be sold without prescription” (Rural 
seller). In contrast, all urban interviewee showed their understanding about GPP, but they 
conceded that there is little enforcement in dispensing practice. “There is no difference 
between GPP and non-GPP pharmacy in terms of regulation compliance. Over the counter 
dispensing of prescription-only drugs is common in every pharmacy”. (Urban seller) 
2.3.7.3 Proposed solutions 
  Rural respondents did not think that GPP could be deployed broadly in the rural setting 
due to the poor conditions of the facilities and education level of the work force. However, if 
regulations are enforced they will shift their business to dispense over the counter drugs like 
vitamins, cough and cold preparation; tonics that are allowed by the law to compensate 
pharmacies for financial losses. The urban respondents believe that GPP brings improvement 
to infrastructure but not to dispensing practices. “To get a GPP certificate, we need to invest 
more in improving our infrastructure; as a result, the pharmacy looks more spacious. 
However, quality of service and dispensing practices has not been much improved”. 
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  Pharmacy workers have the understanding that the GPP policy objective is to improve 
the quality of pharmacy services in terms of infrastructure and quality drug supply. However, 
the awareness about their own professional contribution in promoting rational medicine use 
and its role in public health is very limited.  
  Both urban and rural respondents considered that training for drug sellers and the 
general population was needed to improve their knowledge and awareness about 
antimicrobials and resistance and thought that this would likely have a significant impact on 
controlling inappropriate antimicrobial use in the community. “There will be less pressure to 
give customers antimicrobials if their awareness is improved”. 
  Using a rapid blood test to determine which customers may need antimicrobials was 
considered to be a solution in improving rational antimicrobial use. However, several 
dispensers expressed concerns about losing time and income when the test result recommends 
to not prescribing antimicrobial. They recommended that, this approach should be applied in 
health establishments rather than in drug outlets. “It’s impossible to implement it in pharmacy. 
We need to consider its price, not mentioned to implementation will take a lot of time and how 
to sell medicines along with the test and patient’s preference. Furthermore, kind of infection 
yet remains to be identified”. (Urban owner) “It’s more feasible to be applied in health care 
facilities than in dispensing channel”. (Rural seller)    
2.4 Discussion 
 The results of this study illustrate the widespread inappropriate antimicrobial 
dispensing at private pharmacies in the Hanoi region. With only about 10% complying with 
prescription regulations, the situation in Vietnam is worse than has been reported in Saudi 
Arabia where the proportion was 51% (203) and Jordan with 74% (204). In a cross-sectional 
client simulation study in Syria, 87% of the pharmacies sold antimicrobials without a 
prescription. This proportion increased up to 97% when the client simulators insisted on 
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buying antimicrobials (205). Similar studies in India and Uganda had comparable results: 
95% and 93.5% of visited pharmacies dispensed over the counter antimicrobials (206, 207). 
The most frequent reason for buying antimicrobials was acute upper respiratory tract 
infections, which are generally self-limiting (207, 208). 
There are several successful interventions in other countries that brought important 
reduction in antimicrobial use. As reported in Tanzania, the accredited drug dispensing outlet 
(ADDO) program which combined extensive training, business incentives, authorisation to 
dispense a limited list of medicines to treat common conditions, regulatory enforcement of 
practice standards, and efforts to affect customer demand, has brought improvements in the 
use of antimicrobials. Before the introduction of ADDO program, antimicrobials were sold 
illegally by retail outlets which allowed dispensing over the counter medicines only. After 10 
years of implementation, 63% of antimicrobial were sold with a prescription in ADDO. 
Among 85% client simulators presenting a mild ARI requesting an antimicrobial, only 34% 
of them were sold. For customers describing symptoms of pneumonia, 54 % were sold an 
antimicrobial and 90 % were referred (209). Similarly, unnecessary antimicrobial 
prescriptions remarkably declined as in England by sending social norm feedback to high 
prescribers of antimicrobials in general practice (210). In Vietnam, prescription-only 
regulation is embedded in the Drug Law that was issued in 2005 and re-stated in the Circular 
46 in 2011 about implementing Good Pharmacy Practice (101, 163). In spite of these 
regulations, there is no sanction for non-compliance. This may explain why, to this moment, 
no pharmacy has been penalised for antimicrobial dispensing without a prescription. As there 
is a lack of enforcement of the regulations, self-medication is possible and is viewed as more 
economical and convenient than consulting a health professional (211, 212). Even if a 
pharmacy has a Good Pharmacy Practice registration, the results of this study revealed that 
the awareness of the concept of GPP among drug sellers was poor and they dispensed 
  
 
70 
antimicrobials without a prescription similar to pharmacies without a GPP standard. We also 
observed that more than 80% of the pharmacies rented pharmacist’s licenses. According to 
Vietnamese regulations (Decree 79/2006/NĐ-CP), only pharmacists with at least 5 year 
experience can own a pharmacy(213). However, pharmacists often rent out their license and 
work elsewhere, making it easier for non-pharmacists to own a pharmacy. Despite the limited 
number of pharmacies in our study, we did observe better practices in sites that had a 
pharmacist present. As health promoter in the situation of being the “front-line health 
worker”, pharmacist should promote non-drug solutions for any health problems. 
Strengthening this role of pharmacist in distributing channel might have impact on reducing 
irrational antimicrobials in community. Furthermore, post qualification education of drug 
sellers should also be part of future quality improvement strategies.  
 Antimicrobials represented a considerable proportion of total revenues (24% in urban 
and 18% in rural pharmacies), illustrating that antimicrobials sales contribute an important 
part of total sales of pharmacies. Imported brands were sold more in urban pharmacies, 
whereas rural pharmacies generally mostly sold domestically produced antimicrobials. The 
study also found that in the urban area, patients’ demands are a common factor affecting the 
sales of antimicrobials, with half (50%) of urban clients self-prescribing. In contrast, clients in 
the rural sites more often asked for advice from drug sellers. However, lack of knowledge of 
drug dispensers is common and will not lead to better antimicrobial dispensing practices. The 
qualitative study also disclosed that the government push to have all pharmacies comply with 
GPP standards is likely not a solution due to lack of enforcement and the shortage of a well-
educated workforce (65). According to the Vietnamese General Statistics Office, in 2012, 
there were only 1.4 pharmacists/10,000 inhabitants, and for assistant and elementary 
pharmacists this was about 2 and 0.6 per 10,000 inhabitants. Pharmacy staffs with a university 
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degree mostly work in the big cities with 4.5 pharmacists/1000 inhabitants, despite a serious 
deficiency in remote areas with only 0.2 pharmacists/10,000 inhabitants (65).  
 Overuse of antimicrobials in the community is caused by people buying antimicrobials 
after self-diagnosis or diagnosis by, often poorly trained, health-care providers. The reasons 
for irrational antimicrobial prescribing in Vietnam are the same as in other countries including 
perceived expectations of patients, time constraints, lack of knowledge, lack of diagnosis 
capability and financial benefits for the prescriber (65). Identifying and modifying the 
incentives for inappropriate prescribing remains a major challenge.  
 In terms of impact of implementing pricing policies, high prices of antimicrobials and a 
tendency to sell branded drugs rather than cheaper generics is one of the important factors 
affecting irrational use and inadequate treatment as people often cannot afford to buy a full 
treatment course. The current mechanism of drug price control is not able to achieve the 
desired objectives as the drug prices in Vietnam are higher as compared to international 
comparators (214). The government has no leverage to negotiate on the wholesale prices even 
if those prices are higher than CIF prices (cost, insurance and freight). Retail prices are 
determined by the market, but there is a tendency to sell branded drugs rather than cheaper 
generics in urban areas. According to WHO’s studies in the private sector, there was a large 
variation in mark-ups along the Vietnam medicines supply chain (215). Suppliers can easily 
increase prices and the government cannot control this. It is important to have a more 
structured and enforced price control mechanism, with strong generic policies, good 
procurement systems and single system leverage (such as health insurance and bulk 
procurements) to reduce drug prices.  
 As the symptoms of acute respiratory infections were among the most common reasons 
of antimicrobials purchasing, scale-up of a rapid diagnostic test in pharmacies and drug stores 
could be a solution to reduce antimicrobial consumption in the community (see Chapter 3). 
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Such point of care C reactive protein (biomarker of infection/inflammation) testing has 
previously been evaluated in reducing antimicrobial prescription in the primary care settings 
in Vietnam (216). Further work investigating the potential for POC CRP testing in this 
dispensing channel is needed. 
  Lastly, it was revealed in both the quantitative and qualitative study that there is poor 
awareness of consumers. As shared experiences from several developed countries in Europe 
(217), education campaigns targeting on providers and consumers through mass media 
contributed to reduction of antimicrobial overuse suggesting that public education campaigns 
can be effective.   
 There are some limitations to our study that need to be discussed. Our study was 
conducted only in the Hanoi region, with a relative small sample size and can therefore not be 
generalised to the whole country. However, discussions with doctors and pharmacists from 
other regions, do confirm that the issues are similar elsewhere. In larger pharmacies, some 
transactions may have been missed when large numbers of customers come to shops 
simultaneously. However, we believe this was limited as in larger pharmacies, as two 
observers were present. Awareness of being observed might have influenced antimicrobial 
dispensing practices (Hawthorne effect). To minimise this bias the sellers were unaware 
during the observation that the objective was to assess antimicrobial sales. Questionnaires 
focusing on antimicrobials were done after the observation. Some respondents were both drug 
seller and pharmacy shop owner, which may have affected the results as the owner may 
mostly be interested in profit and their opinion about incentives driving irrational 
antimicrobial dispensing may be different from a drug seller. There was limited participation 
for participants in the urban area to join focus group discussions, which may account for the 
relative paucity of solutions. Only one focus group discussion could be performed in the rural 
setting and in the urban area we conducted in-depth interviews. With relatively few 
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participants in the interview, we were not able to estimate where the saturation was reached. 
However, at the end of the discussion and interviews, little new ideas were recorded, so we do 
think we were close to saturation with our limited number of interviews. Furthermore, the 
study used wholesale prices to assess mark-ups of sold antimicrobials as we were unable to 
obtain purchasing prices from the pharmacies. In this observational study, antimicrobial 
encounters were not interviewed, as it was thought to interfere with normal routine. This may 
have affected the study findings on poor awareness among patients as reported by the 
dispensers. Finally, the limited observation time of three days in each pharmacy will not 
reflect the sales of antimicrobials and dispensing practices fully as these may be subject to 
change due to diseases with seasonality (e.g. influenza season). Furthermore, observation 
conducted only in workday time (9AM-5PM) may not cover the peak times of facilities in 
early morning and late afternoon with sufficient number of clients. Despite these limitations, 
the observations reveal the magnitude of antimicrobial dispensing without prescription. 
2.5 Conclusion 
The revenues from antimicrobial sales are considerable for private pharmacies in both 
rural and urban northern Vietnam. Complying with drug regulations, to dispense 
antimicrobials only with a prescription, would therefore lead to economic loss for pharmacies. 
This would make acceptance and compliance with regulations challenging. Increasing the 
requirement for pharmacies to be GPP certified may only help in case the regulation that a 
pharmacist should be on site is enforced. For non-GPP pharmacies, substituting antimicrobial 
sales with sales of symptom relieving drugs or vitamins may be a strategy to compensate 
pharmacies for financial losses and to motivate them to comply with government regulations. 
Confronted with the situation of not enforcing regulations, continuing professional training 
for drug sellers will be helpful to increase their understanding of antimicrobials, resistance 
and how to dispense it appropriately. As the consumers often demand antimicrobials without 
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a prescription, public awareness campaigns should also be a central component of future 
control strategies. As promoting proper and safe use of antimicrobials is among the objectives 
of the national action plan on combating AMR, findings from this study may serve as targets 
for development of tailored interventions to improve rational antimicrobial use in the 
Vietnamese community.  
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Chapter 3 
Point-of-care C-reactive protein testing to reduce inappropriate use of antimicrobials 
for non-severe acute respiratory infections in adults and children in the Vietnamese 
primary health care setting: a multi-centre randomised controlled trial 
3.1 Introduction 
Worldwide, bacterial pathogens are becoming increasingly resistant to antimicrobials. 
This problem is particularly pressing in developing countries, where the burden of infectious 
disease is high and resources for newer, more expensive antimicrobials scarce (218). Vietnam 
already experiences high levels of antimicrobial resistance. Prevalence of penicillin- (71%) 
and erythromycin-resistance (92%) in Streptococcus pneumoniae in Vietnam is the highest 
among Asian countries (219). Carbapenem-resistance rates are high in Pseudomonas 
aeruginosa (25%) and Acinetobacter baumannii (40%) hospital-acquired infections (HAIs) 
(103). Development of resistance is multi-factorial but a major driver is likely to be the 
frequent and often injudicious use of antimicrobials in humans and widespread use in 
agriculture and aquaculture (60).  
 Findings from my pharmacy study described in chapter 2 showed the proportion of 
antimicrobials dispensed over the counter in the community (88% in urban and 91% in rural 
settings) (220). Reasons for purchasing antimicrobials were predominantly ARIs (54.6%) 
which are largely self-limiting and complications are likely to be rare if antimicrobials are 
withheld (221, 222). The National Institute for Health and Clinical Excellence (NICE) clinical 
guideline 69 reviews the evidence of antimicrobials treatment for upper respiratory tract 
infections (URTI) and a syndromic risk based approach is recommended (223). 
 In the context of poor adherence to regulations, GPP was reportedly unsuitable to 
improve rational antimicrobial dispensing (220). Rapid blood tests to identify clients who are 
unlikely to benefit from antimicrobial treatment is a potential solution to reduce unnescessary 
  
 
76 
dispensing. However, discussions with drug sellers (Chapter 2) indicated that,it is impossible 
to implement such an intervention in drug stores. Of particular concern is losing income if the 
test shows a negative result and antimicrobials are not sold. Additionally, with the current 
available version of the test, it’s inconvenient to perform this in drug stores. Thus, we decided 
to conduct this intervention study in primary health centres where similar overprescription of 
antimicrobials for ARIs has also been previously reported (97, 224).  
  Despite the evidence from randomised placebo-controlled trials (RCTs) showing that 
antimicrobials have limited efficacy in treating a large proportion of ARIs in adults and 
children, concerns of missing a serious infection can precipitate antimicrobial prescription. In 
lower-income settings, where health infrastructure is less developed, physicians may also be 
concerned about patients’ perceived or actual inability to access healthcare if they deteriorate. 
These factors may motivate overuse of antimicrobials. The inappropriate prescribing of 
antimicrobials has the potential to cause drug-related adverse events, increase the prevalence 
of antimicrobial-resistant organisms in the community and increase primary care consultation 
rates for minor illness. Implementation of a rapid, affordable point-of-care test (POC) to aid 
diagnosis and management, and reduce antimicrobial use safely is therefore an attractive 
prospect in improving community consumption of antimicrobials. Findings from the 
intervention study will provide evidence to plan generalisation of this strategy. 
 C-reactive protein (CRP) is a biomarker for the presence of an inflammatory process 
(116, 125).  Several studies in high-income countries have shown that primary health care 
providers who used a point-of-care (POC) CRP test prescribed fewer antimicrobials in 
patients with cough, without adversely affecting patient recovery (151, 225).  Findings of 
usefulness of POC CRP testing in reducing antimicrobial prescription for ARIs in the primary 
care setting have been summarised in Chapter 1. The Genomics to combat Resistance against 
Antimicrobials in Community-acquired LRTI in Europe (GRACE) cluster randomised 
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controlled trial conducted in six European countries showed that guiding antimicrobial 
decisions in primary care with a combination of point-of-care measurement of CRP and 
enhanced communication was associated with the  largest reduction in prescribing rates (CRP 
risk ratio 0·53, 95% CI 0·36–0·74, p<0·0001; enhanced communication 0·68, 0·50–0·89, 
p=0·003; combined 0·38, 0·25–0·55, p<0·0001).  
 No such trials have been performed in the primary health care setting of low and 
middle-income countries (LMICs) where unrestricted antimicrobial access and antimicrobial 
resistance is highest, and different social and clinical factors might affect its impact. Given 
the large number of self-limiting ARI that present to primary care in Vietnam, even modest 
reductions would greatly decrease the absolute number of antimicrobial prescriptions and thus 
one of the major drivers for bacterial resistance. Children in particular are frequently 
prescribed inappropriate antimicrobials for ARI, and any study should also address this 
important group (224). This study sets out to assess the efficacy of CRP POC testing for both 
children and adults presenting with non-severe ARI at primary healthcare centres in Vietnam 
in reducing inappropriate antimicrobial use safely. Findings can potentially be used in other 
resource constrained settings struggling with overuse of antimicrobials in ARIs. 
3.2 Methods 
3.2.1 Study design 
 An open-label randomised controlled trial was conducted in ten selected primary 
healthcare centres in northern Vietnam. Patients presenting with non-severe ARI were 
randomised to either CRP POC testing (intervention) or routine care (control). Randomised 
allocation was concealed from prescribers and patients but not masked as the test result was 
used to assist treatment decisions.    
3.2.2 Study sites  
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 Public health services in Vietnam are decentralised from nation to province, district and 
commune level. Primary health care (district and commune level) provides routine and urgent 
health care and hospital referral to the population. Ten primary healthcare centres with a 
sufficient caseload of at least 5 ARI cases per day were selected within a 60 km radius from 
Hanoi. In urban Hanoi, we invited all twenty existing regional polyclinics to participate; three 
did not respond, two refused to participate, and six did not meet the caseload criteria. Thus, 
the remaining nine urban sites were selected to implement the trial. In rural Hanoi we selected 
the outpatient clinics of one district general hospital (Ba Vi hospital), which is situated 60 km 
west of Hanoi. Caseloads of other non-hospital clinics in rural Hanoi were too low. 
3.2.3 Patients  
 Patients, aged 1 to 65 years visiting one of these primary healthcare centres, suspected 
to have non-severe ARI with at least one focal and one systemic ARI sign/symptom by 
treating physician were eligible for this study. Focal ARI signs/symptoms include: (1) cough, 
(2) rhinitis, (3) pharyngitis, (4) shortness of breath, (5) wheezing, (6) chest pain, or (7) 
auscultation abnormalities. Systemic ARI signs/symptoms include: (1) fever, (2) perspiring, 
(3) headache, (4) myalgia, and (5) feeling generally unwell.  
Exclusion criteria include:  - Severe respiratory disease as determined by treating doctor - Any disease or symptom requiring hospital referral as determined by treating doctor - Immunosuppressed patients (e.g. HIV, long term steroid use) - Suspicion of tuberculosis - Evidence of acute or chronic liver disease (e.g. hepatitis or cirrhosis due to any cause) - Past medical history of: neoplastic disease, congestive cardiac failure, chronic 
obstructive pulmonary disease, insulin-dependent diabetes or renal disease - Pregnancy 
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- No access to telephone - Not able to come for follow up visit on day 4 (±1). - Already taking antimicrobials at the time of presentation - Symptoms present for more than 2 weeks 
 Children were defined as subjects aged 1 to 15 years old. Patients with signs of severe 
ARI were excluded. Other additional specific inclusion and exclusion criteria for age 
categories listed in table 3-1.  
Table 3-1 Additional inclusion and exclusion criteria for age categories 
1-5 years old 6-15 years old >15 years old 
Inclusion  
• Fever duration ≥ 24 
hours (226) 
• No additional criteria  • No additional criteria  
Exclusion 
Any of: 
• Respiratory rate ≥ 40 
breaths/min 
• Unable to feed/drink 
• Hypothermia 
• Vomiting 
 
Any of: 
• Respiratory rate ≥ 30 
breaths/min 
• Temperature ≤ 35 °C or 
≥ 40°C 
• Pulse of ≥ 125/min 
 
Any of 
• Respiratory rate ≥30 
breaths/min 
• Systolic blood pressure < 90 
mmHg  
• Diastolic blood pressure <60 
mmHg 
• Temperature ≤ 35 °C or ≥ 40°C 
• Pulse of ≥ 125/min 
 
3.2.4 Enrolment and randomisation 
 All patients received a routine medical history and examination, consisting of medical 
history, mental status (Glasgow coma score), vital signs (blood pressure, pulse, respiratory 
rate) and temperature. Further examinations were performed at the discretion of the treating 
physician.  
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 Eligible patients were randomised 1:1 to CRP POC testing or control (routine care) 
using an individual randomisation method, stratified by health station and age category (child 
versus adult). The randomisation list was computer-generated using variable block lengths of 
four (with probability 0.75) and six (with probability 0.25). Allocation was concealed by 
opaque sealed envelopes (227), opened at randomisation in strict chronological sequence. To 
protect the patient’s identity, each participant was allocated a study identification number, 
which was used for all study material.  
3.2.5 Assessments 
 For patients in the CRP arm, a finger prick to collect capillary blood was performed 
and analysed using the quantitative NycoCard analyser (CRP single test kit used with the 
NycoCard II Reader, Alere Technologies, Norway) on enrolment (day 0) and retested on day 
4 (± 1 day) (figure 3-1). Patients in the control arm were treated according to routine practice 
and local treatment guidelines on enrolment and the second visit. All patients were followed-
up at two weeks after the initial health clinic visit by a structured telephone interview. 
Physicians were trained to use specific CRP cut-offs, which were based on previous studies 
and adapted for use in children (149-151, 226). For patients aged 6 to 65 years old, when the 
CRP was ≤20 mg/L, it was recommended that antimicrobials not be prescribed. For patients 
aged 1 to less than 6 years old, a CRP ≤10 mg/L was used to recommend that antimicrobials 
not be prescribed. Doctors were trained that adults with CRP ≥ 100 mg/L and children with a 
CRP ≥ 50 mg/L should generally receive antimicrobials and hospital referral should be 
considered for these cases. Between these thresholds no specific recommendation was given 
and clinicians were advised to use their clinical discretion. 
 After 2 weeks, enrolled patients were interviewed via telephone, blinded to the 
intervention, to assess whether:  they have been to any health clinic; taken any medication for 
the same ARI; source of medication; serious adverse events (e.g. admission to hospital); time 
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to resolution of ARI symptoms and their satisfaction with the care provided. The patients 
were given a symptom diary as a memory aid.  
 
 
Figure 3-1 C-reactive protein point of care testing 
The CRP value is obtained out of one drop of capillary blood by finger prick. Result is then 
available within few minutes by CRP POC Nycocard Reader.   
(Source: Medilab product information: NycoCard® Reader II System) 
3.2.6 Urine antimicrobial activity testing  
 Urine samples from enrolled patients (except those lost to follow up, toddlers who 
could not urinate on command at the visit, and women when menstruating) were collected on 
the second visit (day 4±1) for testing for the presence of antimicrobials. In urban sites, 
samples were collected and transferred to the laboratory to be processed and frozen on the 
same day to be assayed in the next weeks. In rural sites, a refrigerator was provided to 
temporarily store samples at 4 °C to be transferred to the laboratory twice a week. These 
samples were then assayed on the same or the next day on arrival in the laboratory. 
 The pansensitive ATCC 25923 S. aureus and ATCC 25922 E. coli were cultured on 
Müller Hinton agar (Oxoid) in the presence of participant’s urine (228, 229). We used a 
positive control from a patient who was on antimicrobial treatment at time of urine collection. 
Negative control urines were from healthy people who had not taken any drug for at least 3 
days before urine collection. A positive result was a zone of clearing >10 mm in either or both 
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agar plates with the two ATCC bacterial strains (figure 3-2). The sensitivity and specificity of 
this test are reportedly 97.4% and 98.9%, respectively (229). 
 
 
 
 
 
 
 
 
 
 
Figure 3-2 Urine test for detecting antimicrobial activity  
3.2.7 Endpoints 
The primary endpoint was the proportion of patients receiving any antimicrobial within 2 
weeks of enrolment. Antimicrobial use was defined as at least one of the following: 
1) Antimicrobial prescription at enrolment (day 0); 
2) Antimicrobial use reported at follow-up visit (day 4±1); 
3) Antimicrobial prescription at second visit (day 4±1); 
4) Antimicrobial activity in urine;  
5) Antimicrobial use reported at follow-up interview (day 14).  
 Subjects were classified as positive for antimicrobial use if at least one of these 
conditions were met, negative if all five criteria were documented as negative, and missing if 
all reported criteria were negative but data were missing for at least one criterion. 
Urine with antimicrobial present 
giving zone to organisms  
This urine shows no 
antimicrobial present with no 
zones of inhibition 
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Secondary endpoints included antimicrobial activity in urine (day 4±1), the proportion 
of patient with immediate antimicrobial prescription at enrolment, any antimicrobial usage in 
subjects without immediate prescription (subsequent antimicrobial use or ‘intervention 
failure”), prescriptions on the second visits in subjects without an immediate antimicrobial 
prescription (clinical management changed based on follow-up evaluation). Additional 
secondary endpoints were the source of any antimicrobial taken but not prescribed at 
enrolment or day 4 (self-medication/drug seller/doctor/other), the frequency of re-
consultations, serious adverse events (hospitalisation or death), time to resolution of 
symptoms, and reported patient satisfaction with participating in the trial on day 14 (measured 
on a scale from 0 to 10). Patients with satisfaction score ≥ 5 were considered satisfied.  
3.2.8 Sample size 
 We expected CRP-guidance to reduce antimicrobial prescription for ARI by at least 
20%: from 80% (224) to 60%. However, increased awareness of the issue through the study 
could itself bring antimicrobial prescription down, reducing the effect of CRP testing. 
Therefore, the trial was powered to detect a reduction of the antimicrobial prescription rate 
from 70% to 60%. To detect such a difference with 90% power and two-sided 5% 
significance level, a total of 477 patients are required per arm. In order to analyse adults and 
children separately, the target sample size was set at 2000 patients (two strata: 50% children 
and 50% adults).  
3.2.9 Statistical analysis 
Statistical analyses were pre-defined in the protocol and the statistical analysis plan. 
The main population for all analyses was the intention to treat population including all 
randomised patients except for those who withdrew immediately and analysis was according 
to the randomised treatment arm. Patients with missing outcomes were excluded from the 
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analysis but for the primary outcome, we also performed an alternative analysis based on 
multiple imputation of outcomes for those patients. Moreover, the analysis of the primary 
endpoint was repeated in the per protocol population which included only subjects for whom 
all components of the primary endpoint as mentioned above were non-missing. For the formal 
comparison of the composite primary endpoint and its components between the two treatment 
groups, we used a logistic regression model of the outcome depending on the treatment group 
and the age stratum (children versus. adults) as fixed effects and the healthcare centre as a 
random effect thereby taking clustering within centres into account. As we observed 
considerable heterogeneity in the primary endpoint between healthcare centres, we decided 
post-hoc to also visualise results by site using forest plots and to perform a standard random 
effects meta-analysis. Time to resolution of symptoms was visualised using Kaplan-Meier 
curves and formal comparisons between the two treatment arms were based on the Cox 
proportional hazards model with the treatment assignment and the age stratum as fixed effects 
and the healthcare centre as a Gaussian random effect (frailty). All data derivations were 
performed with SAS version 9.2 (SAS Institute Inc., Cary, USA) and statistical analyses were 
done with the statistical software R version 3.2.2 (R Foundation for Statistical Computing, 
Vienna, Austria).  
3.2.10 Training of participating sites 
 An initial training workshop was centrally conducted, followed by further training 
during on-site implementation visits at the 10 health centres by the study team. Training 
followed a model developed for a similar study in Maastricht, contextualised to the 
Vietnamese setting and carried out in Vietnamese (149, 230). Training materials were both 
verbal and written, consisting of oral presentations and written information leaflets for the 
doctors and health centres to keep for future reference. The health centres and doctors were 
given a telephone number to contact should any queries arise during the study. Laminated 
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posters and desk reminders with recommended cut-off values for the specific age groups were 
provided. 
3.2.11 Ethical considerations 
 The trial was approved by the ethical committees of the National Hospital for Tropical 
Diseases in Hanoi (39/IRB-NHTD) and the Oxford University Tropical Research Ethics 
Committee (OxTREC Reference: 176-12). Permission for this study was also obtained from 
local authorities. A study doctor or study nurse explained to patients/legal guardian about the 
trial including risks and benefits. After verbal agreement, written inform consent was 
obtained. Patients were reimbursed for their travel expenses for the requested second visit on 
day 4±1. Once consent was obtained a case report form was completed for each patient 
containing all the information related to the study variables. This trial is registered at 
ClinicalTrials.gov under number NCT01918579. 
3.3 Results 
 Patients were enrolled from March 2014 to July 2015. Of 3532 patients screened, 1258 
did not fulfill inclusion criteria, including 417 patients (33%) had already taken antimicrobials 
at presentation, and 237 declined to participate. A total of 2037 patients from 10 centres 
(range: 153-271 patients/site) were enrolled and randomised. One patient immediately 
withdrew after randomisation. 1017 [510 children, 507 adult] were allocated to the CRP 
group and 1019 [518 children, 501 adult] to the control group. The proportion missing 
primary outcome was 11% (115/1017) in the CRP group and 7% (72/1019) in the control 
group. The per protocol analysis contained 773 and 761 subjects in the CRP and control 
group, respectively (figure 3-3). 
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Figure 3-3 Trial flow diagram 
Excluded patients: age<1 or >65 years old: 244; severe respiratory infections: 16; hospital 
referral: 1; suspicion of tuberculosis: 3; liver disease: 6; medical history of neoplastic 
disease, congestive cardiac failure, COPD, insulin-dependent diabetes or renal disease: 110; 
pregnancy: 46; no access to telephone: 9; already taken antimicrobials: 417; symptoms 
present for more than two weeks: 65; not able to come for follow-up visit: 169; decline to 
participate: 237; uncoded: 172. 
 Characteristics of participants at enrolment were similar between both arms regarding 
age, duration of illness, vital signs and clinical symptoms at presentation. Female patients 
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accounted for 60% (1224/2036). Symptoms at presentation were: cough (88%), sore throat 
(82%), coryza (62%), fever (35%), dyspnoea (3%) and earache (3%) (table 3-2).   
Table 3-2 Baseline characteristics by randomised treatment arm at enrolment 
General characteristics  Control (n=1019) CRP (n=1017) 
Gender – female (n, %) 591 (58%) 633 (62%) 
Age (median, IQR) (years) 
  <6 
  6-15 
  >15 
15 (8-41) 
146 (14%) 
372 (37%) 
501 (49%) 
16 (8-39) 
141 (14%) 
369 (36%) 
507 (50%) 
Duration of illness (median, IQR) (days) 2 (2-3) 3 (2-3) 
Vital signs 
  Heart rate (median, IQR) (time/min) 
  Resp. rate (median, IQR) (time/min) 
  SBP* (median, IQR) (mm Hg) 
  DBP* (median, IQR) (mm Hg) 
 
80 (75-86) 
20 (19-23) 
110 (100-120) 
70 (70-80) 
 
80 (75-86) 
20 (19-23) 
110 (100-120) 
70 (60-80) 
Clinical symptoms 
  Cough  
  Sore throat 
  Sputum 
  Coryza 
  Fever 
  Earache 
  Dyspnoea 
  Wheeze     
 
905 (89%) 
833 (82%) 
638 (63%) 
619 (61%) 
347 (34%) 
40 (4%) 
32 (3%) 
22 (2%) 
 
891 (88%) 
830 (82%) 
653 (64%) 
632 (62%) 
364 (36%) 
48 (5%) 
23 (2%) 
40 (4%) 
Data are median (quartiles) or numbers (%). Quartiles refer to the lower and upper quartiles 
of the distribution, i.e. the 25% and 75% quartiles. *Blood pressure is reported for adults 
only. Age, gender, and heart rate were available for all subjects and blood pressure was 
measured in all adults. Respiratory rate was missing for 4 (0.2%) subjects, and clinical 
symptoms were missing for at most 13 (0.6%) of subjects. 
3.3.1 Primary endpoint: Any evidence of antimicrobial use within 14 days of follow-up 
 In the intention to treat (ITT) analysis, 738/947 routine care patients (77·9%) used an 
antimicrobial within 14 days of follow-up compared to 581/902 (64.4%) in the CRP-guided 
group (OR: 0·49; 95%CI 0·40-0.61; p<0·0001). The corresponding effect sizes for the ITT 
analysis based on multiple imputation (OR: 0·50; 95% CI 0·41-0·61; p<0·0001) and the per-
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protocol analysis (OR 0·51; 95%CI 0·41-0·63; p<0·0001) were similar and significant 
reductions were observed across all age groups (table 3-3).  
 In the ITT analysis for children, 374/487 (77%) routine care children had an 
antimicrobial treatment within 14 days compared to 295/448 (65·8%) in the CRP-guided 
group (OR: 0·55; 95%CI 0·41-0·61; p=0·0001). The corresponding figures for adults were 
364/460 (79%) compared to 286/454 (63%) (OR: 0·41; 95%CI 0·3-0·56; p<0·0001) (table 3-
3).     
Table 3-3 Proportion of patients receiving any antimicrobials within 14 days of follow-
up 
Subgroup 
Control (n=1019) CRP (n=1017) Comparison 
events/n (%) events/n (%) OR (95%CI) p value 
ITT – complete 
case analysis£ 
738/947 (77·9%) 581/902 (64·4%) 0·49(0·40-0·61)  p<0·0001 
ITT – multiple 
imputation 
analysis$ 
747/1019 (73·3%) 598/1017 (58·8%) 0·50(0·41-0·61)  p<0·0001 
Per protocol 552/761 (72·5%) 452/773 (58·5%) 0·51(0·41-0·63)  p<0·0001 
Children  
(1-15 years) 
 374/487 (76.8%)  295/448 (65.8%) 0.55(0.41-0.75)  p=0.0001 
Adult  
(>15 years) 
364/460 (79·1%) 286/454 (63·0%) 0·41(0·30-0·56)  p<0·0001 
OR: odds ratio from logistic regression model adjusted for age group and random site effect. 
£Variance of random site effect was estimated as 0.41 implying a intra-class correlation of 
0.41/(0.41+π2)=0.11. 
£An additive binomial regression model for the primary outcome (adjusted for age group and 
site effect) gives an adjusted absolute risk difference of -12.5% (95% CI -16.6% to -8.6%), 
p<0.0001 
$Based on 20 imputed datasets. Reported event numbers and proportions refer to averages 
across all imputed datasets.  
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 There was substantial heterogeneity between the health centres: I2 statistic = 84% 
(95%CI 66-96%) and the pooled median treatment effect estimate (OR: 0·47) from the 
random treatment effects model showed therefore a considerably wider 95% CI of 0·26-0·83 
(figure 3-4).   
 
 
Figure 3-4 Impact of CRP testing on evidence of antimicrobial use during 14 days of 
follow-up (primary endpoint) – random effects meta-analysis by site 
The mid-point of the box represents the median effect estimate for each site. The size of the 
box represents the weight given to each site. Length of the line represents the confidence 
interval (CI) for effect estimate for each site. The diamond below the studies represents the 
pooled median effect estimate. Width of the diamond represents the confidence interval for 
the pooled effect estimate. 
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3.3.2 Secondary endpoint: Immediate versus subsequent antimicrobial use 
(“intervention failure”) 
 CRP guided immediate antimicrobial prescription at presentation was reduced by 20% 
from 647/1019 (63%) in the routine group to 441/1017 (43%) in the CRP arm (OR: 0·41; 
95%CI 0·34-0·49; p<0·0001) in the intention to treat (ITT) analysis. This reduction remained 
significant in per protocol analysis (OR: 0·46; 95% CI 0·37-0·57; p<0·0001). The significant 
reductions were observed across all age groups with 19·8% decline in children (OR: 0·39; 
95% CI 0·30-0·52; p<0·0001) and 20·5% in adults (OR: 0·40; 95% CI 0·30-0·52; p<0·0001) 
(table 3-4).  
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Table 3-4 Summary of secondary endpoints 
 
Endpoint 
Control 
(n=1019) 
CRP 
(n=1017) 
Comparison* 
Estimate (95%CI) p value 
Immediate Abs prescription - events/n (%) 
All patients 647/1019 (63.5%) 441/1017 (43·4%) OR=0·41 (0·34-0·49) p<·0001 
Children 333/518 (64.3%) 227/510 (44.5%) OR=0.39 (0.30-0.52) p<·0001 
Adults 314/501 (62.7%) 214/507 (42.2%) OR=0.40 (0.30-0.52) p<·0001 
Subsequent Abs use - events/n (%)$ 
All patients 91/300 (30.3%) 140/461 (30.4%) OR=0.97 (0.70-1.35) p=0.85 
Children 41/154 (26.6%) 68/221 (30.8%)   OR=1.22 (0.78-1.94) p=0.38 
Adults 50/146 (34.2%) 72/240 (30.0%)   OR=0.73 (0.45-1.17) p=0.19 
Abs management change -events/n (%)$ 
All patients 12/345 (3.5%)   30/510 (5.9%) OR=1.70 (0.85-3.41) p=0.13 
Children 4/170 (2.4%)    8/255 (3.1%)   OR=1.09 (0.31-3.85) p=0.89 
Adults 8/175 (4.6%)    22/255 (8.6%) OR=1.99 (0.86-4.64) p=0.11 
Presence of Abs in urine - events/n (%) 
All patients 314/882 (35·6%) 267/877 (30·4%) OR=0·78 (0·63-0·95)  p=0·015 
Children 159/448 (35.5%) 132/439 (30.1%) OR=0.76 (0.56-1.01) p=0.06 
Adults 155/434 (35.7%) 135/438 (30.8%) OR=0.79 (0.59-1.06) p=0.12 
Time to resolution of symptoms –median (IQR) days 
All patients 5 (4-7) (n=758) 5 (4-7) (n=805) HR=0.92 (0.84-1.02) p=0.12 
Children 5 (4-7) 5 (3-7) HR=0.97 (0.84-1.11) p=0.64 
Adults 5 (4-8) 6 (4-10) HR=0.89 (0.77-1.03) p=0.10 
Hospitalisation -
events/n (%) 
8/874 (1%) 6/901 (1%) - p=0·60 
Re-consultation 
-events/n (%) 
3/1019 (0·3%) 5/1017 (0·5%) - p=0·51 
Satisfaction 
score§ -  
median (IQR) 
9·00 (8·00,10·00) 
[n=542] 
9·00 (8·00,10·00) 
[n= 549] 
- p=0·75 
Number of 
patients satisfied 
(satisfaction 
score>=5) 
541/542  
(99·8%) 
545/549 
(99·3%) 
 p=0·50 
OR: odds ratio from logistic regression model adjusted for age group and random site effect. 
HR: hazards ratio from Cox regression model adjusted for age group and random site effect. 
IQR: inter-quartile range. Comparisons based on logistic regression, Cox regression, 
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Fisher’s exact test (hospitalisation, re-consultation and number of patients satisfied), or 
Wilcoxon rank sum test (satisfaction score). n refers to the number of subjects with an 
evaluable outcome. $Subsequent Abs and Abs management change are reported in patients 
without immediate Abs prescription only, i.e. they refer to non-randomised comparisons 
because the denominator population depends on the randomised treatment arm. §Satisfaction 
score was measured on a scale from 0 to 10 and not available in all patients.  
 Substantial heterogeneity in immediate antimicrobial use between the health centres 
was detected: I2 statistic = 94% (95%CI 87-98%) (figure 3-5).   
 
Figure 3-5 Impact of CRP testing on immediate AB prescriptions on day 0 – Random 
effects meta-analysis by site.  
For each site: the mid-point of the box represents the median effect estimate; the size of the 
box represents the given weight; length of the line represents the confidence interval (CI) for 
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effect estimate. The diamond below the studies represents the pooled median effect estimate. 
Width of the diamond represents the CI for the pooled effect estimate. 
 Subsequent antimicrobial use without immediate prescription (“intervention failure”) 
within 14 days of follow-up was recorded in a larger absolute number of patients in the CRP 
guided group but the relative proportion of intervention failures amongst patients without an 
immediate prescription was similar between the two groups with 140/461 (30·4%) patients in 
the CRP group compared to 91/300 (30·3%) patients in the routine care arm (OR 0·97; 95% 
CI 0·7-1·35; p=0·85). The corresponding effect size was similar across all age groups (table 
3-4). Among 165 patients (72 in the routine care group, 93 in the CRP group) who recorded 
antimicrobials without prescription at enrolment or the second visit, the source of 
antimicrobials was recorded in 133 cases and the most frequent source was drug seller guided 
antimicrobial use (66) followed by doctor’s prescription (39) and self-medication (27), or 
other sources (1). 
3.3.3 Urinary antimicrobial activity presence  
 Antimicrobial activity in the urine sample on day 4±1 was significantly lower in the 
CRP group compared to the routine group. In ITT, this was 30.4% (267/877) in CRP group 
versus 35·6% (314/882) in the routine arm (OR 0·78; 95%CI 0·63-0·95; p=0·015) (table 3-4).  
581/1759 patients were positive for urinary antimicrobial activity. Antimicrobial activity was 
detected in 444/953 patients receiving immediate antimicrobials. The agreement between 
recorded prior antimicrobial use and detection of antimicrobial activity in the urine sample 
was moderate with κ=0·43 (95%CI 0·39-0·47). Amongst those without recorded prior 
antimicrobials use, 46/487 (9%) in the CRP arm and 26/319 (8%) in the control arm had a 
positive urine test. Similarly, the rate of positive urine test amongst patients with recorded 
prior antimicrobials use was 221/390 (57%) in the CRP arm and 288/563 (51%) in the routine 
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care group. This latter proportion was lowest in the control arm of the rural Ba Vi site with 
23/71 (32%) positive urine tests in patients with recorded prior antimicrobials use. 
3.3.4 Change in antimicrobial management  
 Amongst subjects without immediate antimicrobials prescriptions, the proportion of 
subjects with a prescription of an antimicrobial on day 4 (±1) was 30/510 patients (6%) in the 
CRP group compared to 12/345 patients (3%) in the routine arm in ITT analysis (OR: 1·70; 
95%CI 0·85-3·41; p=0·13) (table 3-4).  
3.3.5 Time to resolution of symptoms and serious adverse events 
 Time to resolution of symptoms was similar across both arms (figure 3-6) with a 
median duration of 5 days (IQR 4-7) in both arms (HR 0·92; 95% CI 0·84-1·02) (table 3-4). 
 
 
Figure 3-6 Kaplan Meier curve of time to resolution of symptoms after enrolment by 
treatment arm (for all patients) 
 Time to resolution of symptoms in control (dark) and CRP group (grey) 
HR 0·92; 95% CI 0·84-1·02;  
p value 0.12  
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 Adverse events, defined as hospitalisation or death between enrolment and day 14, 
were rare with zero deaths and 14 hospitalisations: 8 in routine arm and 6 in CRP arm. 3/1019 
patients in the routine group and 5/1017 patients in CRP group needed re-consultation (table 
3-4).  
3.3.6 Patient satisfaction 
 We detected no differences in patient’s satisfaction between randomised arms (table 3-
4). 
3.3.7 CRP levels and immediate antimicrobial prescription 
Of all CRP measurements in this population 75% (758/1017) were below 10 mg/L, 
13% (133/1017) between 11-20mg/L, 10% (101/1017) were 21-50mg/L and only 2% 
(25/1017) had a CRP >50mg/L. For children under 6 years old, 35% (28/81 patients) received 
immediate antimicrobial prescription when the CRP value at enrolment was ≤10mg/L. The 
corresponding figure for adults with a CRP value at day 0 of ≤ 20mg/L was 37% (171/459) 
(table 3-5). Adherence to the intervention algorithm was highly variable across sites. For 
patients aged 6-65 years-old with a CRP value at day 0 of ≤ 20mg/L, the immediate 
antimicrobial prescription rate ranged from 4% (3/75) (in Sai Dong station) to 71% (49/69) 
(in Dong Da station).  
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Table 3-5 CRP levels at enrolment versus immediate antimicrobial prescription  
 
All patients 
(n=1017) 
<6 years old 
(n=141) 
6-15 years-old 
(n=369) 
Adults  
(n=507) 
CRP day 0 events/n (%) events/n (%) events/n (%) events/n (%) 
<=10 mg/L 257/758(33.9%) 28/81(34.6%) 83/268(31.0%) 146/409(35.7%) 
11-20 mg/L 68/133(51.1%) 14/26(53.8%) 29/57(50.9%) 25/50(50.0%) 
21-50 mg/L 91/101(90.1%) 25/28(89.3%) 29/31(93.5%) 37/42(88.1%) 
>50 mg/L  25/25(100.0%)  6/6(100.0%) 13/13(100.0%) 6/6(100.0%) 
 
3.4 Discussion  
 This study shows that access to C-reactive protein (CRP) point-of-care (POC) testing 
reduces unnecessary antimicrobial use for non-severe acute respiratory infections in adults 
and children in primary healthcare in Vietnam, without compromising clinical recovery or 
serious adverse events. Our findings were consistent across all outcome measures we used: 
dispensing and prescribing data, patient self-report and microbiologically confirmed 
antimicrobial presence in urine. This trial is the first study investigating the effects of CRP 
POC testing in a resource constrained setting and the impact of CRP testing on antimicrobial 
use in children has never been assessed before in a randomised controlled trial (RCT).  
 With an overall absolute reduction of 13·5% (77·9% versus 64·4%) in antimicrobial 
use, the effect of CRP testing in our trial is similar to that reported in the Netherlands, where 
the reduction was 12·4% (65·1% versus 52·7%; risk ratio [RR] 0·81) (148) and higher than in 
Norway, where a non-significant reduction was found (RR 0·95; 95%CI 0·76-1·18) (153). 
Cluster-randomised controlled trials in the Netherlands and Russia showed statistically 
significant reductions of 18·3% (149) and 15·3% (150) respectively. The decline in 
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immediate prescription rate was also larger in our study as compared with previous individual 
RCTs (152, 153, 230) but lower than in cluster-RCTs (149-151).   
 There was large heterogeneity in the effect of CRP POC testing across sites. Likely, 
several sites did not adhere to the intervention algorithm. The final decision to prescribe 
antibiotics were at the discretion of the physician making the adherence to algorithm so 
variable and is a fact of how healthcare works. More familiarity and presenting data it is safe 
to follow CRP cut-offs in low resource settings will enhance compliance. Of note the results 
of a previous study in European countries suggests that an intervention combining CRP 
testing and education had the highest impact on prescribing (151). 
 Similar to results from previous trials, no differences regarding recovery, serious 
adverse events and patient’s satisfaction were found after the introduction of CRP testing, 
though given the benign clinical syndrome addressed it was unlikely to be powered to detect 
differences in outcome. One trial has previously documented an increase in hospital 
admissions associated with CRP guided treatment. However, this adverse event was rare (22 
versus 8 among 4264 patients) and concerns regarding this risk must be balanced against 
benefits of reducing inappropriate antimicrobial use on a large scale (151). Such adverse 
events were also exceedingly rare in our study with no apparent difference between the 
groups. According to the National Institute for Health and Clinical Excellence (NICE) clinical 
guidelines 69, the usual average total length of the illness ranges from 4 days to 3 weeks 
depending on type of illness (223). In our trial, median duration of symptoms was about one 
week. Only 19% of patients had median length of the illness more than 10 days (Figure 3-6). 
It might be explained as all recruited patients had non-severe ARI and Vietnamese population 
is also different from UK population with lower healthcare seeking threshold.   
 While most previous large trials only looked at prescribing data or self-reporting on 
antimicrobial usage, testing urinary antimicrobial activity provided additional information in 
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this study. In comparison to levels of immediate antimicrobial prescription, detection of urine 
antimicrobial activity was substantially lower across both arms: 36% versus 30%in the 
routine group. The agreement between recorded antimicrobial use and detection of 
antimicrobial activity in urine was only moderate (κ=0·43) (231) and detection rates in urine 
as a fraction of recorded use were lower in the control arm and lowest in the control arm of 
the rural Ba Vi site. This may be explained if patients stop their antimicrobial treatment 
before the second visit on day 4±1 as suggested by a previous study among children in rural 
Vietnam that reported that 42% (341/818) of patients used antimicrobials for only one or two 
days (232). A further explanation could be the variability in days urines were collected, the 
urines not collected and biliary excretion of several popular antimicrobials such as 
azithromycin or spiramycin.  
 Procalcitonin may be an alternative biomarker to CRP. Procalcitonin was shown to be 
an effective biomarker in reducing antimicrobial use for ARIs in primary care setting in 
European countries (136, 139, 233). However, a well-validated point of care test for 
procalcitonin that is feasible for use in these settings is not yet commercially available as far 
as we are aware. Furthermore, a recent study assessed the diagnostic accuracy of 
procalcitonin and C-reactive protein (CRP) in distinguishing common viral and bacterial 
infections in malaria endemic settings of three Southern Asian countries. This study indicated 
that applied to samples from febrile patients with mono-infections, CRP was a highly 
sensitive and moderately specific biomarker for discriminating between viral and two 
bacterial aetiological groups (Rickettsia/Leptospira), as well as from the bacteraemia group 
and malaria (125). CRP had a higher sensitivity and specificity in discriminating viral and 
bacterial infections compared to procalcitonin in this study.  
 With the large sample size, our trial was robust to assess the intervention effect in 
different age subgroups in a real life situation. This provides us with relevant data on what 
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obstacles need to be overcome to make the intervention even more effective. Our findings 
suggest that CRP testing could be an important component of non-antimicrobial ARI 
management strategies in primary care settings in low and middle income countries. The 
intervention has the potential of being scaled up as several commercially affordable CRP 
rapid POC tests have been evaluated and found to be reliable (234). Before widely 
introducing CRP POC tests as routine care, a cost-effectiveness analysis should be performed 
to assess other additional requirements, including test cost, training and consultation time, 
compared to the reduction in antimicrobial prescription and subsequent burden of resistance. 
To achieve maximal impact on antimicrobial consumption in settings, such as Vietnam, 
where antimicrobial use is commonly off-prescription further work investigating the potential 
for POC CRP testing in pharmacies and drug stores will be needed. This trial provides 
important data necessary for planning such studies. There may be lessons to be learnt from 
the roll out of rapid diagnostic tests in community settings (235). 
 There are several limitations of our study. Due to the study design (individual 
randomisation) over time clinicians may have become familiar with the clinical picture 
associated with low CRP, resulting in reduced antimicrobial prescriptions even in individuals 
randomised to the control arm. A cluster RCT design may have prevented this contamination 
effect but would be more costly. However, this limitation would have led to a reduction in the 
observed effect rather than an overestimation. We may have not captured all antimicrobial use 
by the 2nd visit, the diary, urine test and the day 14 interview. Patients may have not reported 
antimicrobial use due to poor recall or self-perceived misuse of antimicrobials or were 
unaware pills they were given were antimicrobials. However, this bias should be equally 
distributed across both arms. Lastly the heterogeneity of the effect is far from ideal, but is 
likely to represent differences in context that will be explored further in qualitative analyses 
and must be addressed for successful implementation of this strategy. 
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Chapter 4 
Economic Implications of C-Reactive Protein Point of Care Testing in the Management 
of Acute Respiratory Infections in the Vietnamese Primary Health Care Setting 
4.1 Background 
 Acute respiratory infections (ARI) is the syndrome that accounts for the largest 
proportion of human antimicrobial consumption (236, 237). Antimicrobial use for ARI is very 
common in Vietnam, both in- and outside primary health care settings (97), despite a 
predominantly viral aetiology and minimal benefit of antimicrobials in uncomplicated cases 
(238). Treatment decisions are based solely on clinical examination, which in both low and 
high income settings is known to be of poor accuracy in identifying where antimicrobials are 
and are not required. It has been estimated that roughly 70% of examined patients in primary 
care in Vietnam receive an antimicrobial prescription and ARIs are the reason for 51% of 
these prescriptions. Furthermore, 71% of antimicrobials were given in an inadequate dose and 
duration (i.e. the drugs were either given for less than five days or fewer times per day than 
prescribed) (239).  
 Antimicrobial resistance (AMR) is an inevitable consequence of their consumption, 
and while this interaction can be complex it is widely accepted that safe reductions in 
antimicrobial consumption will have the desirable effect of mitigating the burden of AMR. 
The association between prescribing antimicrobial agents and antimicrobial resistance of 
Streptococcus pneumoniae among children under five years-old with acute otitis media 
(AOM) was reported in southern Israel, during 1999-2003. Rapid decrease in prescription 
rates was associated with lower observed resistance rates during the warm versus the cold 
months (p < .001 for each antimicrobial). Each monthly increase in 10 prescriptions/1000 
children was associated with a 1.05-fold increase in the odds of penicillin resistance during 
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that month (95% CI, 1.03−1.07; p < .001). The corresponding OR for erythromycin resistance 
was 1.04 (95% CI, 1.02−1.05; p < .001), for multidrug resistance, it was 1.04 (95% CI, 
1.02−1.06; p < .001) (240). 
 Several biomarkers in blood have been evaluated to guide the use of antimicrobials for 
ARIs in primary care, including C-reactive protein (CRP), procalcitonin and blood leukocyte. 
Recent evidence from diagnostic studies have shown CRP to have high discriminatory power 
in distinguishing between viral and bacterial infections (125, 241) and a meta-analysis of 
randomised control trials found it to significantly and safely reduce antimicrobial prescribing 
(225). Point-of-care (POC) tests for CRP are available and can be performed in general 
practice using a capillary blood sample, with results available within a few minutes (154, 242, 
243). Such an approach is already widely used in a number of high income countries such as 
Norway and Sweden, (149, 244) and is being recommended in the UK by the NICE and 
Public Health England (245). Economic evaluations have concluded that despite a higher cost 
per patient, CRP testing can be cost-effective in the European context due to either direct 
health benefits to patients or the safe reduction in antimicrobial consumption (156, 246, 247). 
 How transferable the limited evidence from high income settings to other contexts is 
not clear. The aim of this study is to describe the economic implications of CRP testing for 
ARI patients and health providers in a lower middle income country (LMIC) setting. The 
study draws on a recent randomised control trial in Vietnam where CRP POC testing was 
compared against current practice in the management of ARIs in primary care, demonstrating 
a significant reduction in antimicrobial consumption with the use of CRP tests, without 
compromising patient recovery and satisfaction (216). Here we explore the direct medical 
costs for patients and providers, and the cost-effectiveness in terms of the cost per 
antimicrobial prescription averted.  We also explore the budget-impact of CRP testing should 
such a policy be adopted at a national scale. 
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4.2 Methods  
 An open-label randomised controlled trial was conducted in 10 primary healthcare 
centres in northern Vietnam to assess the effectiveness of CRP POC testing in reducing 
inappropriate antimicrobial use for patients, aged 1 to 65 years with symptoms of non-severe 
ARI; details of the study are described in Chapter 3. In brief, 2,036 patients (1028 children, 
1008 adults) were enrolled. Among them, 1017 [518 children, 501 adult] were allocated to the 
CRP group and 1019 [510 children, 507 adult] to the routine care (control) group. All patients 
received routine clinical examination at enrolment and follow-up visit on day 4 (±1). Patients 
in the CRP group received additional evaluation by CRP POC testing at day 0 and at the 
second visit. Patients randomised to the control arm were treated according to routine practice 
and local treatment guidelines. Treatment for CRP patients was based on both clinical 
examination and CRP testing results. Different CRP cut-off values were given for different 
age categories to recommend withholding an antimicrobial prescription. All patients were 
required to provide a urine sample in the follow-up visit for testing the presence of 
antimicrobial activity. A telephone interview was done after two weeks of follow-up for all 
patients. The primary outcome was antimicrobial use within 14 days follow-up. Secondary 
outcomes included presence of antimicrobials in urine on day 4±1, immediate versus 
subsequent prescription within 2 weeks, the source of any antimicrobial taken but not 
prescribed at enrolment or day 4 (self-medication/drug seller/doctor/other), the frequency of 
re-consultations, serious adverse events (hospitalisation or death), the duration of symptoms, 
and the reported patient satisfaction. 
 
4.2.1 Cost survey forms 
 A survey was carried out to collect medical and non-medical costs related to the 
management of the illness on the day of enrolment. Medical costs consist of those for 
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examination, routine diagnostic tests (other than CRP testing) and medications. Medical costs 
in Vietnam are partially covered by health insurance and the remainder by patients’ out-of-
pocket; both costs were recorded separately in the forms. The trial recruited outpatients only, 
therefore non-medical direct costs included those for transportation alone. At day 14 a similar 
form was used to collect any subsequent costs during the two-week follow-up period.   
4.2.2 Data analysis 
 The data were cleaned and double entered into an electronic database and checked for 
quality by an independent data analyst. Medical and non-medical cost data were summarised 
using mean and standard deviation (SD) regardless of skewed distributed data (248). Potential 
differences between the CRP guided treatment group and the routine care group were 
compared by t-test and Mann–Whitney U (Wilcoxon rank sum) test for non-normal 
continuous data (248). P-values less than 0.05 were considered significant (2 tailed). All costs 
are reported in US Dollars ($) using the 2015 currency exchange rate from Vietnam Dong 
(VND) of $1 = 22,500 VND. 
4.2.3 Cost-effectiveness analysis 
 The cost-effectiveness analysis estimates the cost per antimicrobial prescription averted 
on the day of attendance at the primary health facility (156). This reflects the demonstrated 
benefit of CRP testing in safely reducing antimicrobial consumption for ARI patients while 
maintaining non-inferior health outcomes, as hypothesised in chapter 3. The cost-
effectiveness analysis is conducted from the health provider perspective and includes the 
costs for antimicrobials, CRP testing and other medical expenditure. The cost-effectiveness 
analysis is followed by a budget impact analysis to estimate the cost implications of 
introducing CRP testing across district level facilities. 
4.2.4 Model structure 
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 We use a simple decision tree to estimate the cost per antimicrobial prescription averted 
with the use of CRP testing as compared with current practice. In the current practice arm the 
trial data are used for the proportion of patients that received treatment in the control group on 
the first day of attendance. In the CRP arm of the model patients are subdivided into two 
groups. The first comprises those with CRP levels at which health workers were 
recommended not to prescribe an antimicrobial (up to a threshold of 10mg/L in children or 
20mg/L in adults). The second group is comprised of patients with either intermediate CRP 
levels in whom health workers were advised to use local guidelines and clinical judgment 
(10-50mg/L) in children or 20mg/L-100mg/L in adults) or those with high CRP values for 
whom an antimicrobial was recommended (>50mg/L in children and >100mg/L in adults), as 
shown in figure 4-1. 
 
 
Figure 4-1 Decision tree outline for the cost-effectiveness model 
 In the subgroup with low CRP levels, we used the proportion of patients that were not 
prescribed an antimicrobial to define the degree of adherence to low CRP test results, which 
in the trial averaged 64%. This value was varied from 50% to 100% to model the implication 
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of varying degrees of adherence to the test. For patients with intermediate or high CRP values 
we assigned the same antimicrobial prescription rate as in the trial (86%), and conservatively 
assumed no advantage in better identification of patients that genuinely required 
antimicrobials (as indicated by high CRP values). In summary, therefore, there was no 
assumed direct health benefit to patients in CRP testing due to better identification of patients 
requiring antimicrobial treatment, or the avoidance of side-effects and allergic reaction in 
patients receiving antimicrobials unnecessarily, only a potential reduction in the prescription 
rate in those with low levels of CRP. 
 The average provider costs for patients in each arm were comprised of a fixed and 
equal cost of medication and diagnostics other than the CRP tests and antimicrobials (which 
did not differ significantly in the trial between the trial arms) and the cost of antimicrobials, 
using a mean unit cost of $1.5, as documented in the trial. The CRP reader and reagents in the 
trial were provided free of charge by the manufacturer; if purchased commercially the 
reagents would cost approximately $3 per test. There are, however, commercially available 
accurate qualitative test such as DTS233 (Creative Diagnostics, USA) and semi-quantitative 
version such as WD-23 (Assure Tech, China) and bioNexia CRPplus (bioMérieux S.A., 
France) (243). The lowest cost test is the WD-23, which costs approximately $0.6/test, the 
quote for the DTS233 is approximately $2.5/test and the bioMérieux test is about $2.2, but no 
longer in production. While these rapid tests require further validation, we used a baseline 
estimate of $1 for the unit cost of the test with a range of $0·5-$3 in the sensitivity analysis. 
The model was then used to estimate the cost per antimicrobial prescription averted across a 
range of estimates for the cost of the CRP test, and for the adherence to the CRP test (in 
avoiding prescription of antimicrobials to patients with low CRP values); other model 
parameters were also included in the probabilistic sensitivity analyses (PSA) as described in 
table 4-1. 
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Table 4-1 Parameter estimates used in the model 
Parameters Point estimate Range/distribution 
for sensitivity 
analysis 
Source 
Antimicrobial 
prescription rate in 
current practice 
63% Beta (α=647,β=370) Primary data from trial 
Percentage of 
patients with low 
levels of CRP 
indicating that 
antimicrobials are 
not required 
85% Beta (α=860,β=150) Primary data from trial 
Antimicrobial 
prescription in 
patients with high 
CRP values 
86% Beta (α=130,β=22) Primary data from trial 
Adherence to test 
result when 
antimicrobials not 
indicated 
64% Range of 50%-100% 
in two way 
sensitivity analysis. 
Beta (α=554,β=311) 
for PSA 
Primary data from trial 
Unit cost per CRP 
test (USD) 
$1 $0.5 - $3 in two way 
sensitivity analysis; 
Gamma (shape=0·2, 
scale=6) for PSA 
(243) 
Unit cost per course 
of antimicrobials 
$1·5 Gamma (shape=0·25, 
scale=6) 
Primary costing data 
from trial 
 
4.2.5 Willingness to pay threshold for safe reductions in antimicrobials 
 Despite the intuitive value of safe reductions in antimicrobial consumption, there are no 
established methods to quantify the health or economic benefits of doing so to determine what 
would be considered a cost-effective intervention with this aim. The societal willingness to 
pay for these gains should equate to the discounted future costs associated with the 
implications of AMR that could be explained by the consumption of antimicrobials. To our 
knowledge only one study has directly quantified the economic costs of antimicrobial 
resistance per antimicrobial consumed (249). The study was carried out in a very different 
context of hospitals in Germany, and the findings were that each defined daily dose (DDD) of 
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a 2nd generation cephalosporin was associated with a cost of €5 due to antimicrobial 
resistance; for other classes of antimicrobials the costs were higher (€11 for fluoroquinolones 
and €15 for 3rd generation cephalosporins).  
 Acknowledging the limitations of generalising these findings, in the absence of more 
relevant data we use these values, having adjusted them by the ratio of GDP/capita (measured 
in PPP) of Vietnam over that of Germany (0·12). We then applied the adjusted estimate of the 
cost of AMR for a DDD of 2nd generation cephalosporin for a five-day treatment course, 
implying that each full course of antimicrobials is estimated with a subsequent cost of $3 due 
to AMR. This should also imply that policy makers are willing to pay (WTP) up to this value 
to avoid the unnecessary use of an antimicrobial. Given the extensive uncertainty surrounding 
this value, we use a range of $0 to $10 for this WTP threshold. These are provisional and 
admittedly poor estimates for the value of avoiding unnecessary antimicrobial consumption; 
we return to this point in the discussion. 
4.2.6 Budget impact analysis 
 The model was then used to estimate the total cost for managing non-severe ARI 
patients in district hospitals and community health centres in Vietnam, the target settings for 
the intervention. Alongside the budget implications we also estimate the total quantities of 
antimicrobials avoided. The total number of community health centres and district hospitals 
were estimated at 600 each (90). The baseline surveys conducted prior to the trial estimated 
approximately 2000 ARI patients per year per community health centre and 20,000 
outpatients at the district hospitals, of whom approximately 50% meet the trial inclusion 
criteria in terms of age and severity, and are therefore included in the budget impact analysis 
as the target population. We again used a range of estimates for the cost of the test and for 
adherence to the test result. The data were analysed and the models written in R version 3.2.2 
(R Foundation for Statistical Computing, Vienna, Austria).  
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4.2.7 Ethical considerations 
 The trial was approved by the ethical committees of the National Hospital for Tropical 
Diseases in Hanoi (39/IRB-NHTD) and the Oxford University Tropical Research Ethics 
Committee (OxTREC Reference: 176-12). Permission for this study also was obtained from 
local authorities. Patients who fulfilled the inclusion criteria were asked to participate by 
signing the consent form. The cost surveys were included in these approvals and consent 
procedures. The trial is registered at ClinicalTrials.gov under number NCT01918579. 
4.3 Results 
 Of the 2036 patients that were enrolled in the trial, cost data were available for 100% of 
patients on day 0 and for 90% (1828/2036) on the day 14 follow up visit. 
4.3.1 Patient and provider costs in the control and intervention arms on first attendance 
 Patients travelled a mean distance of 3·6 km to attend the facility; most patients used 
their own means of transport and travel costs were low (mean < $0·2).  At the day of first 
attendance, the cost for antimicrobials were significantly lower in the CRP guided treatment 
group (mean difference = -$0·18; 95% CI -$0·28 to -$0·08). This was slightly offset by a 
smaller increase in costs for other medication in the intervention arm (mean difference $0·06; 
95%CI $0.01 to $0.12). All other costs were similar between arms (p>0·05) (table 4-2). In 
both groups approximately 90% of the total costs were covered by health insurance and the 
remaining were co-paid by patients.  
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Table 4-2 Summary cost by treatment arm at enrolment (in USD) 
 CRP 
(n=1017) 
Mean (SD) 
Control 
(n=1019) 
Mean (SD) 
Difference mean 
(95%CI) 
p value$ 
Total cost (USD) 1·24 (1·53) 1·31 (1·52) -0·07 (-0·21 to 
0·06) 
p=0·28 
Examination cost 
Total 
HI cover 
Self-paid 
 
0·35 (0·62) 
0·22 (0·60) 
0·12 (0·29) 
 
0·34 (0·34) 
0·20 (0·28) 
0·14 (0·31) 
 
0·01 (-0·04 to 0·05) 
0·02 (-0·02 to 0·06) 
0·02 (-0·05 to 
0·006) 
 
p=0·84 
p=0·24 
p=0·14 
Diagnostic test 
cost 
Total 
HI cover 
Self-paid 
 
0·18 (1·30) 
0·15 (1·04) 
0·04 (0·54) 
0·18 (1·20) 
 
0·12 (0·85) 
0·11 (0·73) 
0·02 (0·16)  
0·07 (0·86) 
 
 
0·06 (-0·04 to 0·15) 
0·04 (-0·04 to 0·12) 
0·02 (-0·01 to 0·05) 
0·11 (-0·02 to 0·24)  
 
 
p=0·23 
p=0·33 
p=0·26 
p=0·11 
 
Antimicrobial 
cost   
Total 
HI cover 
Self-paid 
 
0·51 (1·04) 
0·48 (0·94) 
0·03 (0·17) 
 
0·69 (1·23) 
0·63 (1·04) 
0·05 (0·49) 
 
-0·18 (-0·28 to -
0·08) 
-0·15 (-0·24 to -
0·07) 
-0·02 (-0·05 to 
0·01) 
 
p=0·0004 
p=0·0003 
p=0·22 
Other medications  
Total 
HI cover 
Self-paid 
 
0·39 (0·63) 
0·37 (0·60) 
0·02 (0·09) 
 
0·33 (0·58) 
0·32 (0·56) 
0·01 (0·09) 
 
0·06 (0·01 to 0·12) 
0·05 (0.01 to 0·11) 
0·01 (-0·002 to 
0·01) 
 
p=0·02 
p=0·03 
p=0·13 
$All comparisons were based on t-test.  
4.3.2 Patient and provider costs during the two weeks of follow-up 
 In the two weeks following first attendance, total medical and non-medical costs were 
similar across treatment arms (p>0·05) (Table 4-3), despite a small increase of $0·06 in 
treatment costs in the CRP arm (p=0·02).  Self-reported duration of antimicrobial treatment 
was similar in both arms with median of five days (p=0·44). 
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Table 4-3 Subsequent cost by treatment arm during 14 days (in USD) 
 CRP (n=1017) 
Mean (SD) 
Control (n=1018) 
Mean (SD) 
Difference mean 
(95%CI)$ 
Total cost 1·18 (1·37) 1.28 (1·42) -0.1 (-0·22 to 0·02) 
Treatment cost 0·39 (0·63) 0·33 (0·58) 0·06 (0·01 to 0·12)  
Antimicrobial cost 0·18 (1·46) 0·14 (1·14) -0·04 (-0·07 to 0·16) 
Other medications cost 0·07 (0·53) 0·09 (1·12) -0·02 (-0.09 to 0·06) 
$All comparisons were based on t-test except duration of antimicrobial treatment (Wilcoxon 
rank sum test). All p-value>0.05 except for comparison of treatment cost.  
 In summary, there was no significant difference in household and provider costs for 
patients in each of the trial arms, with a mean total cost from first attendance and during two 
weeks of follow-up in the intervention arm of $2·42, lower but not significantly so than the 
mean cost of $2·59 in the control arm (p=0·18). 
4.3.3 Cost-effectiveness analysis 
 The costs reported above were based on primary data collected during the trial, and 
excluded the cost for the CRP tests that were provided free of charge. In the model, with the 
use of a CRP test with a unit cost of $1, the incremental cost per patient managed with the aid 
of a CRP test would be $0.71. Two parameters are key drivers for this incremental cost – the 
unit cost of the test and the probability that health workers adhere to the results in avoiding 
prescription of antimicrobials to patients with CRP levels below the age-specific threshold. 
When varying these two parameters between a range of $0·5 to $3 for the cost of the test and 
100% to 50% adherence to the test results, as shown in figure 4-2 the difference in costs per 
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patient range from a cost saving of $0·3 (low cost, high adherence) to an incremental cost of 
$2·7 (high unit cost, low adherence).  
 
 
 
 
 
Figure 4-2 Difference in mean cost per patient between CRP testing and current 
practice. 
Given a range of unit costs for the test and varying the level of adherence to test results. For 
the CRP test to be cost saving at the lowest estimate of $0.5, adherence would have to exceed 
80%. 
The effect of CRP testing is a 20% (absolute) reduction in the antimicrobial 
prescription rate, using the trial data for immediate antimicrobial prescription rates, including 
36% of patients with low levels of CRP being prescribed an antimicrobial. If adherence to 
low CRP test results was complete this would result in an absolute reduction of 51%, so that 
only 12% of patients would be prescribed an antimicrobial as compared with current practice 
of 63%. Increasing compliance would require additional costs for training health care 
workers, not accounted for in our study. 
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Using the point estimates of $0·71 in incremental costs and an effect of 20% reduction 
in antimicrobial prescription results in an incremental cost of $3·7 per antimicrobials 
prescription averted. In the two-way sensitivity analyses this implies a range from the 
aforementioned cost saving and very high reduction in antimicrobial prescription rates for the 
low cost test with 100% adherence, up to a cost of $36 per antimicrobials prescription averted 
for a test costing $3 if adherence in patients with low levels of CRP is only 50%. A 
probabilistic sensitivity analyses was also performed varying all model parameters; a cost-
effectiveness plane with the results of 200 Monte-Carlo simulations in figure 4-3 illustrates 
the incremental costs and effects accounting for all parameter uncertainties. 
 
Figure 4-3 Cost-effectiveness plane showing the output of 200 Monte-Carlo simulations.  
The graph illustrates the simulation outputs, showing the incremental costs and gains for 
each simulation, and its positioning in relation to three different WTP thresholds. If policy 
makers were willing to pay $10 per antimicrobial prescription averted, CRP testing would be 
highly likely to be cost-effective, as indicated by the small proportion of instances where the 
simulation outputs are above this threshold. 
In all modelled instances CRP testing safely reduced antimicrobials in a range of 10% - 
50%. While there were a small number of instances where the CRP test was also cost saving, 
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in most instances it was more costly, and in over 55% of instances the incremental cost-
effectiveness ratio was above the WTP threshold of $3. This is indicated in the cost-
effectiveness acceptability curves in figure 4-4, showing that the point at which there was 
over a 50% probability of CRP testing being cost effective was at a WTP value of between $3 
to $5 per antimicrobial prescription averted. A WTP threshold of $10 would imply close to 
100% certainty of CRP testing being cost-effective, given the model assumptions.   
 
 
Figure 4-4 Cost-effectiveness acceptability curves for CRP testing and current practice  
Given the model assumptions and parameter uncertainties, CRP testing (black curve) is more 
likely to be cost-effective if policy makers are willing to pay over approximately $3.5 per 
antimicrobials prescription averted.  
4.3.4 Budget impact analysis 
Lastly, we estimated the total cost and impact of CRP testing if these were to be 
adopted across the Vietnamese community health clinics and at outpatient departments of 
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district level hospitals. Using the baseline estimates of $1 for the unit cost of the test and 64% 
adherence, the model suggested that implementation of the tests at this scale would result in 
an additional annual cost of $4·6m, and avert the prescription of 1·3 million courses of 
antimicrobials. The best case scenario with a low-cost test ($0·5) and 100% adherence with 
test results implies a cost saving of $1·6m and 3·2m antimicrobials avoided. A worst-case 
scenario with a $3 test and 50% adherence implies a budget impact of $19m and 480 
thousand courses of antimicrobial prescriptions averted. 
4.4 Discussion 
 Previously, a trial based cost-effectiveness analysis conducted in the Netherlands had 
shown that although CRP tests cost more per patient in the short term, with a mean cost per 
patient of €37.6 compared to €36·0 in the routine arm, this was balanced by a reduction in 
antimicrobial prescriptions (39% versus 68%, ICER €5·79) and improved quality of life 
(156). A modelling based evaluation largely based on this trial considered the cost-
effectiveness of CRP guided treatment of ARIs in primary care in the UK setting, also 
concluding that it would result in a gain in QALYs, minor cost-savings, and a reduction in 
antimicrobial prescriptions (247). Another observational based economic evaluation 
conducted in Sweden and Norway showed a higher but non-significant increase of €11·3 
(p=0·09) in health care cost and a reduction in antimicrobial prescription of 10% associated 
with CRP POC testing (p=0·08) (155). All three of these studies concluded that CRP POC 
testing was cost-effective in reducing antimicrobial prescription and in cost per QALY gained 
in these high income settings. This study is the first economic evaluation of CRP guided 
treatment in an LMIC. 
The trial results demonstrated that CRP testing could safely reduce antimicrobial 
prescription rates on first attendance by 20%, and that these gains were largely sustained at 
two weeks’ follow up, with a 14% absolute difference. Here we investigated the economic 
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implications of the use of CRP tests from the patient and health system perspectives. The use 
of the CRP test resulted in small and non-significant decreases in direct medical and non-
medical costs for patients and healthcare providers on first attendance and during the two 
weeks’ follow-up.   
When considering the added cost incurred by a CRP test at a unit cost of $1, the 
reduction of approximately 20% in antimicrobial prescription rates would imply a cost of 
$3·7 per antimicrobial prescription averted. If used across the network of community health 
centres and in outpatients attending district hospitals, CRP testing would incur approximately 
$4.6m and avert the prescription of 1·3 million courses of antimicrobials; assuming a weight 
of 5g per full course (e.g. amoxicillin 500mg tablets taken up to three times daily for five 
days; ampicillin 500mg twice daily over five days), this would be equivalent to avoiding the 
consumption of over six tons of antimicrobials every year by primary care patients with ARIs 
in Vietnam. 
Even in high income countries, primary care practices cannot use the test unless it is 
properly resourced (250). Whether such safe reductions in the use of antimicrobials justify 
this use of scarce resources is a challenging question. In LMIC settings this added cost should 
not be shouldered by patients’ out-of-pocket payments, and in the poorest countries it is 
highly unlikely that health systems would or should view this as a priority over interventions 
with more tangible benefits, therefore leaving the funding to patients or health systems will 
result in sub-optimal uptake from a global perspective. Furthermore, different reimbursement 
structures exist among European countries: some may encourage inappropriate use or overuse 
of the test. Pay for performance (P4P) that offers financial incentives to physicians, or 
healthcare providers for meeting certain performance measures can be an effective payment 
model to enhance financial savings and quality improvement (251). P4P metrics may include: 
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(1) Process metrics: to assess if patients are undergoing appropriate CRP testing, as 
defined by evidence-based best practices.  
(2) Outcome metrics: Antimicrobial prescribing rates? Is this improving over time?  
(3) Cost or Utilisation metrics: Are resources being used appropriately? Specific 
measures may include re-consultation rates, algorithm adherence.  
(4) Patient satisfaction metrics: Are patients satisfied with their overall experience?  
A longer term, global public health perspective could well dictate that these added costs 
represent a small fraction of the potential impact of AMR, and such views have recently 
encouraged governmental and international bodies to dedicate large investment to mitigating 
its spread. Recent reports estimating the global impact of AMR have highlighted the need for 
a global funding mechanism such as Diagnostic Market Stimulus pots and Longitude fund, 
similar to the Global Fund for Aids Tuberculosis and Malaria that would be dedicated 
specifically to the development and scale-up of diagnostics and other interventions that 
improve the targeting of antimicrobials and mitigate the impact of AMR (7, 252). Economic 
evaluations such as these can help ensure efficient targeting of this funding. Before scale-up, 
a health technology assessment (HTA) should be performed to assess the opportunity costs of 
implementing as resources for health are always limited. Lessons can be learnt from HTA 
quality standards for stroke in Vietnam. Based on the previous success to establish national 
quality standards for acute stroke in Vietnam, quality standards for appropriate antimicrobial 
use for inpatients with certain conditions (community-acquired pneumonia and acute 
exacerbation of COPD) have been developed by the Vietnam Ministry of Health with support 
from OUCRU and NICE International (80). Linking reimbursement programmes to clinical 
guidelines may improve appropriate antimicrobial use if payment is only made when the 
prescription is performed according to guidelines.  
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The longer term implications of AMR should not be the only incentive for more 
judicious use of antimicrobials. While data to quantify the impact of adverse drug reactions 
(ADR) in the community in low income contexts are scarce, a meta-analysis of prospective 
studies in US hospitals found ADRs to be between the fourth and sixth cause of death during 
admission (253). Although adverse events occur in a small proportion of antimicrobial 
courses, the frequency of antimicrobial use makes them account for approximately a quarter 
of all adverse events recorded in the hospital setting (254, 255). A study of ADR associated 
emergency department visits found antimicrobials to be implicated in a fifth of cases (256). 
Averting such adverse events by reducing antimicrobial consumption is an additional 
argument for the introduction of CRP POC in the primary healthcare setting. 
There were several limitations that need to be discussed. The primary measure of 
effectiveness used in the model was antimicrobial prescriptions averted; this is not equivalent, 
however, to actual antimicrobial consumption averted. In the trial there was indeed a sizable 
proportion of patients that were not prescribed an antimicrobial that opted to purchase these in 
the private sector – approximately a third of patients that were not prescribed an 
antimicrobial. This dilution of the initial effect on prescription is considerable, implying a 
proportional increase in the ICER to ~$5 to avert the consumption of an antimicrobial. If the 
intervention were to be rolled out in routine care, this can and should be supplemented by 
further training and education for health workers and patients to ensure better adherence and 
high efficiency of the test. It is also likely that as with malaria rapid tests, over time these 
could gain greater traction as they become more familiar and trusted (257). 
It is near impossible to quantify the link between current consumption and future costs 
of resistance. In this study, a rudimentary method was used to place a monetary value on the 
avoidance of the consumption of an antimicrobial, using a single available study to enumerate 
this link and place a monetary value representing the cost of AMR per antimicrobial 
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consumed. Even after adjustment, the relevance of this estimate is questionable and methods 
tailored to different contexts, drugs and infections are much needed. 
Similarly, the interpretation of the ICER, the cost per antimicrobials prescription 
averted, is challenging, as compared with for instance the cost per DALY averted which is 
more familiar to policy makers and for which some (albeit highly imperfect) thresholds and 
frames of reference are available. With increasing awareness and resources dedicated 
specifically to interventions targeting safe reductions in antimicrobial consumption, economic 
evaluations using this as a shared measure of outcome will be useful in guiding these 
resources, even if comparison with other health interventions is not clear. 
This analysis was limited in scope to the incremental costs of CRP testing, rather than a 
full economic evaluation, extrapolating to the health and economic benefits of the 
intervention. There are numerous possible cost and health implications associated with CRP 
testing that were not accounted for, including for instance the impact on hospital admission 
rates and their associated high costs, costs of potential reactions to antimicrobials (both 
allergic and other common reactions, such as nausea, vomiting and diarrhoea), as well as the 
potential direct health benefit to patients in better identification of cases that require treatment 
or the avoidance of side-effects and allergic reaction in patients receiving antimicrobials 
unnecessarily. While over-treatment is a huge problem in most areas in both low and high 
income settings, there are still many others where under-treatment of respiratory infection in 
patients with restricted access to antimicrobials still imposes a huge morbidity and mortality 
toll (2, 7). CRP testing in LMICs could therefore have a broader impact on costs and health 
outcomes than those at the focus of the current trial and cost analysis. Nevertheless, the 
introduction of a single test will not bring an improvement in AMR unless it’s placed in a 
comprehensive stewardship program that include education, vaccination and other proper  
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preventive measures such as implementation of quality standards or evidence based 
guidelines for antimicrobial use (258).  
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Chapter 5 
Acceptance of C-reactive protein (CRP) point of care (POC) testing for non-severe acute 
respiratory infections (ARIs) among patients and health care workers in the primary 
health care setting of Vietnam – A qualitative study 
 
5.1 Introduction 
Due to similar presention of clinical symptoms, clinical differentiation between viral 
and bacterial acute respiratory infections (ARIs) is difficult, driving irrational use of 
antimicrobials (259-262). New approaches to reduce irrational antimicrobial use without 
compromising patient recovery must be an urgent priority. While tremendous incentives from 
the Global Innovation Fund and Longitude prize are being given to encourage the 
development of rapid tests which can diagnose bacterial infection (263, 264), there are several 
commercially available point-of-care (POC) tests for biomarkers of bacterial infection that 
can be performed at the site of patient care and can influence clinical decision making by 
providing rapid test results (265-267). One of these biomarkers is C-reactive protein (CRP), 
which has been assessed for clinical and cost-effectiveness in primary care settings of high 
income countries and recommended to guide antimicrobial prescription for bacterial 
pneumonia in primary care (155-157, 268, 269).  
In Vietnam CRP POC testing evaluation has been conducted by our group in a 
randomised controlled trial (RCT) [see chapter 3] and we found this test can significantly 
reduce inappropriate antimicrobial prescription with an overall absolute reduction of 13.5% 
(77·9% versus 64·4%; odds ratio [OR] 0.49, 95% confidence interval (CI) 0.4 to 0.61) (216). 
Our finding supported previous evidence from systematic reviews of individual and cluster 
RCTs in European settings that CRP POC testing offer a significant reduction in antimicrobial 
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use (pooled risk ratio (RR) 0.78, 95%CI 0.66 to 0.92, I2 statistic=68%) (225). The trial-based 
economic evaluation in this setting showed that CRP testing could be cost saving if the unit 
cost per test was $0.5 and adherence exceeded 80% (Chapter 4).  
However, interventions that are proven effective may not be feasible in daily practice 
for a variety of reasons. Careful consideration of potential barriers in daily operation is 
required for effective large-scale implementation of any evidence-based intervention. To 
identify the potential obstacles, it is important to gain insight into the attitudes of patients (or 
their parents if patients were children, hereafter called relatives) and health care workers 
(HCWs) who participated in the trials toward the interventions. This study aims to assess the 
acceptance of CRP POC testing to reduce inappropriate antimicrobial use for self-limiting 
ARIs among patients (or relatives) and HCWs in Vietnam. 
5.2 Methods 
5.2.1 Study design  
In this qualitative study in northern Vietnam, we combined both focus group 
discussions (FGDs) and in-depth interviews (IDIs). Individual interviews were used when 
gathering people for FGDs was challenging to arrange. One FGD was held with 
representative HCWs from ten district health centres that participated in the CRP trial 
(Chapter 3 in this Thesis, clintrials.gov number: NCT01918579). Two individual IDIs were 
performed with HCWs who were not able to participate in the FGD. One FGD with 
patients/relatives in a rural area was conducted in Ba Vi General Hospital, Ba Vi district, 
Hanoi (figure 5-1). Two FGDs and a total of nine individual IDIs with patients and relatives 
were performed in four selected urban districts in Ha Noi (Long Bien, Ha Dong, Dong Da, 
Hai Ba Trung). Participants were invited to these selected sites or to National Hospital for 
Tropical Diseases, Ha Noi, depending on their preference.  
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Figure 5-1 Focus group discussion with patients and relatives in one rural site 
Interview guides were developed in English to cover general and specific issues for 
asking participants to discuss their own knowledge, experience and opinions regarding CRP 
POC testing. The English guides were sent to experts in the field for peer review. The 
revisions were subsequently translated into Vietnamese following by back translation into 
English to check consistency and piloting before use. Two pilots were conducted including 
one with HCW and one with patients to test the questionnaires and revise if needed. Both 
discussion and interviews included the following themes: (1) Attitude towards CRP POC 
testing, (2) Perceived impact of the test on antimicrobial prescription (3) Perceived impact of 
the test on consultation, (4) Suggestions for improvement (table 5-1 & table 5-2).  
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Table 5-1 Interview guide for HCWs 
Type of question Content 
Perception of CRP 
testing 
1. What do you like/dislike about the test? (eg, 
sampling/turnaround time) 
2. Does the test need to be improved? If yes, how should it be 
improved?  
3. What factors make you trust the test/ not trust the test? What 
could make you trust it more?  
Impact on 
antimicrobial 
prescription  
4. How did the test support your treatment decision?  
Any differences between adult/children 
5. What do you think your patients are expecting from seeing 
doctor? 
(Drugs/Antimicrobials/Advice/Reassurance/Diagnosis/Others) 
Impact on 
consultation 
 
6. Did you use the CRP result to discuss with patients about your 
treatment decision?  
7. If not, why not?  
8. If yes, how did it help in persuading patient in case no 
antimicrobials are prescribed?  
Any differences between adult/children 
Recommendations 
 
9. In your opinion, should CRP test be introduced in routine 
practice of your setting? Why/Why not? 
10. What are your recommendations to improve current situation 
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Table 5-2 Interview guide for patients  
Type of question Content 
About Acute 
Respiratory 
Infections and 
health care 
seeking behaviour 
1. What is your understanding about the causes of ARI and it’s 
natural history? 
2. Do individuals use multiple resources when you/your child is 
ill (pharmacy, clinic, hospital...) or do you tend to go for the 
same place each time? 
3. Why did you choose clinic on this occasion? 
Perception of CRP 
testing 
 
4. What do you like/dislike about the test?  
5. Does the test need to be improved? If yes, how should it be 
improved (eg. time, sampling)  
Any different for adult/children? 
6. What factors make you trust the test/ not trust the test?  
7. What could make you trust it more?  
8. In case, CRP test is not covered by health insurance, would 
you be willing to pay for the test? Why/why not? 
Impact on 
antimicrobial use 
9. What do you expect from seeing the doctor with ARI? 
(Drug/Antimicrobial/Advice/Reassurance/Diagnosis/Others) 
10. Did you seek for subsequent antimicrobials if your doctor did 
not give you antimicrobial?  
If yes, which sources? (eg. pharmacy, other clinic, self-
treatment) 
Impact on 
consultation 
11. Did your doctor discuss with you about test result? 
If yes, did you feel persuadable if doctor said no antimicrobials 
are needed? Why/why not? 
12. What other information would you need to help you fully trust 
the test and trust the doctor's opinion that you do not need 
antimicrobials? 
Recommendations 
 
13. In your opinion, should CRP test be done as a part of routine 
diagnosis for ARI patients in primary care settings 
14. What are your recommendations to improve current situation 
 
All discussions and interviews were sound recorded and I was the moderator. An 
assistant took notes during the discussion, including the non-verbal communication of 
participants during the talks, which were used during transcribing of the sound recordings to 
better reflect the discussion. Each FGD lasted approximately 1.5 hours and IDI lasted 30 to 45 
minutes. All FGDs and IDIs were sound recorded and transcripts were made followed by 
coding and thematic analysis for major themes.  
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The study was performed as part of the randomised trial (CRP trial) as described in 
Chapter 3, which was approved by the Institutional Review Board of the National Hospital for 
Tropical Diseases, Ha Noi (approval code: 39/IRB-NHTD) and the Oxford University 
Tropical Research Ethics Committee (OxTrec Reference: 176-12). Participant’s permission 
was obtained by written informed consent. 
5.2.2 Selection of participants  
Participants included HCWs and patients (or their parents if patients were children). 
They were sampled from those who participated in the previous conducted randomised trial 
evaluating CRP POC testing (216). Doctors in six centres where there was only one per centre 
participated in the trial were all invited to the FGD. Two centres had more than one doctor 
involved in patients recruitment, a main study doctor who enrolled more than 80% of centre’s 
sample size was invited to attend in the group discussion. Doctors who enrolled only few 
patients during the trial were not invited because of their limited experience. Two remaining 
sites (Ha Dong centre and Ba Vi hospital) where there were two doctors equally involved in 
the patient enrollment, one per site was invited to participate the discussion, the latter were 
interviewed individually. In the FGDs with patients and relatives, participants were randomly 
selected from the CRP guided group only from all participating study sites, and included both 
those who were not given an antimicrobial and those who did receive an antimicrobial 
prescription regardless of the CRP test result.  The rationale of putting those people in the 
same focus group is to stimulate discussion between the two types of participants. Enrolment 
ceased when no new themes arose from two consecutive FGDs/IDIs (saturation criterion 
met). In qualitative research, methods to reach data saturation are different across study 
designs. However, some general principles and concepts are agreed to assess data saturation 
including: no new data, no new themes, no new coding, and ability to replicate the study 
(270-272). 
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5.2.3 Data analysis 
Data from transcripts were analysed using content analysis as described in Chapter 2. 
The content can be analysed on two levels: (1) Basic level or manifest level: a descriptive 
account of the data; (2) Higher level or latent level of analysis: a more interpretive analysis 
that is concerned with the response as well as what may have been inferred or implied. 
Vietnamese verbatim transcripts were made from the tapes and notes of the FGDs and IDIs. I 
listened to the tapes and read through the text to become familiar with it and to obtain an 
overall view of key contents. Meaning units reflecting the same content were identified, 
abstracted, and then allocated a code. The codes were sorted into coding categories related to 
main themes, according to the procedures of basic content analysis which is a descriptive 
account of the data (202). Connections between and within themes were identified for further 
interpretive analysis. Common themes and quotes were translated into English. 
5.3 Results 
5.3.1 Demographics of study population 
A total of four FGDs with five to ten participants per discussion and eleven individual 
IDIs were conducted. Three of these FGDs were with patients/relatives and one with HCWs 
due to characteristics of study doctors as mentioned in the method section (table 5-3). Two 
individual interviews were with HCWs and nine were with patients/relatives. Of the 39 total 
participants, 33 (85%) were women. Among 27 community members, 11 (41%) were 
relatives and 9 of these were patient’s mothers. 10/12 HCWs were medical doctors, and the 
remaining two were nurses (figure 5-2).  
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Figure 5-2 Flow chart of sampling procedure and study sample 
Table 5-3 Data collection methods and participants involved  
Data collection method (n) Participants (n) 
FGD (1) HCWs (8 doctors, 2 nurses) 
IDIs (2) HCWs (2 doctors) 
FGD (3) Patients (10), Relatives (8) 
IDIs (9) Patients (6), Relatives (3) 
The youngest participant was 23 years old and twelve participants were above the age 
of 50. The majority of rural participants were farmers (6/7) and the highest level of education 
was higher elementary grade (1/7). The highest level of education among urban respondents 
was university degree (3/24). Of the twenty urban participants, occupation was variable and 
included: officer (5), tailor (4), business (4), housewife (2) and retired officer (5) (table 5-4).  
 
CRP trial:  
10 study sites (9 urban, 1 rural) 
33 study HCWs (18 doctors, 15 nurses) 
2,036 patients (1017 CRP, 1019 control) 
1017 in CRP group (518 children, 501 adults) 
Children: 1-15 yrs; adults: 16-65yrs 
Acceptance 
among HCWs 
Acceptance among 
patients/relatives 
 
FGD (3) 
10 patients (9 females/1 male) 
8 relatives (6 mothers/2 fathers) 
11 urban /7 rural respondents 
FGD (1) 
8 doctors/2 nurses 
Only 1 rural doctor 
8 females/2 males 
IDIs (9) 
6 patients (5 females/1 male) 
3 relatives (all mothers) 
All urban respondents  
IDIs (2) 
2 doctors 
1 rural/1 urban 
All females 
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Table 5-4 Demographics of health care workers and patients/relatives 
General characteristics  HCWs (n=12) Patients (n=16) Relatives (n=11) 
Gender – female (n, %) 10 (83.3) 13 (81.2) 9 (81.8) 
Age (median, range) (years) 41 (30-51) 60 (37-63) 41 (23-50) 
 
 
Rural/Urban (n/n) 2/10 4/12 3/8 
Occupation Doctor (n=10) 
 
Farmer (n=4) 
 
Farmer (n=2) 
  Nurse (n=2) Retired (n=5) 
 
Official (n=5) 
   Other (n=7) Other (n=4) 
Four main themes were included in the FGDs and IDIs including: (1) perception of testing, 
(2) impact of testing on antimicrobial prescribing, (3) impact of testing on consulting, and (4) 
proposed suggestions for improvement. The main themes, their categories, and examples of 
codes are shown in table 5-5. Quotes from participants, from both the FGDs and the IDIs, are 
presented in italic in the text that follows.  
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Table 5-5 Themes, categories and a selection of codes  
Themes Categories Codes 
Perception of testing 
 
 
 
 
 
 
Time and convenience 
 
 
Perception of the illness 
Health care cost 
Scepticism  
Short waiting time 
Easy to use 
Does not hurt 
Minor illness 
Need to co-pay  
Whether the test is accurate 
Is there something wrong 
Impact on prescription 
 
Awareness 
Poor adherence 
 
 
 
Financial incentive 
Prescribe more cautiously   
Habit of empirical treatment 
Patient expectation 
Concern of complication 
Self-treatment 
Antimicrobials in stock 
Impact on consultation 
 
Support clinical findings 
Problem when CRP results 
were low 
Stronger evidence 
High expectation of antimicrobials 
Poor communication skills 
Insufficient information about the 
test and its result 
Proposed suggestions Education 
 
Affordability  
Less pressure to prescribe 
antimicrobial 
Be more acceptable if the test is free 
 
5.3.2 Perception of CRP POC testing and identified barriers to implementation 
A large majority of both patients/relatives (25/27 participants) and HCWs (12/12) 
expressed positive attitudes towards CRP POC testing, and found it relatively simple to 
perform using finger prick capillary blood and found that the results were rapidly available.  
“I believe that equipment-based diagnosis is better than solely clinical examination. I think 
this rapid test is enough for mild respiratory disease because it’s convenient for the patient 
and the doctor will know how to treat my disease correctly”. (FGD2, Respondent 2)  
“It’s especially good for children because it does not hurt. I think paediatric hospitals should 
use this kind of testing”. (IDI 7, urban relative)  
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All clinicians responded that CRP POC testing was a useful diagnostic tool without 
adding any burden on their workload. “Compared to other diagnostic methods such as X-ray 
or endoscopy, this test is very simple and does not require expertise and time-consuming 
performance”. (FGD4, Respondent 10) 
In contrast, negative opinions were also expressed. Considering that non-severe ARI is 
not a serious condition, patients may not be willing to pay extra costs for a test like CRP 
POC. According to the regulation of health insurance, patients will need to co-pay 20 percent 
of health care costs once it exceeds allowed limitation (159, 273). Therefore, any extra 
services added would increase the risk of co-payment. All rural participants and two urban 
patients expressed this concern.  
“The more tests you have to take, the more money you need to pay” (IDI5, Urban patient). 
Regarding the belief in the test results, only one patient and one HCW noted scepticism. 
“Whether the test is accurate with such a fast provided result?” (FGD1, Respondent 4). “Most 
CRP results are below 8mg/ml even in patients who seem to have quite severe symptoms that 
make me wonder if something is wrong with this equipment.” (FGD4, Respondent 6) 
5.3.3 Impact of CRP POC testing on antimicrobial prescribing 
All clinicians reported that after gaining experience with the CRP POC test, this 
intervention helped them to prescribe fewer unnecessary antimicrobials.  
“This intervention makes us more aware that we are prescribing antimicrobials too often so 
with CRP POC testing we prescribe more cautiously.” (FGD4, Respondent 8) 
“Before, nearly 100% ARIs patients were treated with antimicrobials. Now, for patients 
having mild symptoms and low CRP values, delayed antimicrobials prescription would be 
applied more frequently” (FGD4, Respondent 7) 
However, there was still resistance among HCWs to accept test results with low CRP 
values. The main reasons for ignoring low test result mentioned were: (1) the habit of treating 
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even mild respiratory symptoms with antimicrobials among HCWs, (2) incorrect knowledge 
of benefit of antimicrobial in preventing complications of ARIs and (3) doctor’s concern 
about “losing patient’s trust” resulting in antimicrobial prescription even when CRP results 
were low.  
All HCWs shared the same opinion that: “I know it’s not necessary to prescribe an 
antimicrobial for ARI but because co-infections often occur, I need to give my patient 
antimicrobials to prevent disease from becoming worse” (FGD4, Respondent 1).  
Three HCWs mentioned: “I want to comply with CRP results and avoid overuse of 
antimicrobials but if I do not prescribe antimicrobials, when my patients get worse, they will 
go to higher healthcare facility and they no longer trust me” (FGD4, Respondent 4) 
The opinion of preventing pneumonia complications, especially in children, by antimicrobials 
was widely reported among HCWs (10/12). 
“If children have fever, it’s necessary to prescribe antimicrobials even with low CRP results. 
Complications of pneumonia easily occurs in these children if they are not treated with 
antimicrobials at beginning” (FGD4, Respondent 3).  
HCWs acknowledged that they prescribed antimicrobials much less based on CRP testing 
than previous empirical treatment. Nevertheless, it was stated by all HCWs that clinical 
examination is more valuable than CRP values in making treatment decision with low CRP 
results.  
 “I agree that the test added a supportive value to the clinical findings. However, it could not 
replace clinician’s experience”. (FGD4, Respondent 2)  
We also detected a contrast between doctors’ thinking and patients’ expectation. Whilst 
almost all doctors thought their patients wanted antimicrobials, just one-third of the patients 
state they expected an antimicrobial prescription. 
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“Without antimicrobial prescription, patients are not satisfied. Medicines are covered by 
health insurance, so they prefer to receive as many as possible. In case they do not use it, they 
can reserve it for future use”. (FGD4, Respondent 9) 
Occasionally, one HCW stated that they were put under pressure to get rid of 
antimicrobial stocks as much as possible by the health centres to get reimbursement from 
health insurance agency. Normally, health insurance advance 80% of estimated drug 
expenditure for health establishments. Quarterly, health insurance will audit and make a final 
payment to clinics based on dispensed medicines (figure 5-3) (274). Therefore, they kept 
prescribing antimicrobials despite low CRP values.  
“There are a lot of antimicrobials in stock that need to be dispensed. Depending on CRP 
results, I tell my patients to use the antimicrobial immediately or keep for another illness 
episode”. (FGD4, Respondent 4) 
Expiry dates of these stocks were not mentioned. However, other respondents did not agree 
with this opinion.   
 
 
 
Figure 5-3 Central drugs bidding model for public health establishments  
Source: Hanoi Health Bureau Office  
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In fact, it was commonly reported that patients/relatives (7/27) reserve medicines 
including antimicrobials at home from the last sickness and use it when they or their children 
have similar symptoms or use previous prescription (5/27 respondents) to buy antimicrobials 
from private pharmacy. Some of them said that they sought antimicrobials from other sources 
such as private clinics or pharmacy when duration of symptoms lasted too long due to delayed 
antimicrobial dispensing.  
Finally, all prescribers said they returned to their old prescribing habits after the CRP 
POC intervention study was stopped as they believe that antimicrobials help shorten the 
duration of symptoms and their patients expect an antimicrobial.  
5.3.4 Impact of CRP POC testing on consulting 
Three-quarters (9/12) clinicians reported that a rapidly available test result supported 
their clinical findings and provided a stronger evidence to convince patients to not use 
antimicrobials.  
“We showed the test result to the patient and said “look, yours is below 8” and compared to 
the recommended cut-offs, you do not need antimicrobials for your sickness. Patients are 
convinced and reassured”. 
However, one-third (4/12) of respondents expressed that it was difficult to consult 
patients who expect an antimicrobial prescription even with low CRP values.   
“Convincing patients who are asking for antimicrobials to accept non-antimicrobial 
management remains a challenge.  Because patients are not assured that they will get better 
without antimicrobial treatment.” (FGD4, Respondent 5)  
Contrasting views were seen among patients/relatives regarding doctor’s consultation. 
Whilst only one-quarter (7/27) respondents acknowledged sufficient explanation from 
doctors/nurses that the test did not indicate anything serious as a reason for not prescribing 
antimicrobials for their sickness, others announced that they did not receive sufficient 
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information including purpose of performing the test and/or how to interpret the results. All of 
them said they would trust the test more if more sufficient information would be provided.  
“Taking an antimicrobial makes me tired; especially it is difficult to finish a full course of 
seven days so normally I stop using it after 2-3 days when symptoms are better or recovered. 
If a doctor can confirm the self-limiting nature of symptoms through elaborate examination 
following by testing, I feel my sickness was being taken carefully and I will be totally 
reassured without antimicrobial treatment.” (IDI1, urban patient) 
“There is hesitance among parents to administer antimicrobials to their baby due to a fear of 
negative impact on their children. Therefore, if doctor said antimicrobials were not needed 
for my children, I have no reason to not be satisfied” (IDI4, urban relative) 
5.3.5 Proposed suggestions for improvement 
Both prescribers (12/12) and patients/relatives (27/27) considered that mass educational 
campaign for the general population would be needed to improve public knowledge and 
awareness about antimicrobials and resistance. This would likely have a significant impact on 
improving appropriate antimicrobial use in the community.  
“There will be less pressure to prescribe antimicrobials if patient’s awareness is improved”. 
(FGD4, Respondent 2) 
“Through mass media, there should be several health programs focusing on antimicrobials to 
improve public awareness about side effects of antimicrobials. By achieving better 
understanding about antimicrobial and resistance, people will be encouraged to limit overuse 
or self-treatment with antimicrobials.” (IDI2, rural patient)   
Secondly, it was widely mentioned that the introduction of CRP POC testing into practice 
would be more adopted if it is well resourced by existing budgets rather than charged to 
patient’s pocket due to low affordability.  
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“Majority of patients seeking primary healthcare facilities are non-rich citizen. Therefore, it 
would be more acceptable if the test cost is free of charge” (FGD4, R8). 
5.4 Discussion 
This is the first qualitative study to assess the perceptions of both HCWs and 
patients/relatives (if patients were children) regarding the use of CRP POC testing to reduce 
unnecessary antimicrobial use for non-severe ARIs. Earlier qualitative studies conducted in 
the European setting included HCWs only. In general, positive attitudes toward the test were 
widely seen among respondents regarding convenience in performance and its impact on 
reducing unnecessary antimicrobial prescription, which were similar to previous qualitative 
findings in European countries (230, 275).  
Discussing the impact of CRP POC testing illustrated that there is a clear need for 
improved information provision to both HCWs and patients/relatives regarding the test and 
the result. There have been several successful complementary interventions in developed 
countries that brought important changes in antimicrobial prescription whilst maintaining 
patient’s satisfaction (151, 156). As reported from a cluster RCT conducted in primary care 
practices in six European countries, the combined intervention between CRP POC testing and 
enhanced communication skills through internet training produced the greatest reduction in 
antimicrobial prescription without estranging patients (151). Doctors in this setting 
recommended using a patient information booklet, which helps explain the intervention more 
fully and makes patients feel more comfortable with the decision not to be prescribed 
antimicrobials. It has also been reported that such information booklets are particularly 
helpful when providing decisions not to prescribe antimicrobials, as they address patient’s 
concerns by providing a written reminder of ‘alarm symptoms’ suggestive of a more severe 
illness that should prompt re-attendance (275). However, we did not discuss this with HCWs 
as well as patients/relatives so its impact remains unknown among our population. To 
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improve public awareness, visual tools such as DVD, posters, leaflets or the old-fashioned / 
traditional commune loud speaker can be an effective way of spreading messages. 
Clinical findings were acknowledged more valuable than CRP values in making 
decision by HCWs. However, a systematic review showed that the predictive value of the 
clinical findings and CRP separately for antimicrobial prescribing in adults presenting with 
acute cough was similar (AUC = 0.89) (244).  
A qualitative approach to study the obstacles to effective implementation is an accepted 
and useful research design for deeper understanding of the reasons for non-adherence to a 
specific intervention (276, 277). Factors associated with low acceptance of the CRP POC test 
among HCWs included: (1) incorrect knowledge of the need for antimicrobials for mild ARI, 
and (2) perceived patient expectations of an antimicrobial prescription. The documented 
scepticism in some HCWs and patients suggests that they may need time to familiarise 
themselves with the test and gain experience in interpreting and applying the results. 
Additionally, we found that financial incentives in dispensing antimicrobials existed as they 
had antimicrobial stock. Furthermore, after the trial, doctors went straight back to keep 
prescribing antimicrobials indicating that not only patients but also prescribers should be 
targeted with proper interventions to change their behavior. These findings emphasise that 
different settings with country-specific health system and cultural features likely have 
different barriers that need to be identified and addressed with appropriate interventions to 
achieve optimal effectiveness in uptake of any new strategy.   
Regarding the cost concerns and accessibility of CRP POC testing in resource 
constrained settings, our economic analysis showed that the CRP POC test added cost which 
should not be shouldered by patients’ out-of-pocket payments, and in the poorest countries it 
is unlikely that health systems should view this as a priority over interventions with more 
obvious benefits. Also, as in the European setting, large scale roll out of the test in primary 
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care practices would need to be properly resourced (250). Therefore leaving the funding to 
patients or health systems will result in sub-optimal uptake from a global perspective. To 
control the global threat of antimicrobial resistance, global funding mechanisms for this 
evidence based intervention are highly recommended to encourage the adoption at scale, 
including LMICs (Chapter 4). On the other hand, further development of cheaper versions of 
the test without requirement for a costly reader would make it more affordable in resource 
limited settings. 
 The strength of this study is that we involved patients or relatives who had their 
children managed with the aid of CRP testing to achieve a more objective view on patient-
related factors such as their acceptance of the test and satisfaction. Secondly, using both 
FGDs and IDIs facilitated the attendance of participants. Gathering people in the FGDs would 
help to gain a broader scope of topics, while IDIs prevent participants from being affected by 
other’s opinions.  Though the number of FGDs and IDIs were relatively small, no new ideas 
were recorded at the end of these, implying saturation was achieved.  
While it offers useful findings, we found several limitations that need to be discussed in 
our study. Firstly, the predominance of female patients/relative may reflect selection bias and 
affect the results as males may have a different point of view. However, in the trial from 
which patients/relatives were selected, female patients accounted for substantial part of 60% 
and mothers were reported to be main caregivers of 83% (687/828) for children under five in 
rural Vietnam (224). Therefore, we believe the impact of this selection bias is minimal. 
Secondly, the refusing rate among young patients was higher than old patients due to their 
availability that may have biased the findings since young patients may have different views 
and awareness.  
CRP POC testing contributes to antimicrobial stewardship in the primary health care 
setting, resulting in declining pressure for antimicrobial resistance development (269, 278). 
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Therefore, long-term and large-scale investment in this intervention offers wider societal 
implications. In order to make this investment as successful and effective as possible in 
resource limited settings such as Vietnam, the identified barriers need to be addressed with 
rational strategies for both HCWs and patients/relatives to improve their acceptance and 
compliance with the CRP POC testing. Furthermore, to promote the systematic uptake of 
research findings into routine practice, implementation science which has been developed to 
address implementation challenges should be studied (279). Proposed approaches include  
(1) theories to understand/explain what influences implementation outcomes (e.g, to 
what extent do health care providers’ attitudes and beliefs concerning CRP POC test predict 
their adherence to the test algorithm in clinical practices?). 
(2) process models which guide stages/phases to implement CRP POC testing into 
practice. 
(3) contextual frameworks, which are checklists of factors relevant to various aspects of 
implementation (e.g, budget, human resource, infrastructure, training, etc) which could be 
evaluated to determine implementation success.   
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Chapter 6 
General discussion, implications & recommendations for future work 
6.1 Contribution of this thesis to existing evidence 
The research presented in this thesis was set out to better understand the incentives 
that support (inappropriate) antimicrobial dispensing in private pharmacies in Vietnam. This 
understanding is important for designing effective interventions to partly improve rational 
antimicrobial consumption. Several proposed solutions including sanctions to improve GPP 
compliance/enforcement, availability of a rapid blood test in addition to history taking and 
physical examination to determine which customers should use antimicrobials, and education 
for both dispensers and customers to improve the current situation were discussed with 
dispensers. Based on the findings from the pharmacy study (chapter 2), settings for the next 
study were selected where we evaluated whether a rapid point of care C-reactive protein test 
is safe and effective to reduce (unnecessary) antimicrobials prescribing for patients with ARIs 
in a randomised controlled trial (chapter 3). Furthermore, the economic impacts of this 
strategy (chapter 4) as well as the acceptability of the test among healthcare workers and 
patients (chapter 5) were investigated.  
 In my thesis I sought to answer the following questions:  
• What are financial and behavioural incentives of private pharmacies driving 
inappropriate antimicrobial dispensing in the community to develop potential 
effective intervention strategies? (Chapter 2) 
• Can a Point-of-Care diagnostic, C-reactive protein (CRP) test reduce antimicrobial 
prescribing safely for acute respiratory infections (ARI) use in the primary care, and 
to what extent? (Chapter 3) 
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• What are the economic impacts of a CRP POC test in the LMIC setting of Vietnam? 
(Chapter 4) 
• What is the acceptance of using a CRP POC test among patients and health care 
workers? (Chapter 5) 
The key findings are synthetised below.  
6.1.1 Antimicrobials dispensing in the private pharmacies 
Antimicrobial dispensing practice in Vietnamese community is characterised by poor 
adherence to regulation. ~90% of the antimicrobials are sold over the counter despite the 
existence of prescription regulation. This situation is similar to what was reported nearly 
twenty years  ago when less than 1% of customers had a prescription (280). The considerable 
contribution of antimicrobials sales to the total revenue of private pharmacies (24% in urban 
and 18% in rural) is likely a key driver. Implementation of the Good Practice for Pharmacy 
(GPP) system alone is not effective to improve dispensing practices as non-compliance with 
regulations is not sanctioned. Better practices have been observed in stores with an on-site 
pharmacists (Chapter 2). However, having an on-site pharmacist is often not feasible due to 
cost and  the small number of pharmacists with a degree, especially in remote areas (281, 
282). Profit incentives the regulatory compliance must be taken into consideration when 
designing interventions to improve antimicrobial dispensing in this setting. 
Most antimicrobials are dispensed for acute respiratory infections (ARIs) which are 
mainly viral in origin. In a recent Vietnamese study it was found that viral pathogens account 
for 72% of all detected respiratory pathogens in ARI outpatients and only 7% are bacterial 
(283). Using a rapid POC test to determine which customers may need antimicrobials could 
be a solution in improving antimicrobial use. Though concerns about losing income when the 
test result recommends to not prescribe antimicrobial were noted among dispensers (250). 
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Proper reimbursement mechanisms could be applied to compensate loss of income due to 
negative test results.  
Although this study revealed the magnitude of inappropriate antimicrobial dispensing 
in the Vietnamese community, there were several limitations that need to be addressed in 
future research. One of the challenges we were confronted with was the variety in the 
antimicrobial inventory of a private pharmacy (figure 6-1). There were hundreds of brand 
antimicrobials in the pharmacies making an inventory during three observation days difficult. 
In future research, this would be possible with for instance five essential systemic generic 
antimicrobials to be inventoried. Furthermore, the chosen observation time was working 
hours only (from 9AM-5PM) while most pharmacies’ opening hours were 8am – 6 or 9pm. In 
the context of high pressure from customers, interviewing customers need to be considered in 
future studies to understand drivers for supporting their self-medication with antimicrobials. 
To change behavioural incentives, education campaigns targeting both providers and 
consumers on AMU and AMR needs to be a component of any intervention strategy (217).  
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Figure 6-1 Antimicrobials sold in a small rural private pharmacy  
Source: Picture has been made by Prof. Heiman Wertheim in a field trip to Thanh Ha 
commune, Thanh Liem district, Hanam province, Vietnam.      
6.1.2 Potential of CRP POC testing in reducing antimicrobials prescription for non-
severe acute respiratory infections in primary care settings 
With a large sample size, our individual randomised control trial is sufficiently 
powered to assess the effectiveness of C-reactive protein point of care testing in reducing 
inappropriate antimicrobial prescription for non-severe ARIs in both adults and children. 
Presently there is a lack of studies from primary care settings addressing POC biomarkers to 
reduce antimicrobial prescribing, especially in low and middle income countries. Also, 
virtually no data exist on CRP POC testing in children. Using POC tests to reduce 
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antimicrobial prescribing is an ongoing debate to which we believe this study adds new and 
useful information (225, 284, 285).  
 Large between-site heterogeneity was found in the effect of CRP POC testing across 
ten study sites (I2=84%, 95%CI 61%-96%), an important limitation. This heterogeneity was 
significantly higher than what has been reported in Denmark with I2=47% (152). There was 
no single reason that fully explains the observed between-site differences, though varying 
levels of adherence to the CRP algorithm is part of this story. Further qualitative 
investigations are needed to identify the potential barriers that need to be overcome to make 
the intervention even more effective (Chapter 5).   
 The rate of pneumonia was assumed very low in our population basing on previous 
work showing that, among 563 ARIs outpatients visiting a tertiary referral hospital for 
paediatrics in Vietnam, only 1.2% was clinically classified as pneumonia (283). Still, a very 
high proportion of those with low CRP values that rule out the risk of pneumonia were 
prescribed antimicrobials, indicating poor adherence to the CRP value and treatment 
guidelines. Notably, these prescriptions were made by well-trained doctors, illustrating that 
either the limited knowledge and awareness in responsible use of antimicrobial also exist 
among health care workers or prescribing antimicrobials is considered as a defensive 
measure. Whichever the cause was, these barriers needs to be addressed. Lessons can be 
learned from high-income settings where the combination of CRP POC testing and education 
showed the highest impact on improved prescribing (151).  
 To reduce the total antimicrobial consumption and thus resistance in low-middle 
income countries where most antimicrobial utilisation decisions are made outside of the 
health care facility (Chapter 1), investigating the potential for POC CRP testing in pharmacies 
and drug stores will still be needed. Given the mild to moderate clinical symptoms with 
virtually no adverse outcomes (1%), it is hard to assess safety of the trial in more severe 
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conditions of ARIs. Further evidence on the risks of not prescribing based on POC CRP and 
guidance in the application of test results to different populations, including patients with 
comorbidities associated with elevated systemic inflammatory CRP (such as rheumatoid 
arthritis and chronic obstructive pulmonary disease) also needs to be investigated (250, 286-
288). 
6.1.3 Economic impact of CRP POC testing  
Utilising primary cost and clinical outcome data from the CRP trial, we were able to 
explore the cost-effectiveness of the intervention, its economic implications for households, 
as well as for the health system in Vietnam if implemented at scale, and places this in the 
broader context of global efforts and financing for interventions to reduce the burden of 
AMR.   
 Although these findings indicate that CRP testing can avert a significant proportion of 
human antimicrobial consumption, the answer for justified investment of this strategy in 
LMICs remains unclear. Neither patients nor highly resource constrained health care settings 
in these countries should bear this added cost. To balance the cost for reducing antimicrobials 
consumption and potential global impact of AMR in a longer term, a similar global funding 
mechanism which has been aided for improving diagnostics and thus controlling tuberculosis 
and malaria is highly recommended.  
There are several major problems with health economics models for AMR. As it is 
difficult to quantify the long term clinical consequences of AMR, current estimates may be 
over- or underestimating the real costs. Furthermore, not all reductions in antimicrobials are 
equal as antimicrobials are differently associated with the development of resistance. The 
value of reducing antimicrobial overuse in different settings, such as pharmacies/communities 
or hospitals, will also not necessarily be the same. Thus, this needs to be considered when 
comparing the results of different antimicrobial stewardship interventions. It is possible that 
  
 
145 
antimicrobial stewardship interventions may result in negative health outcomes. It is difficult 
to account for these negative health outcomes without using DALY and QALYs within a 
cost-effectiveness analysis. They would not be captured by a cost per prescription averted, 
which has been used in our current cost analysis. However, economic evaluations using this 
as a shared measure of outcome will be useful in guiding investment resources, even if 
comparison with other health interventions is not clear.  
6.1.4 Acceptance of CRP POC testing among HCWs and patients/relatives  
By discussing with HCWs and patients or their legal guardians who experienced the 
additional diagnostic support of CRP POC testing in making treatment decision and 
consultation, we were able to understand their perceptions towards the test and how these 
affect subsequent HCW prescription practices, patient adherence and behaviour. This 
knowledge is vital in improving the uptake of POC CRP at large scale in Vietnam as well as 
similar contexts in other LMICs.  
Both patients and HCWs showed positive attitudes towards CRP POC, similar to 
findings in high-income settings (230, 275). However, there was still poor adherence to CRP 
test results indicates that overcoming the habit of treating even mild respiratory symptoms 
with antimicrobials among HCWs or self-medication with antimicrobials among 
patients/relatives is the main challenge. Previous studies have used educational approaches 
with success to improve awareness among HCWs and reduce inappropriate antimicrobial 
prescribing (151, 289, 290).  
 Besides identified knowledge and awareness related barriers that could be addressed by 
educational approaches (151), there was also a financial obstacle that needs to be overcome. It 
was stated that there was pressure to get rid of antimicrobial stocks for insurance 
reimbursement. Findings from Europe suggest that a reimbursement program where payment 
is only made when the tests are performed according to guidelines. Similar pay for 
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performance mechanisms for antimicrobials prescribing could also be applied to address 
financial incentives (250). Since the intervention will be further evaluated for use in the 
private sector (pharmacies, drug outlets) where many ARI patients seek care, the 
considerations of the pharmacies and customers regarding what costs of a CRP rapid test is 
acceptable for stocking, selling and purchasing them to guide treatment recommendation need 
to be discussed. 
6.2 Implications for practice and policy 
In 2015 a global action plan on antimicrobial resistance was issued by WHO that 
emphasises the need for more evidence to develop effective policy interventions in the 
struggle against the global problem of antimicrobial resistance, especially in LMICs (286). 
Along with surveillance and infection control, responsible use of antimicrobials is considered 
to be the most effective policy area within and between nations with different income levels 
(8).  
While investigations of new biomarkers and diagnostic tests to further improve antimicrobial 
targeting in ARI continue, this study confirms that use of commercially available CRP tests 
can be an effective, scalable and economically viable approach, even in highly resource 
constrained settings. Without proper resources, adoption of the POC test in primary settings is 
impossible even in high-income countries (250). Encouraging such an approach with support 
of global financing mechanisms can ensure that such policies are implemented in low and 
middle income countries, which often face more tangible causes of morbidity and mortality 
than the insidious, global public health threat posed by antimicrobial resistance (291).   
6.3 Future research recommendations 
  Besides biomarkers such as CRP and procalcitonin, other diagnostic indicators such as 
2-transcript host RNA signatures were shown to be useful in distinguishing bacterial from 
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viral infection in febrile children, though further investigations of this test in different 
populations and clinical settings are needed (146). Currently, the Longitude prize offers an 
awards of £10 million for the development of a toolkit for overall antimicrobial stewardship, 
in particular a cost-effective, accurate, rapid and easy-to-use POC test kit for bacterial 
infections to support a long-term path in smarter antimicrobial use, indicate a tremendous 
effort is being put into this approach to combat antimicrobial resistance (59). In line with the 
international and national current efforts, and based on the results of this thesis, we propose 
the recommendations and future work as follows: 
1. Findings from our trial showed that the large heterogeneity of the effect across studied 
sites is likely attributable to different adherence to the algorithm. Evidence from previous 
cluster RCT studies in the primary care settings of six European countries indicated that 
the combined intervention of the CRP POC test and enhanced communication skills were 
associated with the largest reduction in prescribing rates (151). Therefore, investigating 
this combination in both primary healthcare stations and drug stores in a cluster RCT 
design is being considered to gain optimal impact on reducing community antimicrobial 
consumption. 
2. A full economic evaluation of the trial, that also takes into account the potential cost, 
health benefit and negative health outcomes associated with CRP testing by using DALY 
or QALYs within a cost-effectiveness analysis is needed to more accurately quantify the 
economic benefits of the intervention in resource constrained settings. Future trials under 
consideration will include this. 
3. Rapid detection of pathogens by detection of pathogen RNA/DNA enables appropriate 
antimicrobial therapy prescription, and is currently being investigated (292). A diagnostic 
strategy that includes sensitive biomarkers and pathogen-specific tests needs to be further 
investigated for improving antimicrobial use management. 
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4. Since financial incentives play an important role in current antimicrobial dispensing 
practices in the community, using pay for performance (P4P) incentives could be a 
prospective intervention to evaluate. Lessons can be learnt from the association of 
facility-based incentives coupled with training and improvement in treatment of non-
malarial fevers in Kenya (293) and the Antimicrobials Smart Use (ASU) programme 
where a P4P model was integrated in a multifaceted intervention and was associated with 
promoting rational use of medicines in Thailand (294).  
5. To date, there is limited evidence of over-the-counter medicines such as non-steroidal 
anti-inflammatory drugs or cough preparations in reducing symptoms of ARIs (295, 296). 
In the context of high prevalence of self-treatment with antimicrobials, investigation of 
effectiveness and safety of alternative over the counter medications for self-limiting 
infections is further needed. 
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Appendix A 
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Antibiotic sales in public and private pharmacies in rural and urban Vietnam: 
an observational study 
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Appendix A1 Pharmacy observation form 
Q1. Pharmacy’s Code _______ 
Q2. Opening times (24 h clock) 
 Monday Tuesday Wed Thurs Fri Sat Sun 
From        
To        
 
Q3. Estimated average number of customers per day: ___ 
Q4. Does pharmacy have GPP certificate: yes ¨         not yet ¨ 
Q5. Pharmacy’s owner is a:        Pharmacist ¨           License renter  ¨  
Q6. Pharmaceutical background of pharmacy owner [mark highest level attained] 
Pharmacist (Pharmacy degree)      ¨ 
Assistant pharmacist (college pharmacy degree)     ¨ 
Elementary pharmacists (six month course)    ¨ 
High school                  ¨ 
Primary school        ¨     
Other_______        ¨ 
Q7. Pharmaceutical background sellers. Total number:______   
Background:   Assessable (number)  
Pharmacist and higher   ____ 
Assistant pharmacist   ____ 
Elementary pharmacist   ____ 
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High school            ____ 
Primary       ____ 
Other __________   ____ 
Q8. Is there a drug manual present (e.g. MIMS, Vidal, other)?  
Yes ¨ 1.______________ (EN/VN) Publ Year_____ 
  2.______________ (EN/VN) Publ Year_____ 
  3.______________ (EN/VN) Publ Year_____ 
No ¨ 
Q9. Is there a therapy guide or tool available for drug sellers that will help to decide what drug 
to give based on symptoms? 
Yes ¨ Specify____________________________________ 
No ¨ 
Q10. Have you seen these manuals or tools being used during observation?  
Frequently  ¨  
Occasionally ¨  
Rarely  ¨  
Never  ¨ 
Q11. Inventory drugs pharmacy: 
Generic Name 
antibiotic  
Brand name Unit 
 
Dose 
per unit 
Selling Price 
per unit 
Purchase Price 
per unit 
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A2. Transaction observation form   
Observation date ___/___/2010        Day 1 / 2 / 3     Time ____:_____ (24h clock) 
Observer name_____________________   Pharmacy’s Code______ 
Customer number (sequential order) _____ 
Q1. Gender     Male¨   Female¨   
Q2. Estimated age:  10-15¨     16-25¨      26-40¨       41-60¨         >60¨ 
Q3. Visit for:   self¨       other person¨       If other        child¨  adult¨ 
Q4. Reason for visit [check all that apply]:  
¨ I A00-B99 Infectious and parasitic diseases 
¨ Upper respiratory tract infection       
¨ Lower respiratory tract infection       
¨ Diarrhoea        
¨ Intestinal worms       
¨ Ear infection       
¨ Eye infection       
¨ GU infection       
¨ Skin infection       
¨ Other infection:__________    
¨ II C00-D48 Neoplasms     
¨ III D50-D89 Diseases of blood(forming organs), immune system  
¨ IV E00-E90 Endocrine, nutritional and metabolic diseases    
¨ V F00-F99 Mental and behavioural disorders  
¨ VI G00-G99 Diseases of the nervous system  
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¨ VII H00-H59 Diseases of the eye and adnexa  
¨ VIII H60-H95 Diseases of the ear and mastoid process  
¨ IX I00-I99 Diseases of the circulatory system  
¨ X J00-J99 Diseases of the respiratory system  
¨ XI K00-K93 Diseases of the digestive system  
¨ XII L00-L99 Diseases of the skin and subcutaneous tissue  
¨ XIII M00-M99 Diseases of the musculoskeletal system and connective tissue  
¨ XIV N00-N99 Diseases of the genitourinary system  
¨ XV O00-O99 Pregnancy, childbirth and the puerperium 
 
Q5. Does customer bring a prescription?  Yes ¨   No ¨ 
Q6. If prescription available, are drugs sold according to prescription? 
Yes ¨   No ¨, because______________________ 
Q7. Who made final choice of drugs in case no prescription: 
Customer requested  ¨    Seller recommended ¨ 
Q8. List of sold drugs 
No Name  Unit 
(tablet, solution, 
injection, 
suppository 
Dose per 
unit 
Number 
of units 
sold 
Price per 
unit 
Total 
money 
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Appendix A3 Questionnaire for owners and drug sellers 
Interview date __ / __ / ____ 
Interviewer’s Name ____________________________ 
Q1. Pharmacy Code_______ 
Q2. Interviewee         pharmacist ¨      owner ¨             seller ¨ 
Q3. Age ____      
Q4. Gender   ¨ Male        ¨ Female 
Q5. How many different generic drugs do you sell in your pharmacy?   
1 ¨            2¨             3 ¨     other, specify _______ 
Q6. Which type of drug do you sell most? VIDAL / IMS categories (one option only, and 
write down the subcategory for type chosen)  
¨ Gastro-intestinal/hepatobiliary   ¨ Hematopoietic 
¨ Respiratory      ¨ Neuro-muscular system 
¨ Hormones       ¨ Contraceptives  
¨ Antibiotic              ¨ Other chemotherapeutics 
¨ Genito-urinary system    ¨ Endocrine / metabolic system 
¨ Vitamins / minerals     ¨ Nutrition    
¨ Eye/Ear, mouth, throat    ¨ Dermatological / skin 
¨ Anesthetic local / general    ¨ Allergy / immune system 
¨ Antidotes, detoxifying    ¨ Intravenous solutions 
¨ Other ___________     ¨ No answer   
Q7. Do you regularly co-sell drugs with antibiotics? 
1.¨ Yes, I co-sell with (more than one answer allowed): ……….…………………………….. 
2.¨ No 
Q8.  Who supplies antibiotics to your pharmacy and/or where do you buy? (more than one 
answer allowed) 
Q9.  Domestic antibiotics from  ………………………………….. 
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Foreign antibiotics from……………………………………… 
Q10. Which type of drug brings the highest profit for your pharmacy?  (one option only, 
and write down the subcategory for type chosen) ¨ gastro-intestinal/hepatobiliary 
 ¨ Hematopoietic 
¨ Respiratory     ¨ Neuro-muscular system 
¨ Hormones      ¨ Contraceptives  
¨ Kháng sinh     ¨ Other Chemotherapeutics 
¨ Genito-urinary system   ¨ Endocrine / metabolic system  
¨ Vitamins / minerals    ¨ Nutrition     
¨ Eye/Ear, mouth, throat   ¨ Dermatological / skin 
¨ Anesthetic local / general   ¨ Allergy / immune system 
¨ Antidotes, detoxifying   ¨ Intravenous solutions 
¨ Other ___________    ¨ No answer   
Q11. From your total profit, what is the contribution of antibiotic sales? (one option only) 
1.¨ <20% 
2.¨ >20%-40% 
3.¨ >40%-60% 
4.¨ >60%-80% 
5.¨ >80%  
6.¨ Don’t know 
7.¨ No answer 
Q12. Which Antibiotic brings more profit to your total profit? (1 option only) 
¨ Domestic 
¨ Imported 
¨ Same 
¨ Don’t know 
¨ No answer 
Q13. What type of antibiotic do you sell most? (1 option only). ¨ Domestic   
¨ Imported 
¨ Same 
¨ Don’t know 
¨ No answer 
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Q14. Do you use information on antibiotic resistance to guide your antibiotic dispensing 
practices? 
¨ Yes      ¨ Don’t know 
¨ No      ¨ No answer  
Q15. Do you have promotional agreements with any pharmaceutical companies / distributors 
to sell foreign branded antibiotics?  
¨ Yes      ¨ Don’t know 
¨ No      ¨ No answer  
Q16. Do you have promotional agreements with any pharmaceutical companies / 
distributors to sell domestic antibiotics?  
¨ Yes      ¨ Don’t know 
¨ No      ¨ No answer 
Q17. Do you have promotional agreements with any health workers to prescribe specific 
drugs?  
¨ Yes  ¨ No   ¨ Don’t know              ¨ No answer 
Q18. Which of the following do you think are important causes for inappropriate AB 
selling in your region? State if you strongly disagree, disagree, agree, strongly agree or if you 
are neutral by circling. 
1. There is too much pressure from patients that demand antibiotic  
¨	strongly disagree –  ¨	disagree – ¨	neutral –  ¨	agree – ¨	strongly agree 
 ¨ Don’t know   ¨ Refused to answer 
2. If I did not sell antibiotics without prescription I would lose many customers. 
¨ strongly disagree –  ¨ disagree – ¨ neutral –  ¨ agree – ¨ strongly agree 
  ¨ Don’t know   ¨  Refused to answer 
3. Pharmacy quality standards are low and current GPP policy is a good policy. 
¨	strongly disagree –  ¨	disagree – ¨	neutral –  ¨	agree – ¨	strongly agree 
¨ Don’t know   ¨  Refused to answer 
4. Antibiotics should only be sold with a prescription 
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¨	strongly disagree –  ¨	disagree – ¨	neutral –  ¨	agree – ¨	strongly agree 
¨ Don’t know   ¨  Refused to answer 
5. Antibiotic resistance is an important health problem in Vietnam. 
¨	strongly disagree –  ¨	disagree – ¨	neutral –  ¨	agree – ¨	strongly agree 
¨ Don’t know   ¨  Refused to answer 
6. Over-use of antibiotics contributes to antibiotic resistance. 
¨	strongly disagree –  ¨	disagree – ¨	neutral –  ¨	agree – ¨	strongly agree 
¨ Don’t know   ¨  Refused to answer 
7. Doctors do not prescribe appropriately 
¨	strongly disagree –  ¨	disagree – ¨	neutral –  ¨	agree – ¨	strongly agree 
¨ Don’t know   ¨  Refused to answer 
8. Knowledge seller insufficient to do appropriately 
¨	strongly disagree –  ¨	disagree – ¨	neutral –  ¨	agree – ¨	strongly agree 
¨ Don’t know   ¨  Refused to answer 
9. Pharmaceutical companies and distributors promote selling antibiotics. 
¨	strongly disagree –  ¨	disagree – ¨	neutral –  ¨	agree – ¨	strongly agree 
¨ Don’t know   ¨  Refused to answer 
10. Antibiotic sales are too profitable, I cannot stop otherwise I will lose too much 
income. 
¨	strongly disagree –  ¨	disagree – ¨	neutral –  ¨	agree – ¨	strongly agree 
¨ Don’t know   ¨  Refused to answer 
11. Other…………………………….. 
¨	strongly disagree –  ¨	disagree – ¨	neutral –  ¨	agree – ¨	strongly agree 
¨ Don’t know   ¨  Refused to answer 
12. Antibiotics are sold appropriately in Vietnam and we should not change the way we 
work. 
¨	strongly disagree –  ¨	disagree – ¨	neutral –  ¨	agree – ¨	strongly agree 
¨ Don’t know   ¨  Refused to answer 
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Appendix A3  Focus Group Discussion 
1) Financial incentives (touch on themes below) 
a) The importance of Ab sales in comparison with other drugs for profit? 
b) What factors affect the sale of antibiotics? Can we change these factors or not?  
c) What is the role of the pharmaceutical industry and distributor? 
d) What is the role of the doctor? 
e) Role of patient/customer? What type of patient demands antibiotic without 
prescription and is this common? 
f) Why are antibiotics still sold even if there is no prescription? 
g) If customer request antibiotics in unnecessary cases, would you sell or not? Why? 
2) Knowledge and government regulation 
a) Is there enough attention to antibiotics and resistance in training curriculum of 
pharmacists/sellers?  
b) What about knowledge patient? If better knowledge, will there be less pressure 
to give them antibiotics? 
c) Do you use guides in pharmacy to dispense antibiotics? 
d) Is regulation sufficient? Why? 
e) What do you know about antibiotic resistance and the role of inappropriate 
antibiotic use?  
f) Will GPP help to improve this? Why? 
3) Solutions 
a) What would happen if AB’s sale decline due to compliance with regulations of 
selling drugs (antibiotics)? (e.g. sell more vitamins? Have financial problem??) 
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b) Do you think a rapid blood test  to determine which customers should use 
antibiotics is a good idea? 
c) What do we need to do to improve the situation of Abs use and resistance in 
Vietnam? With the role of pharmacists (or pharmacy’s owners), what can you 
do? Role industry? Role governemnt? 
d) GPP? 
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Appendix B 
CRP trial – Study protocol and case report forms 
Efficacy of point-of-care C-reactive protein testing to reduce inappropriate use of 
antibiotics for acute respiratory infections in the primary health care setting of Hanoi – 
a randomized controlled trial 
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1. Background 
Around the world, bacterial pathogens are becoming ever more resistant to antibiotics. The 
global problem of antimicrobial resistance is particularly pressing in developing countries, 
where the burden of infectious disease is high and cost constrains the replacement of older 
antibiotics with newer, more expensive ones [1]. 
Vietnam already experiences high levels of antibiotic resistance in both the community and 
hospital setting (GARP report 2012). Development of resistance is multi-factorial but 
primarily it is caused by injudicious use of antibiotics in both human and animal medicine [2-
4]. According to a community-based study undertaken in 1999, 78% of antibiotics were 
purchased in private pharmacies without a prescription. 67% of the participants consulted the 
pharmacist while 11% decided themselves about antibiotic use [5]. Only 27% of the 
pharmacy staff had correct knowledge about antibiotic use and resistance [6]. Some studies 
report the prevalence of “Tu Lam Bac Sy” – patients being their own doctors – to be even 
higher [7]. 
The results from this data raise concern about drugs being sold without prescription and the 
common practice of self-medication. Importantly, decreasing antibiotic use will limit the 
spread and development of antibiotic resistant bacteria. The goal is that antibiotics are used 
only in people with bacterial infections that can be cured by antibiotics, and not by people 
who will not benefit from them [8]. 
Inappropriate antibiotic prescribing is a particular problem for acute respiratory tract 
infections (ARI) presenting to primary care throughout the world and studies have shown this 
to be the case in Vietnam too [9]. Distinguishing serious from self-limiting ARI is a 
challenging task, with the primary care physician often forced to rely solely upon careful 
history and examination. Concern over missing a serious infection often influences an 
understandably cautious approach. In lower-income settings, where health infrastructure is 
less developed, physicians may also be concerned about patients’ ability to access healthcare 
if their condition deteriorates further. These factors often motivate inappropriate antibiotic use 
for self-limiting infections. Implementation of an objective, quantitative, affordable and 
practical point-of-care test (POC) to aid diagnosis is therefore an attractive prospect. 
This study sets out to assess the effect of implementing a simple POC diagnostic, C-reactive 
protein (CRP) test, to improve rational antibiotic use in the community setting.  
2. Rationale 
CRP, a 24kDa protein synthesized by hepatocytes, is normally present at very low serum 
concentrations of a few micrograms per milliliter. In the presence of infection, transcription of 
CRP is rapidly induced by pro-inflammatory cytokines, particularly IL-6, and serum 
concentration can rise 1000-fold within 24-48 hours [10]. Transcription is also rapidly 
switched off after the acute phase response has subsided. Acting as an opsonin, CRP flags up 
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pathogens and damaged host cells for phagocytosis by binding to ligands on their cell 
surfaces. Apart from deranged liver function, very little is thought to interfere with CRP 
production. These characteristics make it a good biomarker for the presence of a significant 
inflammatory process – a process that may benefit from antibiotic intervention. 
The idea that CRP is elevated in bacterial and not viral ARI presenting to primary care has 
recently come under scrutiny. Whilst an elevated CRP can aid differentiation between 
bacterial and viral infections in intensive care units[11] the situation in primary care is not as 
clear-cut: rises in CRP may be influenced by other factors, for example adults vs. children[12-
14] and lower respiratory tract infections (LRTI) vs. upper respiratory tract infections (URTI) 
[15]. In addition, the majority of studies were performed using laboratory CRP values rather 
than the newer POC test methodology proposed in this study. 
However, in order to reduce inappropriate community antibiotic prescribing safely (the 
proposed aim of this study), it is more important to distinguish self-limiting form serious 
infections, than bacterial from viral. Many studies have shown that POC CRP tests can do 
this: a study in the Netherlands showed that general practitioners who used the POC CRP test 
prescribed fewer antibiotics (31% vs. 53%) in patients with cough, without adversely 
affecting patient recovery [16, 17]. A result of a POC CRP test is available within 3 minutes 
and studies have shown that the result can exert a strong influence on antibiotic prescribing 
rates in primary care [16, 18]. Given the large number of self-limiting ARI that present to 
primary care in Vietnam, similar results would greatly reduce the absolute number of 
antibiotic prescriptions and thus one of the major drivers for bacterial resistance. 
A significant proportion of antibiotic overuse for community ARI in Vietnam occurs in 
children. A study of 100 Vietnamese children found that only 17% of those that received 
antibiotics had a laboratory confirmed CRP > 10mg/mL [9]. Whilst data for POC CRP testing 
in children in primary care are lacking, there is much evidence that POC CRP test results in 
children corroborate well with laboratory CRP measurements [19][20]. Hence, the effects of 
POC CRP testing on antibiotic prescribing rates in adults detailed above, can safely be 
extended to children above 5 years of age with non-severe ARI. [21] Based on a recent study, 
for children aged 1 to 6 years old, CRP values should be combined with fever duration to rule 
in or rule out bacterial infections. CRP cut-off level of 11 mg/dl or higher obtained >24h of 
fever corresponding with the risk of 75% of bacterial infection could be used to rule in 
bacterial infection. [22] 
3. Objectives  
To assess the efficacy of CRP POC testing for patients presenting with non-severe ARI at 
primary healthcare centers in Vietnam in reducing inappropriate antibiotic use safely. 
4. Study design 
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Open-label 1:1 randomized controlled clinical trial of CRP POC test (Nycocard, Axis-Shield 
or equivalent) guided antibiotic prescription versus standard-of-care prescription without a 
CRP POC test result. The CRP POC tests are easy to use with time from sample collection to 
result of about 5-10 minutes. Patients, aged 1 to 65 years, that visit one of 10 selected primary 
healthcare centers in northern Vietnam, with symptoms of non-severe ARI, among them, 
patients aged 1 to 6 with fever duration >24h, are eligible for this study. All patients will be 
followed-up at 2 weeks after the initial health clinic visit with a structured telephone 
interview.  
As participation in the study itself may raise awareness amongst the health center staff and 
local community, current antibiotic prescribing rates will be assessed in an observational run-
in period before the intervention. Doctors will be asked to complete (CRF) record forms for 
patients presenting to their health center with non-severe ARI. This aims to capture current 
antibiotic prescribing habits before the study is launched. 
Inclusion criteria: 
- Patients, aged 1 to 65 years, that visit one of the 10 selected primary healthcare 
centers. Among them, patients aged 1 to under 6 must have fever duration >24h at the time of 
presentation. 
- Suspected to have acute respiratory tract infection (ARI) by treating 
physician.Informed consent 
An ARI is defined as: 
First consultation for the current episode of ARI (duration less than 2 weeks) regarded by the 
physician to be caused by an ARI with at least 1 of following focal signs and symptoms: (1) 
cough, (2) rhinitis (sneezing, nasal congestion, or runny nose), (3) pharyngitis (sore throat), 
(4) shortness of breath, (5) wheezing, (6) chest pain, or (7) auscultation abnormalities. At 
least 1 of the following systemic signs and symptoms had to be present: (1) fever, (2) 
perspiring, (3) headache, (4) myalgia, and (5) feeling generally unwell. 
Exclusion criteria: 
- Severe respiratory disease as determined by treating doctor 
- Any disease or symptom requiring hospital referral as determined by treating doctor 
- Immunosuppressed patients (e.g. HIV, long term steroid use) 
- Suspicion of tuberculosis 
- Evidence of acute or chronic liver disease (e.g. hepatitis or cirrhosis due to any cause) 
- Past medical history of: neoplastic disease, congestive cardiac failure, chronic 
obstructive pulmonary disease, insulin-dependent diabetes or renal disease 
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- Pregnancy 
- No access to telephone 
- Not able to come for follow up visit on day 4 (±1). 
- Already taking antibiotics at the time of presentation 
- Symptoms present for more than 2 weeks 
- Meeting any of the criteria below (referral recommended) 
Adults  
Presence of any of the following is a sign of severe disease and an exclusion criterion: age > 
65, altered mental status (Glasgow Coma Score < 15), respiratory rate ≥30 breaths per min, 
systolic blood pressure < 90 mmHg, diastolic blood pressure <60 mmHg, temperature ≤ 35 °C 
or ≥ 40°C, pulse of ≥ 125/min. These exclusion criteria are based on a modified CRB-65 
system as recommended by the British Thoracic Society for severity scoring of pneumonia in 
primary care [23]. It has been validated as the simplest (albeit in elderly patients)[24] and 
most cautious[25] of primary care scoring systems and is therefore appropriate for our study. 
Children (Age ≥ 1 years and < 16 years) 
In addition to the above criteria the following are additional exclusion criteria relevant to 
children (age ≥ 1 years and < 16 years). Children are defined as < 16 years old consistent with 
the age cut off used in Vietnam. 
Tachypnea, signs of chest wall in drawing, reduced consciousness, confusion, dehydration, 
hypothermia, severe malnutrition, unable to feed or drink, vomiting, and convulsions.  
These danger signs in children are based on the integrated management of common childhood 
illnesses (IMCI) of the World Health Organization (WHO, 2012). Whilst they were primarily 
developed for children ≤ 5 years of age they are included here as an extra precaution. 
• Randomisation 
Eligible patients are 1:1 randomised to CRP testing or control by the health station’s doctor 
using an individual randomisation method, stratified by health station and age category (child 
versus adult). This SNOSE randomisation method was used successfully in a similar study in 
Europe[17, 26] and ensures that a patient is irrevocably allocated to one arm of the trial 
immediately on enrollment, i.e. the treating physician finds out which arm of the trial the 
patient is allocated to only after they have committed to enrolling them. The allocation is 
concealed by envelope. 
• Intervention 
For patients aged 6 to 65 years old: 
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-  CRP levels ≤20 mg/L, a ‘wait and see’ policy (no antibiotics) is recommended 
- CRP levels >20 mg/L will be treated with antibiotics as clinically indicated in 
consultation with existing local guidelines 
For patients aged 1 to under 6 years old with fever duration >24h:  
- CRP levels ≤10 mg/L, a ‘wait and see’ policy (no antibiotics) is recommended  
- CRP levels >10 mg/L, will be treated with antibiotics as clinically indicated in 
consultation with existing local guidelines 
Doctors will be trained that adult patients with CRP levels of ≥ 100 mg/L and children with 
CRP levels of ≥ 50 mg/L should in principle be treated with antibiotics. All enrolled patients 
will be evaluated clinically at the health center on day 4 (± 1 day) after enrollment (day 0). 
This in the CRP test arm will be also be retested for CRP on day 4 (± 1 day). Clinical features 
and CRP levels will be interpreted as on day 0. 
Patients randomized to the control arm will be treated according to routine practice and local 
implemented treatment guidelines. Each site will only get enough CRP tests for the 
intervention group and will be numbered to ensure that no CRP tests are used for control 
patients. 
As the study progresses the treating physician may begin to recognize patterns in the 
presenting symptoms of patients who are later verified to have a high CRP. This may result in 
more appropriate prescribing of antibiotics even for the patients who are randomized to the 
non-CRP test arm. To counteract this two steps have been taken. Firstly, the observational 
run-in period before the intervention aims to capture current antibiotic prescribing habits and 
secondly, this has been accounted for in the sample size calculation. 
5. Training of physicians and centers 
Training will be based on a model developed for a similar study in Maastricht, contextualized 
to the Vietnamese setting. Training will be both verbal and written, consisting of oral 
presentations and written information leaflets for the doctors and health centers to keep for 
future reference. All training (both written and verbal) will be carried out in Vietnamese. 
Training will be carried out at a workshop in Hanoi and at on-site implementation visits at the 
10 health centers. Members of the study team will conduct all training. The health centers and 
doctors will be given a telephone number to contact should any queries arise during the study. 
Doctors and centers will also be given laminated posters and desk reminders with cut-off 
values for the specific age groups. 
Training will be conducted after the observational run-in period so that new knowledge about 
ARI and the role of antibiotics can be shared with them. 
 178 
 
 
 
6. Study location 
Ten primary healthcare stations in northern Vietnam. The health stations will be selected 
within a 60 km radius of Hanoi and need to have a sufficient caseload of approximately 5 ARI 
cases per day and an on-call certified clinician. 
7. Primary and secondary endpoints 
Primary endpoints: proportion of patients receiving any antibiotic within 2 weeks of study 
enrollment.  
Secondary endpoints: treatment cost on Day 0 and at 14 days, duration of symptoms (fever, 
any respiratory symptom), proportion of patients with an immediate versus subsequent 
prescription within 2 weeks, frequency of re-consultation, source of any subsequent antibiotic 
(self-medication vs. pharmacist vs. doctor vs. other), serious adverse events (admission to 
hospital or death), presence of antibiotics in urine on day 4 (±1 day). Furthermore we will 
assess the number of patients that needed their clinical management changed based on 
evaluation on the second visit. The attitudes and satisfaction of patients and health center staff 
towards the POC test.  
8. Sample size calculation 
In general, we expect CRP-guidance to reduce antibiotics prescription for ARI by at least 
20%: from 80% to 60%. However, it may be that the participation of the health station in a 
randomized trial and the overall awareness in the community due to the study by themselves 
bring antibiotics prescriptions down and hence reduce the CRP effect. Therefore, the trial is 
powered to detect a reduction of the antibiotics prescription rate from 70% to 60%. To detect 
such a difference in an individual randomized trial with 90% power and two-sided 5% 
significance level, a total of 477 patients are required per arm. 
As community health stations may vary regarding quality, urban versus rural and patient 
caseload, and we want to analyze both adults and children, we will enroll 2000 patients (two 
strata: 50% children and 50% adults); i.e. 200 per health station. This sample size will allow 
us to robustly assess the CRP effect in both the subgroups of children and adults separately 
and to assess potential differential CRP effects in these subgroups. 
In addition, with 1000 patients per stratum (child – adult), we will have sufficient power to 
show whether the duration of symptoms is similar in the two arms (CRP test versus no CRP 
test), i.e. that the intervention is safe: if CRP-guidance truly doesn’t result in a longer 
durations of symptoms and the (between-patient) standard deviation of the duration of 
symptoms is 4 days, the 95% confidence interval for the difference in the duration of 
symptoms between the two arms for each stratum will exclude differences of >0.7 day in 
favor of the control arm with 80% power.  
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9. Definitions 
• Acute respiratory infection 
A first consultation for a current episode of ARI (duration less than 2 weeks) regarded by the 
physician to be caused by an ARI with at least 1 of following focal signs and symptoms: (1) 
cough, (2) rhinitis (sneezing, nasal congestion or runny nose), (3) pharyngitis (sore throat), (4) 
shortness of breath, (5) wheezing, (6) chest pain, or (7) auscultation abnormalities. At least 1 
of the following systemic signs and symptoms had to be present: (1) fever, (2) perspiring, (3) 
headache, (4) myalgia, and (5) feeling generally unwell. 
• Severe ARI 
Presence of any of the following is a sign of severe disease and an exclusion criterion for 
adults: age > 65 years, altered mental status (Glasgow Coma Score < 15), respiratory rate ≥30 
breaths per min, systolic blood pressure < 90 mmHg, diastolic blood pressure <60 mmHg, 
temperature ≤ 35 °C or ≥ 40°C, and pulse of ≥ 125/min. These exclusion criteria in adults are 
based on a modified CRB-65 system. 
• Danger signs in children 
Tachypnea, signs of chest wall indrawing, reduced consciousness, confusion, dehydration, 
hypothermia, severe malnutrition, unable to feed or drink, vomiting, and convulsions.  
These danger signs in children are based on the integrated management of common childhood 
illnesses (IMCI) of the World Health Organization (WHO, 2012). Whilst they were primarily 
developed for children ≤5 years of age they are included here as an extra precaution.  
10. Patient enrolment & consent  
Patients with non-severe ARI presenting at participating primary healthcare centers will be 
approached and informed about the study and asked if they would like to learn more about 
what the study involves. If so, a health station nurse will assist the health station study doctor 
in obtaining consent by describing the study, answering relevant questions and referring any 
clinical queries to the study doctors. 
A study team doctor will take the consent by ensuring the participant has understood all 
aspects of the study and signs an informed consent form. Patients who are illiterate will have 
a witness present while the consent form is read to them and while their questions are 
answered.  The witness will confirm this procedure by signing the consent form.  
Once consent is obtained a CRF will be completed for each patient containing all the 
information related to the study variables. The patient will be randomly and irrevocably 
assigned to one arm of the study immediately at enrollment. Each patient will be assigned a 
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study number which will increase sequentially e.g. 0111, 0112, 0113 etc. These numbers will 
be used on all labels, data collection sheets and the database in order to protect the patient’s 
identity. They study number is made up of a health center code (0 to 9 relating to the different 
health centers), age stratum (1 for child and 2 for adult), study code (corresponding to one of 
the two interventions: to test, 1, or not to test CRP, 2) and patient code (relating to the order 
of patient recruitment, 1 to 200 at each health center) 
11. Study procedures  
• Enrollment 
Eligible subjects will be approached for consent to participate in the study. The consent form 
will be in Vietnamese and patients/their relatives will be explained all of the study 
procedures, tests, risks, benefits and other details of the informed consent form.  All questions 
asked by the patient or relative will be answered until the study staff is sure that all aspects of 
the study are understood. After that, they will be asked to sign the consent form if they agree 
to participate.  
• Randomisation 
Before randomisation, patients will receive a brief medical examination to verify absence of 
exclusion criteria. In case no exclusion criteria are present the patient will be individually 
randomized as detailed above. 
• Enrollment Case Record Forms 
Interview and clinical examination will be done on the day 0, and a telephone interview on 
day 14 (+1 day) for all study participants. Participants in CRP test arm will be evaluated again 
on day 4 (± 1 day) (depending on their availability and weekend) by clinical examination and 
2nd CRP test. A telephone number needs to be provided and the documentation will therefore 
not be anonymous until end of follow up. Patients will be asked about costs relating to ARI 
treatment on Day 0 and at Day 14.  
• Assessments 
All patients will receive a routine medical history and examination as part of the enrollment 
process, consisting minimally of: medical history (including duration of symptoms, fever, 
cough, dyspnea, throat ache), mental status (Glasgow coma score), hydration status, blood 
pressure, pulse, respiratory rate, temperature (ear thermometer), Ear-nose-throat (ENT) 
examination and lung auscultation. Depending on presenting symptoms and underlying illness 
further examinations are performed at the discretion of the treating physician. 
For those in the CRP test arm, a finger prick to collect capillary blood will be performed and 
analyzed using the Nycocard analyzer (Axis Shield, Norway or equivalent) on day 0 and day 
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4 (± 1 day). Those in the control arm will receive treatment according to local guidelines, 
which is generally ampicillin or oral 2nd generation cephalosporins for non-severe ARI and 
will be re-evaluated on day 4 (± 1 day). 
Patients in the CRP test arm will receive treatment that is guided by the CRP level and 
clinical symptoms on day 0 and day 4 (± 1 day). The treating physician will decide based on 
his/her clinical evaluation whether or not to comply with the guidance below (provided at the 
training sessions). 
For patients aged 6 to 65 years old: 
-  CRP levels ≤20 mg/L, a ‘wait and see’ policy (no antibiotics) is recommended; 
- CRP levels >20 mg/L will be treated with antibiotics as clinically indicated in 
consultation with existing local guidelines 
For patients aged 1 to under 6 years old with fever duration >24h:  
- CRP levels ≤10 mg/L, a ‘wait and see’ policy (no antibiotics) is recommended ; 
- CRP levels >10 mg/L, will be treated with antibiotics as clinically indicated in 
consultation with existing local guidelines 
- Doctors will be trained that adults with CRP ≥ 100 mg/L and children with a CRP ≥ 
50 mg/L should generally be treated with antibiotics. Referral to a hospital for further 
diagnosis needs to be considered for these cases. 
Immediate antibiotic prescribing rates and type of antibiotic at the initial primary healthcare 
center visit will be recorded for both arms.  
On the follow up visit on day 4 (±_1 day), urines will be collected from all enrolled patients 
and checked for presence antibiotics using a bio-assay. All these samples will be stored up to 
5 years after study completed. Antibiotic use will be assessed by interviewing the caretaker 
and checking the diary. For children that cannot urinate on command, special urine collection 
bags will be provided.  
After 2 weeks, enrolled patients will be assessed by telephone and receive an interview to 
assess; whether they have been to any health clinic since the last health station visit; 
subsequent medication use for the same ARI; source of medication; serious adverse events 
(e.g. admission to hospital); and duration of ARI symptoms. The attitudes and satisfaction of 
patients and health center staff towards the test will also be assessed. 
The patient will be given a simple symptom diary as a memory aid, to reduce recall bias at the 
follow-up telephone call. They will also be educated with regards the following alarm 
symptoms; breathlessness on minimal exertion; severe coughing interfering with breathing; 
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seizures or fits; coughing up blood; confusion; and loss of consciousness. They will be given 
a telephone number they can ring if they are concerned. 
The 14-day (+1 day) telephone interviewer will be blinded for the intervention. However, the 
information regarding the intervention may be revealed by information provided by the 
patient or his/her legal guardians. The interviewer will be trained to assess in a non-biased 
way. No one in the study team has a conflict of interest in the favor of the CRP POC test. In 
case of persistent symptoms or progression, the patient is recommended to seek medical 
attention. 
12. Data management  
• Data entry 
All clinical information will be recorded or placed in the patient’s notes, in keeping with local 
practice. Relevant data will be recorded onto a CRF and checked for accuracy before single 
data entry onto an electronic database (CLIRES). Internal checks of the entered data will be 
done to look for outliers and errors.  After the follow up is finished the CRFs will be 
anonymized by removing patient identifiers and telephone numbers. Data entry will therefore 
be anonymous. 
• Data analysis 
Analysis of the primary endpoint and the total probability of an antibiotics prescription: 
The primary endpoint of this trial is the proportion of any antibiotic prescriptions within 2 
weeks of randomisation between the two arms. The primary comparison between the 
treatment arms will be a logistic regression with the treatment assignment, and the age 
stratum (children vs. adults) as fixed effects and the healthcare center as a random effect. P 
values (2 sided) below 0.05 are considered significant. A two-sided 95% confidence interval 
(CI) for the odds ratio of receiving antibiotics prescription rate (primary endpoint) will be 
calculated.  
The primary endpoint (total proportion of patients with any antibiotic prescriptions within 14 
days, both immediate and subsequent) will also be investigated in subgroups to assess 
whether the reduction in antibiotics prescribing is homogeneous across subgroups. 
Specifically, intervention effects and appropriate interaction tests for heterogeneity will be 
calculated in the following pre-defined subgroups: 
- Age stratum (adults vs. children) 
- Healthcare center 
- Febrile versus non-febrile patients 
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Additionally, we will compare the proportion of ‘intervention failures’ in both treatment 
arms, i.e. the proportion of patients without initial antibiotics prescriptions who received 
antibiotics for any reason before the end of follow up.  
Analysis of secondary endpoints: 
The duration of symptoms will be visualized using Kaplan-Meier curves and estimates (and 
95% confidence intervals) of median durations in both groups. Formal comparisons between 
the two treatment arms will be based on Cox proportional hazards model with the treatment 
assignment, and the age stratum (children vs. adults) as fixed effects and the healthcare center 
as a Gaussian random effect (frailty). Subgroup analyses for the same subgroup analyses as 
for the primary endpoint will be performed. 
The proportion of patients in the CRP test arm that need adjustment of their treatment based 
on a change in the CRP levels and clinical evaluation on day 4 (±1) will calculated. 
The proportion of urines in which antibiotic activity has been detected by the bioassay will be 
compared between both groups. 
The frequency of re-consultation will be compared between the two arms in the same way as 
the primary endpoint. .  
The other secondary endpoint will be summarized by using descriptive statistics. 
Serious adverse events monitoring: 
Data on SAEs will be sent each week to an independent study statistician who will monitor 
for serious adverse events (SAE): admission to hospital or death between initial consultation 
and follow-up telephone call, in both arms. If a total of 10 SAE are reported, an interim 
analysis between the two study arms will be conducted and the study team will decide 
whether it is safe to continue with the study in case of statistical significance. In case the 
study continues the next SAE interim analysis will be done after the next 10 SAEs, and so on. 
13. Ethical considerations   
The protocol will be submitted for external peer review as well as for review by the ethical 
committees of the National Hospital for Tropical Diseases in Hanoi and the Oxford 
University Tropical Research Ethics Committee (OxTrec). Permission for this study also will 
be obtained from local authorities. 
• Informed consent 
The patients will be asked to provide informed consent to participate in the study, receive a 
medical examination (5 minutes) and, possibly, a capillary blood sample (2 minutes). Patients  
will be asked to come back on day 4 (± 1 day) for a 2nd medical evaluation and a urine test. 
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Those in the CRP arm will be retested for CRP. Patients or their relatives or legal 
representative will be approached and told about this study. They will be informed of the 
aims, methods, urine storage time, possible risks and benefits of the study by a member of the 
research team.  
If the patient is willing to join the study, he/she will sign the consent form; the same will 
apply to relatives or legal representative. The consent form will be countersigned by the 
attending doctor. A copy of the consent form will be given to the patient or his/her 
relative/legal representative. As this study concerns patients with non-severe ARI, and who 
need to be able to keep a diary, adults will be able to provide informed consent without the 
need of a legal representative. 
• Alternatives to enrolling  
If informed consent is not obtained, then the patient will not be part of this study. He/she will 
receive the usual care for ARIs according to implemented treatment guidelines.    
• Study withdrawal 
Patients or parents / guardians are free to withdraw their consent / consent for their relative at 
any time. Patients will still be entitled to study related benefits, as outlined in the consent 
form, up to the point of withdrawing their consent.   
• Risks & Benefits 
- Risk 
Risks for participating in this study is that the medical visit will take longer than usual and 
mild discomfort due to the capillary blood collection. Another risk is in cases needing 
antibiotics and the CRP test shows a low level. However, as these are non-severe ARI, the 
risk of a delay in antibiotics is minimal. Patients will be informed to seek new medical 
consultation in case the symptoms progress or persist. They will also be provided with a study 
telephone number to call if they are concerned, given a patient information leaflet and 
educated about the following alarm symptoms; breathlessness on minimal exertion; severe 
coughing interfering with breathing; seizures or fits; coughing up blood; confusion; loss of 
consciousness. 
SAE will also be monitored as detailed above to detect any difference between the 
intervention and control arms of the study. 
- Benefits  
Patients will receive a more thorough examination than usual and may receive a better 
diagnosis of their disease. Furthermore, through information provided by this study, patients 
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will be more educated in management of ARI, a common illness. Patients will receive 
compensation (value not exceeding 1 US dollar) as a token of appreciation for their 
participation and reimbursed for travel expenses, if any. 
• Patient confidentiality 
Patients will be assured that all information generated in this study will remain confidential. 
Their names will not appear in the database. Any scientific publications or reports will not 
identify any patient by name or initials. When the research team review the patient notes, they 
are also bound by professional confidentiality.    
14. Management of the study 
The execution of this study will be a joint effort between the Oxford University Clinical 
Research Unit (OUCRU) and the National Hospital for Tropical Diseases (NHTD). The 
investigators have overall responsibility for managing this study. 
15. Financing and Insurance/indemnity 
CRP test will be funded by the Oxford University Clinical Research Unit. Indemnity will be 
provided by the University of Oxford.   
16. Publications 
Data from this study will be published in peer-reviewed journals. Authorship and reporting of 
this work will follow international guidelines. Authors will have made a note worthy 
contribution to the work. 
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Appendix B1 Inclusion – Exclusion form for 1-5 years-old 
Inclusion-Exclusion (1-5 years old) 
Site code [__|__]           Screening number [__|__|__|__]     Initials [__|__|__|__|__]        
Inclusion criteria 
Must be “Yes” for criteria from 1-4  
1. Age ≥ 1 and ≤5                                                                          ¡ Yes ¡ No 
2. Clinical examination: 
a. Suspected to have acute Respiratory tract infection                       ¡ Yes ¡ No 
b. Respiratory rate <40                                                                ¡ Yes ¡ No 
            [__|__]/min                                                     
c. GCS=15 (normally comunicate)                                           ¡ Yes ¡ No 
d. Temperature ≥380C                                                                           ¡ Yes ¡ No 
            [__|__|__]0C 
e. Ferver duration >24h                                                                        ¡ Yes ¡ No 
            [__|__]h 
3. Symptom duration ≤  2 weeks                                                  ¡ Yes ¡ No 
4. Informed consent                                                                             ¡ Yes  ¡ No 
Exclusion criteria 
If any questions is answered “YES”, the patient is NOT eligible 
5. Severe respiratory diseases                                                              ¡ Yes ¡ No 
6. Any disease or symptom requiring hospital referral                              ¡ Yes   ¡ No 
7. Danger signs (signs of chest wall indrawing, reduced consciousness, confussion, 
dehydration, hypothermia, unable to feed or drink, malnutrition, vomiting and 
convulsions)                   
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                                                                                                                       ¡ Yes   ¡ No                                                                                                                                                 
8. Immunosuppressed patients (e.g. HIV, long term steroid use)                   ¡ Yes    ¡ No                                                                                                                                                
9. Suspicion of TB                                                                               ¡ Yes    ¡ No                                                                                                                                                
10. Evidence of acute or chronic liver disease                                        ¡ Yes    ¡ No 
11. Past medical history of: neoplastic disease, congestive cardiac, failure, COPD, insulin-
dependent diabetes or renal disease                                                         ¡ Yes  ¡ No 
12. No access to telephone ¡ Yes ¡ No 
13. Already taking antibiotics at the time of presentation                             ¡ Yes ¡ No 
14. Can’t come on day 3/4                                                                            ¡ Yes ¡ No 
Enrollment 
15. Patient code                         05HN-[__|__]-[__|__|__|__]               
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Appendix B2 Inclusion-Exclusion form for 6-65 years-old 
Inclusion-Exclusion (6-65 years-old) 
Site code [__|__]           Screening number [__|__|__|__]     Initials [__|__|__|__|__]        
Inclusion criteria 
Must be “Yes” for criteria from 1-4  
16. Age ≥ 6 and ≤65                                                              ¡ Yes ¡ No 
17. Clinical examination 
f. Suspected to have acute Respiratory tract infection          ¡ Yes ¡ No 
g. Respiratory rate <30                                                  ¡ Yes ¡ No 
            [__|__]/phút                                                     
h. Heart rate <125                                                    ¡ Yes ¡ No 
           [__|__|__]/phút                                                     
i. GCS=15 (normally comunicate)                              ¡ Yes ¡ No 
j. Systolic BP ≥90 and diastolic BP ≥60 (for adults only)     ¡ Yes ¡ No 
           [__|__|__]/[__|__|__] mmHg          
k. Temperature  >350C and <400C                               ¡ Yes ¡ No 
           [______]0C 
 
18. Symptom duration ≤  2 weeks                                          ¡ Yes ¡ No 
19. Informed consent                                                                  ¡ Yes ¡ No 
Exclusion criteria 
If any questions is answered “YES”, the patient is NOT eligible 
20. Severe respiratory diseases                                                               ¡ Yes ¡ No 
21. Any disease or symptom requiring hospital referral                              ¡ Yes ¡ No 
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22. Danger signs in children (signs of chest wall indrawing, reduced consciousness, 
confusion, dehydration, hypothermia, unable to feed or drink, malnutrition, vomiting 
and convulsions)                                                                              ¡ Yes        ¡ No                                                                                                                                                
23. Immunosuppressed patients (e.g. HIV, long term steroid use)           ¡ Yes        ¡ No                                                                                                                                                
24. Suspicion of TB                                                                                      ¡ Yes        ¡ No                                                                                                                                                
25. Evidence of acute or chronic liver disease                                       ¡ Yes        ¡ No 
26. Past medical history of: neoplastic disease, congestive cardiac, failure, COPD, insulin-
dependent diabetes or renal disease                                                ¡ Yes        ¡ No 
27. Pregnancy                                                                                         ¡ Yes        ¡ No 
28. No access to telephone                                                                ¡ Yes        ¡ No 
29. Already taking antibiotics at the time of presentation                            ¡ Yes        ¡ No 
30. Can’t come on day 3/4                                                                            ¡ Yes        ¡ No 
Enrollment 
31. Patient code                         05HN-[__|__]-[__|__|__|__]               
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Appendix B3 Examination at enrolment (Day 0) 
Examination on Day 0 
Patient Code 05HN-[__|__]-[__|__|__|__]                 Patient initials [__|__|__|__|__] 
1. Symptom 
Cough             ¡ Yes ¡ No  
Sputum   ¡ Yes ¡ No 
Coryza   ¡ Yes ¡ No 
Dypsnea   ¡ Yes ¡ No 
Wheeze   ¡ Yes ¡ No 
Earache   ¡ Yes ¡ No 
Chills               ¡ Yes ¡ No 
Sore throat   ¡ Yes ¡ No 
Fever               ¡ Yes ¡ No 
Sweating   ¡ Yes ¡ No 
Rigors    ¡ Có ¡ No 
2. Duration of symptom (from the first symptom)  [__|__] Days 
3. Vital signs 
            Heart rate                                     [__|__|__]/min 
             Blood pressure (for adult only)            [__|__|__]/[__|__|__] mmHg          
            Respiratory rate                                    [__|__|__]/min  
4. Respiratory Examination  
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            Respiratory Distress                    ¡ Yes            ¡ No       
            Crepitations                                 ¡ Yes            ¡ No       
            Wheeze                                       ¡ Yes            ¡ No       
             Other_______________________________________________ 
5. ENT Examination   
             Throat red                                  ¡ Yes               ¡ No         
             Throat pus                                  ¡ Yes              ¡ No         
             Tympanic membrane red            ¡ Yes              ¡ No         
             Other_______________________________________________ 
6. CRP test                        ¡ Yes If Yes, answer Q.6a           ¡ No 
6a. CRP value                       ¡ >200      [__|__|__]      ¡ <8 mg/L     
7. Antibiotics prescribed  ¡ Yes ¡ No 
8. Antibiotics details  
      ¡ Amoxicillin    ¡ Ampicillin       ¡ Azithromycin    ¡ Cephalexin                                           
      ¡ Cefaclor         ¡ Cefixim            ¡ Cefuroxime       ¡ Clindamycin 
Other: _____________________________________________________ 
9. Date to come back on day 3/4 [__|__]/[__|__]/[__|__|__|__] (dd/mm/yyyy) 
10. Date for telephone follow-up  [__|__]/[__|__]/[__|__|__|__]  (dd/mm/yyyy) 
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Appendix B4 Examination on follow-up visit day (Day 4) 
Examination on Day 4 
Patient Code: 05HN-[__|__]-[__|__|__|__]                 Patient initials: [__|__|__|__|__] 
1. Show up on Day 3/4                       ¡ Yes ¡ No, reason: __________________ 
2. Since the last visit, have you used any antibiotics         ¡ Yes    ¡ No     ¡ Unknown 
3. Since the last visit, have you admitted to hospital         ¡ Yes     ¡ No 
4. Symptom 
Cough ¡ Yes ¡ No  
Sputum   ¡ Yes ¡ No 
Coryza   ¡ Yes ¡ No 
Dypsnea   ¡ Yes ¡ No 
Wheeze  ¡ Yes ¡ No 
Earache  ¡ Yes ¡ No 
Chills ¡ Yes ¡ No 
Sore throat   ¡ Yes ¡ No 
Fever  ¡ Yes ¡ No 
Sweating   ¡ Yes ¡ No 
Rigors ¡ Có ¡ No 
5. Vital signs 
Heart rate   [__|__|__]/min 
Blood pressure       [__|__|__]/[__|__|__] mmHg          
Respiratory rate   [__|__|__]/min  
6. Respiratory Examination  
        Respiratory Distress                    ¡ Yes            ¡ No       
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        Crepitations                                 ¡ Yes            ¡ No       
        Wheeze                                       ¡ Yes            ¡ No               
 
Other ________________________________________ 
7. ENT Examination 
             Throat red                                  ¡ Yes               ¡ No         
             Throat pus                                  ¡ Yes              ¡ No         
             Tympanic membrane red            ¡ Yes              ¡ No         
             Other_______________________________________________ 
 
8. Symptom progress 
  Better 
  Not change 
  Worse 
9. CRP test  ¡ Yes ¡ No 
If Yes, answer Q.9a 
9a. CRP value                     ¡ >200      [__|__|__]      ¡ <8 mg/L     
10. Antibiotics prescribed at this visit    ¡ Yes ¡ No 
11. Antibiotics details 
      ¡ Amoxicillin    ¡ Ampicillin       ¡ Azithromycin    ¡ Cephalexin                                           
      ¡ Cefaclor          ¡ Cefixim             ¡ Cefuroxime        ¡ Clindamycin      Other 
_________________________________________________ 
 
12. Urine sample provided                   ¡ Yes           
                                                               ¡ No, reason ________________________ 
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Appendix B5 Interview on Day 14 
Interview on Day 4 
Patient Code: 05HN-[__|__]-[__|__|__|__]                 Patient initials: [__|__|__|__|__] 
1. Informant               ¡ Patient ¡ Mother ¡ Father      ¡ Other ___________ 
2. Since visiting the centre 14 days ago, how long do the symptoms last (from Day 0)                        
                                                                                                            [__|__]          (days)  
3. Within 14 days, did you use any antibiotics?          ¡ Yes     ¡ No     ¡ Don’t know     
3a. If yes, what source of antibiotics:  
      ¡ Doctor      ¡ Pharmacist      ¡  Self-medication       ¡ Other, specify: __________ 
4. In your opinion, has the illness improved, worsened, or remained the same since you 
left the clinics 14 days ago? 
¡ Recovered 
¡ Improved 
¡  Stayed the same (if yes, ask to Q9) 
¡  Worsened (if yes, ask Q9) 
¡  Not sure 
5. Is there any serious adverse events (SAEs) occurred during 14 days?            
¡ No      
¡ Yes, please specify as below    
1. Hospitalisation   
2. Death    
  
5a. For any SAEs as above, please specify: 
Occurred date [__|__]/[__|__]/[__|__|__|__] (dd/mm/yyyy) 
Reason:    a. Related to current disease   
                  b. Other diseases  specify__________ 
                  c. Other  specify__________ 
6. Patient’s satisfaction score (range: 0-10): ___________ 
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Appendix B6 Patient contact form 
Interview on Day 4 
Patient Code: 05HN-[__|__]-[__|__|__|__]                 Patient initials: [__|__|__|__|__] 
1. Informant               ¡ Patient ¡ Mother ¡ Father      ¡ Other ___________ 
2. Contact Date:  [__|__]/[__|__]/[__|__|__|__] (dd/mm/yyyy)                                     
3. Reason for contact : 
__________________________________________________________________________ 
__________________________________________________________________________ 
__________________________________________________________________________ 
4. Action of study team with agreement of patient 
_______________________________________________________________________ 
_______________________________________________________________________ 
_______________________________________________________________________ 
 
Appendix B7 Patient symptom diary  
Patient Code: 05HN-[__|__]-[__|__|__|__]                 Patient initials: [__|__|__|__|__] 
DAY 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Fever                
Cough                
Sputum                
Coryza                
Dyspnea                
Wheeze                
Earache                
Chills                
Sweating                
Rigors                
Sore 
throat 
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Appendix C 
Cost survey forms – Economic Impact analysis 
Economic Implications of C-Reactive Protein Point of Care Testing in the Management 
of Acute Respiratory Infections in the Vietnamese Primary Health Care Setting 
 
 
 
 
 
Principal investigator  Yoel Lubell, Mahidol Oxford Research Unit 
 
Co-investigator Heiman Wertheim, Oxford University Clinical Research Unit 
   Do Thi Thuy Nga, Oxford University Clinical Research Unit  
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Appendix C1 Cost survey on Day 0 
Cost survey on Day 0 
Patient Code: 05HN-[__|__]-[__|__|__|__]                 Patient initials: [__|__|__|__|__] 
1. Informant               ¡ Patient ¡ Mother ¡ Father      ¡ Other ___________ 
PRE-CLINIC, TREATMENT & TRAVEL COST TO CLINICS (in vnd) 
2. Before coming to the clinics today, what did you do to treat this illness? (Tick all that 
apply) 
£  Nothing 
£  Went to a clinic/hospital  
£  Got drugs from pharmacy 
£  Other, specify _________________ 
 
3. How much have you spent in treating this illness before coming to the clinics today, 
including costs of any medicines and any fees charged by providers? 
Medicines fee:      |__|__|__|-|__|__|__|   
Examination fee:  |__|__|__|-|__|__|__|   
Diagnosis fee:      |__|__|__|-|__|__|__|   
Other:                  |__|__|__|-|__|__|__|   
4. How much money did you spend on transport to come to the clinics today? 
                                  |__|__|__|-|__|__|__|   
CLINICS DIAGNOSIS AND TREATMENT ON DAY 0 
5. How much have you pay for examination fee today?                    
£ Cover by HI:            |__|__|__|-|__|__|__|   
£ Self-paid:                 |__|__|__|-|__|__|__|   
6. Have any diagnostic tests been performed at the clinics today? 
Test     Covered by HI           Cost                     Self-paid                             Cost  
£ None                       
£ X-ray         £             |__|__|__|-|__|__|__|               £                      |__|__|__|-|__|__|__|     
£ Blood test  £            |__|__|__|-|__|__|__|                £                      |__|__|__|-|__|__|__|     
£ Endoscopy £            |__|__|__|-|__|__|__|                £                      |__|__|__|-|__|__|__|     
£ Other:         £            |__|__|__|-|__|__|__|                £                      |__|__|__|-|__|__|__| 
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7. Have any medications have been prescribed to you today? 
                            Covered by HI       Cost                 Self-purchased               Cost  
£   Nothing                          
£   Antibiotics                £        |__|__|__|-|__|__|__|                   £          |__|__|__|-|__|__|__|                                                                                          
£  Cough preparations   £        |__|__|__|-|__|__|__|                   £          |__|__|__|-|__|__|__|                                                                                                                                                                                       
£   Fever, pain killer      £        |__|__|__|-|__|__|__|                   £          |__|__|__|-|__|__|__|                                                                                                                                                                                               
£   Anti-histamin           £        |__|__|__|-|__|__|__|                   £          |__|__|__|-|__|__|__|                                                                                                                                                                                            
£   Corticoids                 £        |__|__|__|-|__|__|__|                   £          |__|__|__|-|__|__|__|                                                                                                                                                                                               
£   Vitamin                    £        |__|__|__|-|__|__|__|                   £          |__|__|__|-|__|__|__|                                                                                                                                                                                                      
£   Other                        £        |__|__|__|-|__|__|__|                   £          |__|__|__|-|__|__|__|                                                                                                                                                                                          
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Appendix C2 Cost survey on Day 14 
Cost survey on Day 14 
Patient Code: 05HN-[__|__]-[__|__|__|__]                 Patient initials: [__|__|__|__|__] 
1. Informant               ¡ Patient ¡ Mother ¡ Father      ¡ Other ___________ 
TREATMENT AND COURSE OF ILLNESS SINCE DAY 0 (in vnd) 
2. Since leaving the health centre 14 days ago, what have you done to treat this illness, 
and how much have you spent including 2nd visit? 
£ Nothing                                                                                                              
£ Went for 2nd study visit                     
£ Went to drug store                    
£ Returned to this clinics (except 2nd  
£ Went to another clinics                     
£ Went to hospital                                
£ Hospital admission                            
£ Consulted traditional healer              
£ Other, specify________________ 
3. For each option about, please specify the cost for  
Transportation fee:      |__|__|__|-|__|__|__|   
Examination fee:         |__|__|__|-|__|__|__|   
Diagnosis fee:              |__|__|__|-|__|__|__|  
Medicine fee:              |__|__|__|-|__|__|__| 
Other:                          |__|__|__|-|__|__|__|   
4. Since leaving the health centre 14 days ago, what kind of medications you had to buy 
for this illness, and how much did they cost? 
                                                             Cost (vnd) 
£  Nothing  
£  Antibiotics                               |__|__|__|-|__|__|__|  
£  Cough preparations                 |__|__|__|-|__|__|__| 
£  Fever, pain killer                     |__|__|__|-|__|__|__|  
£  Vitamin                                   |__|__|__|-|__|__|__| 
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Part one 
RATIONAL  
 
 
BACKGROUND 
 
Since the discovery of penicillin antibiotics, hundreds of antibiotics and similar drugs have 
been invented and used. The discovery of antibiotics marked a new era of medicine 
development for the treatment of bacterial infections. 
In addition to the role of medicine known to man, anti-bacterial drugs have been widely used 
in livestock, poultry, aquaculture and cultivation for the treatment, prevention and control of 
animal diseases, as well as for production purposes. As a result of continuous exposure to 
antimicrobial drugs, the proportion of drug-resistant bacteria in the feces of these animals is 
relatively high. 
Antibiotics are of great benefit in the treatment and care of patients and the veterinary if they 
are prescribed and ed properly. However, that these drugs have been widely used, prolonged 
and abused would make microbes adaptable to drugs, enabling many bacteria to become 
resistant and as a result, the drugs are becoming less effective or ineffective. Drug resistance 
is not only a concern of clinicians in the treatment but also the concern of the whole society 
for public health. 
Drug resistance (AMR) is a condition of microorganisms (such as bacteria, viruses, fungi and 
parasites) are resistant to the antibiotics which used to be susceptible to microorganisms. 
Resistant organisms (bacteria, viruses, parasites) that can withstand the attack of anti-bacterial 
drugs (such as antibiotics, antiviral, anti-malarial drugs), therefore, the application of 
methods, specific therapy, drugs becomes ineffective, the infection will be prolonged (even 
fatal) and can spread to others. AMR is the corollary of the process of drug use in the 
treatment and particularly becomes more serious where abuse of antibiotics is increasingly 
more common. 
Bacteria resistant to most antibiotics have appeared in the world, also called XDR bacteria. 
 
In Vietnam, most of the examination and treatment facilities are facing with of spread of 
bacteria resistant to many antibiotics. The level and speed of drug resistance are increasing, at 
alarming level. The burden of drug resistance is increasing due to the increasing cost of 
treatment, prolonged treatment,. That will affect patients’ health, community and social 
development. In the future, many nations will be able to face the possibility of having no 
effective drugs to treat infectious diseases if they do not make appropriate interventions. 
Currently, drug resistance is not a new issue, but it has become dangerous and urgent, 
requiring the comprehensive effort to help the humankind avoid the risk of returning to the 
era without antibiotics. The World Health Organization (WHO) said that we live in the era 
dependent on antibiotic and requires global responsibility to protect valuable source of 
antibiotics for the next generation. 
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On the World Health Day 2011, WHO chosen the drug resistance prevention slogan “No 
action today, no cure tomorrow” and urged the nation to have timely plan to deal with drug 
resistance. 
Hence, it is essential for Vietnam to build a comprehensive, overall, long-term Plan for the 
prevention of drug resistance in the current period. 
I. PRACTICAL BASIS 
1. Status of drug resistance 
1.1. Drug resistance in the world 
The problem of drug resistance has become alarming around the world, especially the 
developing countries. The burden of the cost for treating infectious diseases is relatively large 
due to the replacement of older antibiotics with new expensive antibiotics. 
In 2011, drug-resistant TB situation was happening in most countries. There are about 
640,000 cases of multidrug-resistant tuberculosis (MDR - TB) worldwide, about 9% of which 
is XDR - TB [1]. 
Falciparum malaria parasites resistant to artemisinin is emerging in Southeast Asia. 
Resistance to anti-malarial drugs of previous generation such as chloroquine and sulfadoxine-
pyrimethamine is widespread in most endemic countries [2]. 
The global approach to antiretroviral drugs to treat HIV patients increases the risk of drug 
resistance. The resistance of the virus to drugs is a threat to humanity. Approximately 15% of 
patients treated have resorted to second and tertiary drug regimen. The cost of this drug is 100 
times higher than primary regimen. The increasing resistance of HIV poses a challenge to 
maintain global outreach programs in low-income countries. These countries need to 
strengthen health services and improve the quality of care for people with HIV to minimize 
the spread of resistant viruses. 
Data of ANSORP monitoring studies from 1/2000 to 6/2001 of 14 centers from 11 countries 
in Southeast Asia shows the high proportion of resistance of bacteria S. pneumoniae. 483 of 
the 685 strains of S. pneumoniae isolated from patients (52.4%) are not susceptible to 
penicillin, 23% at intermediate level and 29.4% resistant to penicillin (MIC ≥ 2 mg/l). Results 
of bacterial isolation showed the highest rate of resistance to penicillin in Vietnam (71.4%), 
followed by South Korea (54.8%), Hong Kong (43.2%) and Taiwan (38.6 %). Erythromycin 
resistance rate is also very high in Vietnam 92.1%, Taiwan 86%, South Korea 80.6%, and 
Hong Kong 76.8% and China 73.9%. Data from multicenter surveillance studies clearly 
demonstrated the speed and resistance rate of S. pneumoniae in Asian countries, where the 
most incidence of diseases in the world [3]. 
According to data from the 2005-2007 KONSAR study in South Korea hospitals showed that 
Methicillin-resistant S. aureus (MRSA) was 64%; K. pneumoniae resistant to third-generation 
cephalosporins was 29%; E. coli resistant to fluoroquinolone 27%, P. aeruginosa resistance 
33%, Acinetobacter spp. resistance 48%, P. aeruginosa resistant to amikacin 19%, 
Acinetobacter spp. resistance 37%. vancomycin-resistant E. faecium and imipenem-resistant 
Acinetobacter spp. is increasing. Resistance rate detected in the laboratory of E. coli and K. 
pneumoniae to third-generation cephalosporins and P. aeruginosa to imipenem is higher in 
hospitals [4]. 
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Antibiotics effectively treated for Shigella dysentery were previously resistant, so WHO is 
currently recommending ciprofloxacin. However, the rate of ciprofloxacin resistance 
increasing rapidly reduces both the safety and effectiveness of treatment, especially for 
children. 
AMR has become a serious problem in the treatment of gonorrhea (caused by N. 
gonorrhoeae), even related to the oral cephalosporin (final treatment remedy) and is 
increasing worldwide. That Gonococcal infections can not be treated will lead to increasing 
morbidity and mortality, thus reversing the gains made in the program to control the sexually 
transmitted diseases. The control of these diseases has been badly affected by the 
development and spread of drug resistance. 
New resistance mechanism such as beta-lactamase NDM-1 has emerged among gram-
negative bacilli. This may invalidate the result of strong antibiotics - usually only final 
prescription against multidrug-resistant strains of bacteria. 
1.2. Situation of antibiotic use and resistance in Vietnam 
1.2.1. Antibiotic use in community: 
According to the survey results of the antibiotics sold in pharmacies in urban and rural areas 
of Northern provinces showed poor awareness of antibiotics and antibiotic resistance of the 
people and drug sellers, particularly in rural areas. Among the total 2,953 pharmacies under 
investigation: 499/2,083 pharmacies in urban areas (accounting for 24%) and 257/870 
pharmacies in rural areas (accounting for 29.5%) sold antibiotics prescribed. Antibiotics 
accounted for 13.4% (urban) and 18.7% (rural) in pharmacies’ total sales. Most antibiotics are 
sold without a prescription: 88% (urban) and 91% (rural). Antibiotics are sold to treat cough 
31.6% (urban) and fever 21.7% (rural). Three antibiotics are sold the most: 
ampicillin/amoxicillin (29.1%), cephalexin (12.2%) and azithromycin (7.3%). People often 
ask for antibiotics without a prescription: 49.7% (urban) and 28.2% (rural) [5]. 
1.2.2. Antibiotic use and antibiotic resistance in hospitals 
The review of results of the sensitivity of antibiotics carried out in 2003-2006 showed that 
resistance rate of Klebsiella spp. to cephalosporins of 3rd generation, 4th generation, 
fluoroquinolones and aminosid has increased from > 30% in 2003 to > 40% in 2006; to 
Pseudomonas spp. from > 40% in 2004 to > 50% in 2006 and to Acinetobacter spp. from > 
50% in 2004 to > 60% in 2006. Although imipenem/cilastatin, carbapenem have just been put 
into Vietnam markets for nearly 10 years, their susceptibility to gram-negative bacilli with no 
enzymatic generation is reducing. Imipenem /cilastatin resistance rate of Pseudomonas spp. 
has increased over the years: 12.5% (2003), 15.5% (2005) and 18.4% (2006) [5]. 
According to data reported by 15 hospitals under the Ministry, Provincial General Hospitals 
in Hanoi, Hai Phong, Hue, Da Nang, Ho Chi Minh city, ... about the use of antibiotics and 
antibiotic resistance in the period 2008 - 2009 showed that, 30-70% of gram-negative bacteria 
resistant to cephalosporins of 3rd generation and 4th generation, nearly 40-60% resistant to 
aminoglycosides and fluoroquinolones in 2009. The sensitivity to imipenem of nearly 40% of 
Acinetobacter strains decreased. 
Using antibiotics averagely 274.7 DDD/100 day-bed. This rate is significantly higher 
compared with Dutch report at the same period as 58.1 DDD/100 day-bed and higher than 
that of 139 reports from hospitals of 30 European countries in 2001: 49.6 DDD/100 day-bed. 
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The correlation between antibiotic use and antibiotic resistance is evident when the ratio of 
gram-negative bacteria resistant to cephalosporins of 4th generation is high in places with 
greater consumption of antibiotics [6]. 
According to the results “study antibiotic use in hospital-acquired infections in intensive care 
units in some health facilities” shows the most four isolated strains Acinetobacter spp, 
Pseudomonas spp, E. coli, Klebsiella spp. Frequency of Acinetobacter spp or Pseudomonas 
spp. infections marked dominant proportion (> 50%) in nosocomial pneumonia (ventilator or 
no ventilator). These 4 isolated strains were multidrug-resistant bacteria. A specially high 
resistance is detected in cephalosporin of 3rd and 4th generations (66-83%), followed by the 
group of aminosid and fluoroquinolones with resistance ratio over 60%. 
The high resistance is also reflected in the use of antibiotics in the initial empirical results 
inconsistent with antibiotic regimen 74% [7].  
1.2.3. Use anti-TB and drug-resistant TB 
Report of WHO 2012 estimates, Vietnam ranks 12 of the 22 countries with high tuberculosis 
burden globally, ranking 14th out of 27 countries with MDR-TB burden in the world. 
MDR-TB rate was 2.7% among new TB patients (approximately 4,800 patients), 19% of re-
treatment TB patients (approximately 3,400 patients). In 2011 WHO estimated about 3,500 
MDR-TB patients (95% CI: 2,600-4,700) among TB patients detected [8]. 
However, in recent years, tuberculosis has become more complicated due to the impact of 
HIV/AIDS and drug resistance. 
According to WHO, drug-resistant TB is a particularly serious problem. Result of treatment 
for patients with drug-resistance is often poor, especially MDR-TB patients. The cost of 
treating MDR-TB patients is hundreds of times higher than the non-drug-resistant TB patients 
and some cases can not be treated. Currently, the proportion of MDR in new TB patients in 
Vietnam is at <3%, but it is not small in comparison with the big number of patients with 
smear positive pulmonary TB (+) recently detected in Vietnam each year. Moreover, there are 
about 350 people with chronic tuberculosis each year, and most of them are MDR-TB 
patients. This is worsening the current status of drug resistance. 
The cause of drug resistant TB bacteria may be due to bacteria transforming themselves to 
survive; patients do not comply with the treatment regimen, voluntary discontinuation, dose 
reduction ...; due to environmental pollution, spitting, littering in public places ... These 
causes are main factors which increase TB patients and drug resistance in Vietnam. 
1.2.4. Use of HIV drug and HIV resistance  
Since the first cases had been detected in 1990, up to 31th March 2012, the number of people 
living with HIV was 199,744, of which 49,369 people entered AIDS phase, 52,681 people 
died from AIDS. The speed is still on the rise, but there are signs of slowing down in recent 
years due to the implementation of the intervention program. 
In Vietnam, ARV drugs have been used from the mid-1990s but have been limited in some 
provinces and cities, especially in Hanoi and Ho Chi Minh City with a one-drug regimen or 
combination of the two types of ARVs. 
Since 2005, the three-drug combination regimen in highly active antiretroviral therapy 
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(HAART) has been mentioned in national guidelines for diagnosis and treatment of 
HIV/AIDS of the Ministry of Health. In particular, the issue of compliance with antiretroviral 
therapy is considered as one of the prerequisite for the success of treatment. 
The use of ARV also created the appearance of strains of HIV resistant to ARV and the risk 
of the spread of drug-resistant strains in the community. In countries where ARV has been put 
in use for many years, 5-27% of people newly infected with HIV carry the virus HIV-1 strains 
resistant to one or more antiretroviral drugs. 
In a study on drug resistance conducted in Ho Chi Minh City, the rate of HIV drug resistance 
of people who are drug addicts, prostitutes and patients with sexual transmitted diseases 
unprecedented access to ARV was 6.5%. The research results of Pasteur Institute in Ho Chi 
Minh City in pregnant women without access to ARV and new HIV infections (under the age 
of 30, the number of lymphocytes CD4+>500 cells/mm3 without ARVs) showed that the rate 
of HIV resistance is low <5%. Another study in Ho Chi Minh City showed that, the rate of 
drug-resistant HIV in pregnant women participating in PMTCT at the time before taking drug 
was relatively low 0.6%. Two weeks after birth, the percentage of pregnant women were 
found to be carrying drug-resistant HIV reduced to 17.53% and down to 3.06% two months 
after birth. 3TC resistance mutations often found in groups of pregnant women using 
combination regimens AZT+3TC and NVP resistance mutations in pregnant women using sd-
NVP. The 3TC resistance mutations often found among women taking combination therapy 
and the AZT +3 TC NVP resistance mutations in pregnant women using sd-NVP. Although 
after discontinuing oral prophylaxis, the rate of virus with resistance mutation decreases 
gradually, drug-resistant strains can persist at levels below the detection threshold and are 
possible to reoccur when mothers are treated with the regimens using resistant drugs. 
In 2008, the Ministry of Health developed the national plan for prevention, monitoring HIV 
drug resistance as recommended by WHO. The national plan includes contents related to: (1) 
collect early warning indicators of drug-resistant HIV; (2) monitor the appearance of drug-
resistant HIV among patients on ARV therapy grade 1; and (3) investigate the appearance of 
drug-resistant HIV among HIV-infected people without ARV. 
Since 2008, Vietnam has annually collected data regarding ARV treatment results along with 
the collection of early warning indicators of HIV drug resistance in representative 
antiretroviral treatment facilities nationally . 
The monitoring of HIV drug resistance among newly HIV-infected people without ARV 
showed the rate of HIV resistance below 5%. 
1.2.5. Use of antibiotics and antibiotic resistance in livestock, cultivation 
In order to limit the risk of diseases in livestock industry, people have the habit of using many 
antibiotics, stimulants including prohibited active ingredients and veterinary drugs to 
stimulate growth or prevention and treatment for animals. If it is not well controlled, the use 
of the active ingredient, veterinary drugs in livestock production will cause a great risk for the 
environment and human health such as drug resistance, antibiotic resistance in humans, 
residual antibiotics from feces, urine to plants and to humans through water resources, ... In 
livestock industry, there is so much abuse of synthetic antibiotics. The number of households 
using antibiotics 3-6 active elements accounts for 27% of pig farms for meat, 24% of farms of 
small pigs and 10% of chicken farms (Vu Dinh Ton et al 2010). The use of antibiotics and 
veterinary chemicals based primarily on experience will often lead to the increase of doses 
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and treatment regimen. Use of antibiotics in disease symptoms (44%), as directed by 
veterinary staff 33%, the use of antibiotics as recommended by the manufacturer for 17% and 
only 6% of the farms use antibiotics following the antimicrobial susceptibility testing results 
(Nguyen Quoc An, 2009) [5]. 
1.2.6. Hospital infections and infection control in hospitals 
Hospital infection is one of the challenges and concerns in Viet Nam and around the world. 
Many studies show that hospital infection increases mortality, prolongs hospital stay, 
increases duration of antibiotic use, increases antibiotic resistance and increases treatment 
costs. 
U.S. statistics show that the cost of a hospital infection case is usually 2 to 4 times higher than 
a case without hospital infection. Of which, costs incurred by sepsis related to intravascular 
devices is set from 34,508 dollars to 56,000 dollars and pneumonia in patients with 
ventilation support is from US $ 5,800 to US $ 40,000. In the U.S., each year 2 million 
patients are estimated to be hospital infections, causing 90,000 deaths, costs US $ 4.5 billion 
of hospital fees. 
Hospital infection in Vietnam has not been fully determined. Very little document and 
monitoring of hospital infection has been published. The expenditure for manpower and 
financial resources to cope with nationwide hospital infection has not yet determined. Three 
national cross-sectional surveys were carried out. The 1998 survey on 901 patients in 12 
hospitals nationwide showed that the rate of hospital infection was 11.5%, of which, wound 
infections accounted for 51% of the cases of hospital infection. In 2001, the rate of hospital 
infection was 6.8% in 11 hospitals and hospital pneumonia was the most common cause 
(41.8%). That in 1998 survey in 19 hospitals nationwide was 5.7% and hospital pneumonia 
was the most common cause (55.4%). There have never been a national study to assess the 
cost of hospital infection. 
The diseases caused by hospital infection has higher level of MDR than infectious diseases in 
community. Hospital infection is caused by bacteria with high resistance such as S. aureus 
resistant to methicillin (MRSA) and vancomycin-resistant enterococci, multidrug-resistant A. 
baumanni, P. aeruginosa acounted for considerable proportion. 
Situation of hospital infection control: The BCC system is not completed as required; staff for 
management of BCC are insufficient, not qualified, most of them have not been trained; lack 
of infrastructure and necessary facilities for BCC particularly in district hospitals; many 
critically professional missions on BCC have not been done; lack of a database of hospital 
infection, diseases, drug-resistant microorganisms, ... 
2. Causes of resistance 
2.1. Use of inappropriate antimicrobial drug 
The overdose, insufficient dose or abuse of antimicrobial drug has caused resistance, creating 
favorable conditions for resistant microorganisms to emerge, change and spread. In fact, 
many patients buy antibiotics for self-treatment without prescription, use of antibiotics for 
treatment of cases which are not caused by pathological infections; inappropriate use of 
antibiotics and drug to bacteria, viruses, parasites .... use of improper dosage, and time ... 
2.2. Control and inspection of drug quality are limited 
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Quality control system can not meet the actual needs due to lack of testing capacity for many 
active ingredients; can not control the quality of all production lots of each product circulating 
in the market. 
2.3. Prevention and control of infectious diseases are ineffective 
Ineffective prevention and control of infectious diseases help increase the spread of drug-
resistant bacteria. The patients treated in hospitals are the major source of spread of resistant 
microorganisms from one person to others. 
2.4.The monitoring system of drug resistance has not been established 
At present, there is not a national network for monitoring drug resistance in Vietnam. The 
monitoring of drug resistance is only set up and implemented in some hospitals, such as the 
Central Tropical Diseases Hospital, Bach Mai Hospital, Children's Hospital No.1... 
However, the monitoring activities are not done frequently. The lack of testing facilities 
accurately identifying microbial resistance leads to difficulties in the detection of newly 
emerging resistant microbes, therefore, it is impossible to act quickly to control the drug 
resistance. 
2.5. Use of antimicrobial drugs in livestock is not properly controlled 
Antibiotics are increasingly widely used in livestock to promote growth and prevent diseases. 
This can lead to microbial resistance and cause drug resistance in humans. 
2.6. The expertise regulations of health care is not regularly updated  
There have not been enough instruction for diagnosis and treatment or updated guidelines for 
many infectious diseases. In addition, the regulation on the use of antibiotics, antibiotic 
regimen, microbiological testing has not been completed; the inspection and supervision of 
the implementation process at the local level is not frequent enough. 
2.7. Awareness of community, health workers on drug resistance is limited. 
People's habits “heal myself” and “imitate” prescriptions lead to the arbitrary use of 
antibiotics, contributing to increased drug resistance. In addition, limitations of health 
workers, equipment of some health facilities, especially at the lower levels, regional and 
remote areas, lack of conditions for antibiotic regimen lead to improper use of  antibiotics by 
patients. 
3. The consequences and the burden of drug-resistance 
Drug resistance is not a new phenomenon, however, it is becoming more serious and its 
growth rate is badly affecting community health. As a result, after 70 years since the 
introduction of antibiotics, we have to face with the possibility of a future without effective 
antibiotics for treatment for a number of infectious diseases, especially the surgery and 
treatments such as cancer chemotherapy and human body parts, tissue transplant. 
In addition, drug resistance has induced scarcity, lack of new antimicrobial drugs, especially 
in patients with infections caused by multidrug-resistant organisms (MDR). 
The social costs and financing in the treatment of drug-resistant infections put a significant 
burden on individuals, families and society, due to prolonged duration of treatment, bad 
prognosis and waste of costs for drugs due to inappropriate medication use. 
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II. LEGAL BASIS 
1. Law on health examination and treatment No. 40/2009/QH12 dated November  23rd 2009 
2. Law on Pharmacy No. 34/2005/QH11 dated June 14th, 2005 
3. Law on Prevention and Control of Infectious Diseases No. 03/2007/QH12 dated November 
21st, 2007. 
4. Law on prevention and control of viral infection causing immunodeficiency syndrome 
(HIV/AIDS) No. 64/2006/QH11 dated  June 29th, 2006. 
5. Decree No. 63/2012/ND-CP dated August 31st, 2012 of the Government defining the 
functions, tasks, powers and organizational structure of the Ministry of Health. 
6. Decision No. 1208/QD-TTg dated September 4th, 2012 approving the national target 
program on Health for the period 2012-2015 by the Prime Minister. 
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Part two 
CONTENTS OF PLAN 
I. OBJECTIVES 
1. The overall objective 
Promote prevention of drug resistance, contributing to improving the quality and 
effectiveness of the prevention and control of epidemics, medical examination and treatment 
to protect, care for and improve people's health. 
2. Specific objectives 
2.1. Raise awareness of community and health workers on drug resistance.  
2.2. Strengthen, improve national surveillance system on the use of antibiotics and drug 
resistance 
2.3. Ensure adequate supply of quality medicines to meet the needs of people. 
2.4. Promote proper safe use of drugs 
2.5. Promote infection control. 
2.6. Promote proper safe antibiotic use in livestock, poultry, aquaculture and cultivation 
II. ACTIVITIES  
1. Raising awareness of the community and health workers about drug resistance 
1.1. Activities 
a) Compile documents for continuous training and develop IEC communication materials. 
b) Organization of communication activities, including direct communication (seminars, 
talks, consultations, ...) and indirect communication in mass media (TV spots, radio spots, 
knowledge, articles, ...). 
1.2. Time and schedule for implementation 
Phase 1 (from 2013 to 2016): 
a) Develop communication materials: brochures, posters, flip pictures, video spot, television 
spot for propaganda, dissemination on the causes and consequences, measures to prevent drug 
resistance. 
b) Develop materials to guide health workers, community on prevention of drug resistance. 
c) Organize seminars, talks and consultation to answer questions about prevention of drug 
resistance on mass media. 
d) Organization of communication and education activities on the prevention of drug 
resistance on mass media from the central to local levels. 
e) Launch the month for prevention of drug resistance in the country. 
e) Organize training conferences, disseminate and educate laws on on the prevention of drug 
resistance 
g) Organize continuous training, training in communication skills, monitoring and evaluation 
of prevention of drug resistance. 
Phase 2 (from 2016 to 2020): 
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Maintain communication activities in addition to the survey, assessment of community’s 
knowledge about drug resistance. 
2. Enhance, improve the capacity of the national surveillance system on antibiotic use 
and resistance 
2.1. Activities 
a) Developing and completing documents regulating clinical microbiology laboratory; 
standard testing procedures, building standard microbiology laboratories and reference 
laboratories; 
b) Establish drug resistance surveillance system; 
c) Participating in curriculum development for training in microbiology and antibiotics in 
universities, medical- pharmacy schools; 
d) Continuing education and training to enhance the capacity of the clinical microbiology 
laboratory, scientific research capacity of staff on the resistance; 
e) Developing training cooperation programs on drug resistance prevention between domestic 
and abroad medicine – pharmacy schools; 
e) Developing a database of antibiotic use and resistance. 
2.2. Time and schedule for implementation 
2.2.1. Phase 1 
a) Develop and improve standard test procedures, guidelines for clinical microbiology 
laboratory. 
b) Establish the National Center of clinical microbiology laboratory. 
c) Conduct training, continuous training on technical expertise of the clinical microbiology 
for laboratory staff at the national standard center and 30 laboratories nationwide. 
d) Build functions, tasks, organizational structure, human resources and equipments for 
laboratories of clinical microbiology.                                                                                              
e) Organize abroad training courses on drug resistance surveillance system. 
e) Set up a network of monitoring of antibiotic use and resistance in 30 laboratories across the 
country. 
g) Develop forms, tracking software and reports of the use of antibiotics, reports of drug 
resistance. 
h) Carry out scientific research on drug resistance. 
i) Participation in scientific conferences on drug resistance in the country and abroad. 
2.2.2. Phase 2 
a) Develop a database of antibiotic use and resistance. 
b) Develop evaluation indicators, establish a system for collecting and processing 
information, develop websites for tracking, monitoring and evaluation of drug resistance. 
c) Organize scientific conferences on drug resistance prevention. 
3. Ensure adequate supply of quality essential drugs 
3.1. Activities 
a) Improving, updating the documents defining the list of essential medicines, major drug 
categories used in the examination and treatment; 
b) Investing in production supply the market with drugs of good quality, reasonable price; 
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c) Implementing comprehensive management of drug quality during the entire process of 
production, export, import, distribution and use of drugs. 
3.2. Time and schedule for implementation 
3.2.1.Phase 1 
a) Update list of essential medicines, major drug categories that are consistent with the pattern 
of disease and socio-economic conditions of Vietnam; in line with advances in science and 
technology in healthcare in each specific stage and technical capabilities of each level. 
b) Monitoring and surveillance of counterfeit drugs circulating in the market. 
c) Continue to promote the implementation of the project “The Vietnamese use drugs made in 
Vietnam with priority”. 
d) Develop and propose mechanisms to prioritize the production of generic drugs for 
pharmaceutical companies in the country. 
e) Investment in production to supply the market with drugs of good quality, reasonable price. 
3.2.2. Phase 2 
Continue some activities of the phase before 2015 combined with topical scientific workshop 
on enhancing patients’ access to essential medicines.  
4. Strengthen safe and rational use of drugs 
4.1. Activities 
a) Developing and completing documents and manuals regulating rational drug use, 
antibiotics and treatment; 
b) Conducting workshops, seminars, training, ongoing training on good prescribing practice, 
clinical pharmacy practice. 
c) Building capacity for the Council of Drugs and Treatment; 
d) Conducting workshops, seminars on evaluation of the rational safe use of drugs, 
assessment of activities of Council of Drugs and Treatment. 
e) Monitoring , inspecting and supervising the rational safe use of drugs in the examination 
and treatment facilities. 
e) Developing and completing the training program, ongoing training on clinical pharmacy 
practice. 
4.2. Time and schedule for implementation 
4.2.1. Phase 1 
a) Develop, update and promulgate treatment guidelines. 
b) Develop guidelines for the use of antibiotics for medical staff and community. 
c) Conduct training, continuous training of clinical pharmacy practice, good prescription. 
d) Develop regulations for the operation of the Council of Medicines and Treatment. 
e) Conduct training, continuous training in treatment guidelines for health workers. 
e) Evaluate the compliance to treatment guidelines in health facilities. 
g) Develop documents defining the assessment of drug use. 
h) Develop indicators for the assessment of drug use in hospitals and community. 
i) Do monitoring and evaluation of drug use, monitoring the treatment compliance and 
operation of Council of Medicines and Treatment in health facilities. 
k) Conduct conference on the assessment of drug use, operation of Council of Medicines and 
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Treatment in health facilities. 
4.2.2. Phase 2 
a) Cooperate in research on the use of drugs, especially antibiotics 
b)  Do continuous training and training nationally and internationally on drug information, 
drug use, clinical pharmacy practice 
c) Conduct management, information collection, evaluation of indicators of drug use 
d) Conduct scientific conferences on antibiotics and antibiotic resistance. 
5. Strengthen infection control. 
5.1. Activities 
a) Improve and update documents on infection control; 
b) Continuing education, training, inspecting, monitoring and evaluating the implementation 
of infection control for health workers. 
c) Promote the monitoring system and report of data to form the database of national infection 
control. 
5.2. Time and schedule for implementation 
5.2.1. Phase 1 
a) Add, update and promulgate legal documents, policies, national technical regulations and 
BCC hospital guidelines. 
b) Improve the organization of infection control in accordance with Circular No. 18/2009/TT-
BYT dated 14/10/2009 guiding the implementation of BCC in the examination and treatment 
facilities. 
c) Conduct continuing training and training to improve their knowledge and skills to practise 
infection control for health workers and specialized BCC staff at health facilities. 
d) Develop the monitoring indicators in infection control. 
e) Establish monitoring systems and reporting data on hospital infections from hospitals under 
the Ministry of Health and provincial hospitals. 
5.2.2. Phase 2 
a) Promote scientific research in the BCC field. 
b) Regularly organise national scientific workshops once/year and international 
scientific workshops on infection control once/5 years. 
6. Strengthen safe, appropriate antibiotic use in livestock, poultry, aquaculture and 
cultivation  
6.1. Activities 
a) Develop documents and manuals prescribing antibiotics, growth drug in livestock, poultry, 
aquaculture and cultivation.  
b) Develop list of permitted antibiotics and prescribe limitations of antibiotic residues in 
livestock, poultry, aquaculture and cultivation  
c) Establish monitoring system of safe appropriate use of antibiotics in livestock, poultry, 
aquaculture and cultivation.  
6.2. Time and schedule for implementation 
 216 
 
 
 
6.2.1. Phase 1 
a) Develop documents prescribing antibiotic use in livestock, poultry, aquaculture and 
cultivation.  
b) Make the list of antibiotics and prescribe restricted antibiotic residues in livestock, poultry, 
aquaculture and cultivation  
c) Establish the monitoring system of antibiotic use in livestock, poultry, aquaculture and 
cultivation.  
6.2.2. Phase 2 
a) Cooperate in research and evaluation of antibiotic use and resistance in livestock, poultry, 
aquaculture and cultivation.  
b) Evaluation of antibiotic use and resistance in livestock, poultry, aquaculture and 
cultivation. 
c) Continue to implement activities to prevent drug resistance. 
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                                                            Part three 
 
                                                            SOLUTIONS 
 
I. POLICY AND MANAGEMENT 
 
1. Gradually improve the system of legal documents and instructions on technical expertise in 
infectious disease control, infection control, surveillance of drug resistance, enhancing 
rational drug use. 
2. Improve the system of documents on antibiotic use in livestock, poultry, aquaculture and 
cultivation. 
3. Strengthen inspection and supervision of the implementation of professional rules relating 
to treatment guidelines, medication use, hospital pharmacy, infection control in health 
facilities. 
4. Enhance the assessment of tuberculosis epidemiology, medicine and equipment, 
tuberculosis with HIV/AIDS, situation of TB drug resistance. 
5. Closely monitor the quality of drugs, prevent poor quality drugs, counterfeit drugs from 
circulating in the market. 
6. Increase the capacity of program management: prevention of tuberculosis, HIV/AIDS, drug 
resistance, infection control. 
 
II. INFORMATION, EDUCATION AND COMMUNICATION,  
1. Promote dissemination, advocacy, legal education on the rational safe use of drugs. 
2. Raise awareness of community, health workers, people who work in the fields of livestock, 
poultry, aquaculture and cultivation on antibiotics and drug resistance. 
3. Mobilize people to follow The month for prevention of drug resistance. 
4. Strengthen education and communication for the entire population, gradually socializing 
TB prevention: advocacy, requirement, use of all society components, relatives of patients 
participating in the tuberculosis prevention at all levels and under different forms. 
III. TECHNICAL EXPERTISE AND TRAINING 
1. Complete expertise guidance, technical procedures in health examination and treatment, 
microbiology testing, drug resistance surveillance as the basis for the implementation of units. 
2. Enhance training, improve qualification for health workers, diversifying forms of training, 
continuous training, additional training, domestic and international training on diagnosis and 
treatment of diseases, especially infectious diseases; microbiology testing, infection control, 
surveillance of drug resistance in health facilities. 
3. Complete training frame, curriculum in microbiology and antibiotics in universities, health 
schools. 
4. Increase investment in infrastructure, support facilities and equipment to meet the demands 
of infection control, microbiology testing, monitoring drug resistance, drug quality control. 
5. Upgrade laboratories, research centers on microbiology at central hospitals, universities. 
6. Continuously improve the quality of drugs and bioequivalence assessment. 
7. Ensure adequate supply of medicines in the list of essential drugs used in the examination 
and treatment. 
8. Complete system for collecting statistical data and reports, gradual modernization, 
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application of information technology to manage information on the national network. 
9. Coordinate activities between the national TB control and other national health programs at 
district, commune and village levels. 
IV. FINANCE 
Investment from the state budget, ODA funding and other legitimate funds to implement the 
National action plan to combat antimicrobial resistance in the period from 2013 to 2020: 
1. In the country: the units ensure funding to implement activities within assigned missions 
and state budget distributed in the annual and 5-years plan. 
2. Mobilize resources from international organizations, non-governmental organizations: 
WHO, UN forestry fund, GARP - Vietnam, UNAIDS, WB, ... V. SCIENTIFIC 
RESEARCH AND INTERNATIONAL COOPERATION 
1. Strengthen research and transfer of new techniques in the diagnosis and treatment of 
infectious diseases, microbiology testing, quality control, microbiology laboratory. 
2. Enhance the capacity of study on drug use, drug resistance research, especially research on 
multi-drug resistant bacteria. 
3. Promote research on hospital infections. 
4. Coordinate with relevant agencies to promote cooperation in research: assessment of 
antibiotics use, antivirals, parasite; study on drug resistance  especially study on multi-drug-
resistant bacteria. 
5. Strengthen international cooperation, experience exchange and sharing, participate in 
workshops, specialized scientific conferences, forums on prevention and control of infectious 
diseases, rational drug use, hospital infection, quality control of microbiological testing, drug 
resistance. 
6. International cooperation on continuous training, research on drug use, clinical pharmacy 
practice. 
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                                                                  Part four  
 
                                                         IMPLEMENTATION 
 
I. ESTABLISHMENT OF STEERING COMMITTEE 
1. Chairman: Minister of Health 
2. The Deputy Chairmen: Deputy Minister of Health, Ministry of Agriculture and Rural 
Development 
3. The Commissioners: Leaders of Departments of examination and treatment 
Administration, Food Safety, Preventive Medicine, HIV/AIDS, Drug Administration, Health 
Environmental Management, Science Technology and Training ... Leaders of Departments of 
Planning - Finance, Facilities and health services Works, Health Insurance, ... Inspector of the 
Ministry of Health; relevant Departments of Ministry of Agriculture and Rural Development. 
4. Secretaries: Representatives of relevant Departments, agencies of Ministry of Health, 
Ministry of Agriculture and Rural Development. 
5. The sub-committees: 
a) Sub-Committee on infection control 
b) Sub-committee on treatment (Infection, intensive care, HIV/AIDS, TB) 
c) Sub-Committee on monitoring, inspection and examination of the use of antibiotics: 
- Prevention, diagnosis and treatment in health facilities and communities 
- Livestock, poultry, aquaculture and cultivation. 
d) Subcommittee on logistics 
e) Sub-committee on education and communication 
6. Permanent Division: Department of examination and treatment Administration 
II. ASSIGNMENT OF RESPONSIBILITY 
1. The agencies of the Ministry of Health 
1.1. Department of Examination and treatment administration: 
a) Act as the focal point to collaborate with other relevant units to direct and guide the 
implementation; summing up the results of operations in the plan to report to the Ministry of 
Health; 
b) Develop technical expertise guidance on infection control, treatment regimens, surveillance 
of drug resistance and drug use; 
c) Examine and supervise the implementation of professional rules relating to treatment 
guidelines, drug use, infection control in health facilities; 
d) Establish the system of national drug resistance surveillance; monitoring, management, 
warning of the resistance and the danger of drug resistance; develop the database on antibiotic 
use and resistance; training, continuous technical professional training on clinical 
microbiology for laboratory staff at the national standard center and 30 laboratories 
throughout the country; 
e) Establish the system of monitoring and reporting data on hospital infections from hospitals 
under the Ministry of Health and provincial and cities hospitals under central authority; 
e) Monitoring and evaluation of drug use, compliance monitoring, promoting activities of the 
 220 
 
 
 
Council of  Drug and Treatment in health facilities; 
g) Evaluate TB epidemiology, drugs and equipment, tuberculosis with HIV/AIDS, TB drug 
resistance. 
 
1.2. Drug Administration 
a) Implement measures to improve the quality of drugs and bioequivalence assessment. 
b) Provide enough drugs in the list of essential drugs mainly used in health facilities. 
c) Monitoring and surveillance of counterfeit drugs circulating in the market. 
1.3. Bureau of HIV/AIDS prevention and control 
a) Collect data regarding antiretroviral treatment outcomes; collecting early warning 
indicators of HIV drug resistance in nationally representative facilities treating HIV/AIDS. 
b) Monitoring, supervision and evaluation of HIV drug resistance in patients receiving 
therapy and new HIV infected patients without ARV. 
c) Implement measures to improve capacity for HIV resistance testing laboratory. 
1.4. Department of Preventive Medicine 
Tracking, monitoring, doing research, evaluation of the use of antibiotic and antibiotic 
resistance in community 
1.5. Department of Food Safety 
Tracking, monitoring antibiotic residues in foods directly affecting people's health. 
1.6. Inspector of the Ministry 
Inspecting the sale of antibiotics without prescription. 
1.7. Department of Planning – Finance 
a) Guide relevant departments in estimating the annual budget as assigned in the plan. 
b) Investments from the state budget, official sources for development assistance and other 
legitimate funding sources to implement the National Action Plan to Combat Antimicrobial 
Resistance in the period 2013-2020. 
c) Arrangement, allocation of regular budget for hospitals to implement solutions of 
prevention of drug resistance. 
1.8. Health Insurance Department, Bureau of Environmental Health Management 
Coordinate with relevant agencies to implement the Action Plan in accordance with the 
functions assigned. 
1.9. Bureau of Science, Technology and Training 
a) Propose, support, give priority to research and new techniques transfer in diagnosis of 
infectious diseases, microbiology testing. 
b) Training to strengthen the capacity of study on assessment on drug use, drug resistance 
studies, especially study of multidrug-resistant bacteria, study of hospital infection. 
c) Strengthen continuous training with appropriate forms domestic and abroad to improve the 
qualification of  health workers. 
d) Improve the curriculum frame, curriculum for microbiology, antibiotic in medical and 
pharmaceutical training units. 
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1.10. Department of Communications and emulation, commendation 
Assume the prime responsibility and coordinate with the relevant departments in the 
dissemination and propagation, education to raise awareness of community and health 
workers on prevention of drug resistance and mobilize them to perform the month for actions 
against drug resistance. 
1.11. Department of Health in provinces and cities under central management 
Guide provincial health facilities in plan development and implementation; allocating 
resources to implement the national action plan against drug resistance in the period 2013-
2020 in accordance with the specific circumstances of each locality. 
1.12. Hospitals 
a) Develop a specific plan in accordance with the conditions of each unit to implement the 
National action plan against drug resistance in the period 2013-2020.  
b) Allocate resources for the prevention of drug resistance: upgrade microbiology 
laboratories; strengthening infection control; monitor and control the use of inappropriate 
antibiotics, ... 
2. Ministry of Agriculture and Rural Development 
Ministry of Agriculture and Rural Development assigns its agencies in collaboration with the 
Ministry of Health to direct and guide relevant agencies to develop regulations on the use of 
antibiotics, list of antibiotics, antibiotic residues limits used in livestock, poultry, aquaculture 
and cultivation. Inspection, testing and monitoring the use of antibiotics in livestock, poultry, 
aquaculture and cultivation. 
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